Sign In

Poster Sessions

Poster sessions provide an opportunity for authors to display and discuss their research. More than 2,000 basic science and clinical posters are scheduled for presentation. Exclusive networking opportunities enable attendees and researchers to connect and establish new collaborations during these sessions.

ePosters

ePosters will be available for viewing throughout The Liver Meeting® and beyond! Review the formatting and submission guidelines for additional information.

Poster Session I: Friday, October 20, 8 am-5:30 pm

Presentation time: Noon – 1:30 pm

Animal Models

  • 265: Hepatic NK cells play an important role in the development of AIH by contributing to hepatic inflammation
  • 266: Clara cell 10KDa protein alleviated fulminant hepatitis induced by MHV-3 via inhibiting FGL2 expression on macrophages
  • 267: A novel nanoparticle-based approach to study axes between the liver and other organs
  • 268: Depletion of metallothionein aggravates alcoholic liver injury by regulating oxidative burst of neutrophils
  • 269: WXSH0213, a dual CCR2 and CCR5 antagonist, ameliorates nonalcoholic activity score and liver fibrosis in MCD mice
  • 270: Systemic administration of Toll-like receptor 9 agonist could alter the phenotype of myeloid derived suppressor cells with subsequent intrahepatic CD8+T cell expansion and inhibits the hepatoma growth
  • 271: NK cells of C57BL/6 mice offer stronger protection than NK cells of Balb/c mice in low immunogenic liver metastases
  • 272: Fractalkine mediated locally accumulated CX3CR1+ macrophages recruit iNOS+ macrophages and neutrophils by production of MCP-1 chemokine to lead immune mediated hepatitis
  • 273: Enhancement of NAFLD Risk by Vinyl Chloride: Role of Adipose Tissue in a Mouse Model.
  • 274: Inhibition of Toll-Like Receptor 4 Ameliorates Experimental Post-Ischemic Injury in the Cholestatic Liver through Inhibition of High-Mobility Group Box Protein B1 (HMGB1) Signaling
  • 275: Characteristics of inflammatory cells in liver metastasis tumor and intraperitoneal dissemination of murine pancreas cancer models.
  • 276: Sodium butyrate ameliorates S100/FCA-induced autoimmune hepatitis through regulation of intestinal tight junction and toll-like receptor signaling pathway.

Autoimmune and Cholestatic Liver Disease

  • 277: Unmet Need of Patients with Primary Biliary Cholangitis (PBC) Based on Alkaline Phosphatase (ALP) Threshold Using Large Database with Electronic Medical Records (EMRs) and Claims Data: A Cross-sectional Analysis
  • 278: Ursodeoxycholic Acid is Associated with a Prolonged Transplant-free Survival in All Patients with Primary Biliary Cholangitis – there is no such thing as non-response.
  • 279: Radiologic progression in primary sclerosing cholangitis (PSC) by two-dimensional magnetic resonance cholangiopancreatography (MRCP): Prospective data from a randomized controlled trial
  • 280: Epidemiologic trends and treatment survival benefits in a US cohort of patients with primary biliary cholangitis (PBC)
  • 281: Time-dependent factors associated with diminished transplant-free survival in patients with primary biliary cholangitis and an optimal response to ursodeoxycholic acid after one year of treatment
  • 282: The Critical Recognition of Lipoic Acid as an Antigen in Patients with Primary Biliary Cholangitis
  • 283: Mechanisms and Therapeutic Implications of MAFG Dysregulation in Cholestatic Liver Injury and Cancer
  • 284: Elevated Hepatic Biochemistry Predicts Recurrent Primary Sclerosing Cholangitis in the First 12 Months Following Liver Transplantation
  • 285: An Open-Label Study of Abatacept in Patients with Primary Biliary Cholangitis with an Incomplete Biochemical Response to Ursodeoxycholic Acid
  • 286: Secretin receptor antagonist treatment reduces biliary damage and liver fibrosis in a mouse model of early stage primary biliary cholangitis (PBC), but not advanced PBC
  • 287: Cholestasis induced intestinal dysbiosis augments liver disease in a murine model of primary sclerosing cholangitis
  • 288: Pruritus in Primary Biliary Cholangitis is Associated with Decreased Brain Functional Connectivity
  • 289: A Comprehensive Evaluation of Dominant Biliary Strictures for Malignancy in Primary Sclerosing Cholangitis
  • 290: Recurrence of Primary Biliary Cholangitis after Liver Transplantation Affects Graft Survival: A Multi-Center Study from the Global PBC Study Group
  • 291: MicroRNA profiling in plasma of patients uncovers unique microRNA signatures associated with liver inflammation, cirrhosis, nonalcoholic steatohepatitis and hepatocellular carcinoma that predict the progression of Primary Sclerosing Cholangitis.
  • 292: Quantification of biliary tree volume in patients with PSC using three dimensional (3D) reconstruction of magnetic resonance cholangiopancreatography (MRCP): Clinical associations and prognostic significance
  • 293: Impairment of anion exchanger 2 may be related to abnormal expression of mitochondrial antigens in primary biliary cholangitis
  • 294: Persistent reduction of mucosal-associated invariant T cells in primary biliary cholangitis
  • 295: Circulating markers of bacterial translocation predict liver transplantation free survival in primary sclerosing cholangitis
  • 296: Development of a Dose Regimen for Obeticholic Acid in Patients with Primary Biliary Cholangitis and Hepatic Impairment
  • 297: Efficient quantification of abnormal lipoproteins associated with liver disease by nuclear magnetic resonance spectroscopy.
  • 298: Changes in serum bile acid levels associated with bezafibrate add-on therapy in patients with primary biliary cholangitis and inadequate biochemical response to ursodeoxycholic acid: results from the BEZURSO trial (NCT01654731)
  • 299: Anti-GP2 IgA autoantibodies are associated with liver cirrhosis and severity of the disease in primary sclerosing cholangitis (PSC)
  • 300: Moving from early to moderate or advanced biochemical disease stage during follow-up is associated with an increasing risk of clinical events in primary biliary cholangitis patients.
  • 301: Increased expression and altered localization of cathepsin Z is associated with progression to jaundice-stage in primary biliary cholangitis
  • 302: Serum Metabonomic and Gut Microbial Profile in Patients with Primary Biliary Cholangitis with Pruritus and the Effect of Ileal Bile Acid Transporter Inhibition
  • 303: Gut derived β7+CD8+ T cells are enriched in the hepatic tissue of PSC-IBD patients implicating a role for extra intestinal lymphocyte trafficking in the pathogenesis of primary sclerosing cholangitis associated with inflammatory bowel disease
  • 304: Are the PR3-ANCA autoantibodies present in patients with PSC? Prospective analysis including markers of liver injury and health-related quality of life assessment
  • 305: Characterization of a liver tissue epigenome in primary sclerosing cholangitis
  • 306: Efficacy of Obeticholic Acid Treatment Through 24 Months of Open-Label Extension in Patients with Primary Biliary Cholangitis and Cirrhosis: Data From POISE
  • 307: Reductions in Abnormal Direct Bilirubin with Obeticholic Acid in Patients with Primary Biliary Cholangitis
  • 308: Hispanics with Primary Biliary Cholangitis present for Liver Transplant Listing at a Younger Age and with more Severe Hepatic Decompensation
  • 309: Clinical characteristics and Predictors of Mortality in Hospitalized Patients with Primary Biliary Cirrhosis in the US.
  • 310: Incidence, Prevalence and Outcome of Primary Biliary Cholangitis in Sweden
  • 311: Week-4 Biochemical Response Predicts 1-Year-Response to Ursodeoxycholic Acid in Primary Biliary Cholangitis Patients
  • 312: Liver Transplant (LT) Candidates with Primary Biliary Cholangitis (PBC) Experience Higher Wait List Mortality: Data from the Scientific Registry of Transplant Recipients (SRTR)
  • 313: Pathological features of primary sclerosing cholangitis identified by bile proteomic analysis
  • 314: Suboptimal Adherence to Screening Guidelines for Primary Sclerosis Cholangitis in a Canadian Centre
  • 315: Validation of the GLOBE Score and the UK-PBC Risk Score in Japanese patients
  • 316: Pruritus, dryness, fatigue and health-related quality of life in Japanese patients with primary biliary cholangitis
  • 317: Diverse spectrum of liver and systemic diseases in AMA-positive subjects
  • 318: The risk predictive values of UK-PBC and GLOBE scoring system and performance of biochemical response criteria in Chinese patients with primary biliary cholangitis (PBC) on ursodeoxycholic acid
  • 319: Endoscopic Therapy with a Large Caliber Fenestrated Stent is Effective and Safe in Patients with Dominant Strictures and Primary Sclerosing Cholangitis
  • 320: Collagen proportionate area correlates with histological stage and predicts clinical events in primary sclerosing cholangitis.
  • 321: Repeat Liver Transplantation for Recurrent Primary Sclerosing Cholangitis: Survival Assessment in 15-year Experience
  • 322: Health status and disease burden in Primary Sclerosing Cholangitis are mainly determined by fatigue and pruritus
  • 323: Early identification of candidates for second-line therapies in PBC using a UDCA-response model
  • 324: Financial burden and predictors of disparities in Hospitalized patients with Primary Biliary Cirrhosis in the US
  • 325: The macrophage activation marker sCD163 is associated with disease severity in patients with primary biliary cholangitis
  • 326: Development of Endoscopy signs of Portal Hypertension in a group of selected patients with Primary Biliary Cholangitis treated with Ursodeoxycholic Acid: Results of a prospective and prolonged study
  • 327: Hepatic involvement of Graft-Versus-Host-Disease and elevated total bilirubin levels portend poor prognosis after allogenic stem cell transplantation.
  • 328: Concordance of pruritus scales in primary biliary cholangitis (PBC) patients: Pruritus visual analogue scale (VAS) and 5-D itch scale in clinical trial settings
  • 329: Cystic biliary dilatations in primary sclerosing cholangitis: an unusual entity with prognostic value
  • 330: Autoimmune liver disease in the UK: a national primary care evaluation of disease geo-epidemiology
  • 331: Transient Elastography (TE) And Acoustic Radiation Force Impulse Imaging (ARFI) Can Predict Degree Of Advanced Fibrosis For Autoimmune Hepatitis In Biochemical Remission
  • 332: Exploring the Impact of Autoimmune Hepatitis on Health-Related Quality of Life
  • 333: Multi-parametric MRI imaging correlates with clinically meaningful surrogates of disease activity in autoimmune hepatitis
  • 334: HLA Class I Alleles outside the Extended DR3 Haplotype are Protective Against Autoimmune Hepatitis
  • 335: The Gut Microbiome in Autoimmune Hepatitis Links to Disease Progression and is Significantly Different from Lupus and Healthy Controls
  • 336: Dysbiosis of oral microbiota and its association with salivary immunological biomarkers in autoimmune liver disease
  • 337: Is there any predictor for relapse after treatment withdrawal in autoimmune hepatitis patients in the real life?
  • 338: Acute presentation of autoimmune hepatitis in adults and children: histological spectrum and features distinguishing it from drug-induced liver injury and acute viral hepatitis
  • 339: B-cell depletion with Rituximab demonstrates excellent laboratory efficacy at 6 months in patients with complicated autoimmune hepatitis
  • 340: Enhanced Immunoregulation Is Likely To Be The Mechanism Of Pregnancy-Mediated Tolerance In Autoimmune Hepatitis
  • 341: Diagnostic and therapeutic variability in the management of Autoimmune Hepatitis (AIH).
  • 342: Flare of Autoimmune Hepatitis as a cause of acute on chronic liver failure and its response to steroid therapy
  • 343: Increased Mortality in Autoimmune Hepatitis
  • 344: Autoimmune hepatitis nationwide survey in Japan - subanalysis report
  • 345: Forkhead Box M1 Regulates Methionine Adenosyltransferase Genes Differentially to Drive Liver Cancers
  • 346: High prevalence of Overlap Syndrome of Primary Biliary Cholangitis and Autoimmune Hepatitis and association with advanced fibrosis in Hispanic patients in Los Angeles.
  • 347: CCL5 modulates Neutrophil cytotoxicity and Protects against Invariant NKT activation Mediated Hepatit
  • 348: Biochemical response to ursodeoxycholic acid predicts histologic primary biliary cholangitis progression
  • 349: Proscpective multi-center study of prevalence of autoimmune hepatitis
  • 350: Oral administration of anti-eotaxin-1 monoclonal antibody is biologically active in the gut and alleviates immune-mediated hepatitis: A novel personalized therapy for immune-associated liver diseases
  • 351: Effects of interferon-free treatment on chronic hepatitis C patients with autoimmune liver diseases
  • 352: Utilization of Second-Line Therapeutics in Autoimmune Hepatitis at a Tertiary Care Center
  • 353: Trends in Liver Transplantation among Patients with Primary Biliary Cholangitis
  • 354: Characteristic T cell receptor repertoires in CD4+ T cells of primary biliary cholangitis
  • 355: The unique patterns of change in the metabolic variables of patients with primary biliary cholangitis
  • 356: Characterization of patients with primary biliary cholangitis(PBC) and autoimmune hepatitis(AIH) attended in a community hospital in East Harlem, New York.
  • 357: The occurrence rate of clinical events in Japanese PSC cohort –a potential role as surrogate endpoints for clinical trials-
  • 358: The Extracellular Matrix (ECM) Turnover Profile In Cholestatic And Autoimmune Liver Diseases – An Exploratory Study
  • 359: Real world effectiveness of Obeticholic Acid in the treatment of Primary Biliary Cholangitis
  • 360: Addressing the mechanisms of primary sclerosing cholangitis (PSC): Defining the frequency of immature CD57-NKp46high CD56dim CD16+ NK cells
  • 361: Prognosis in patients with primary biliary cholangitis based on histological stage at diagnosis. A nationwide population-based study
  • 362: Bilirubin and lithocholic acid induce osteocyte damage which may partially explain the development of osteoporosis in cholestatic disease
  • 363: Comparison of Transient Elastography and Magnetic Resonance Elastography in Primary Biliary Cholangitis

Basic Fibrosis Research and Stellate Cell Biology

  • 364: Ocurrence of endothelial-to-mesenchymal transition in fibrotic livers
  • 365: Platelet-derived Growth Factor Receptor Alpha Contributes to Hepatic Fibrosis by Promoting Hepatic Stellate Cell Proliferation and Migration During Chronic Liver Injury
  • 366: HMGB2, A Driver of Stellate Cell Activation and Experimental Hepatic Fibrosis
  • 367: A novel FXR agonist EDP-305 potently suppresses hepatic stellate cell activation and hepatic fibrosis in chronic mouse models of biliary and metabolic liver disease
  • 368: Glucagon-like peptide-1 receptor agonists inhibit inflammatory macrophage activation and improve the major components of NASH in an optimized CDAA mouse model
  • 369: Sphingosine kinase 1 promotes liver fibrosis by preventing miR-19b-3p-mediated inhibition of CCR2
  • 370: Role for a Rhamm-hyaluronan axis in scarless liver repair
  • 371: Endotoxin (lipopolysaccharide) is not required to drive hepatic fibrosis
  • 372: Activation of NOX2 in older mice by the aging protein p52Shc leads to accelerated fibrosis in NASH
  • 373: Hepatocytes undergo caspase-1-induced pyroptotic cell death during NLRP3 inflammasome activation and release NLRP3 particles that are engulfed by hepatic stellate cells
  • 374: YAP Regulated SOX9 Expression Promotes Liver Fibrosis.
  • 375: AGER1/RAGE imbalance and accumulation of AGEs result in inflammation, expansion of ductular cells and fibrosis in NASH
  • 376: Transforming growth factor beta and IL-4/IL-13 signaling collaborate to prevent abnormal cystic liver formation during Schistosoma mansoni infection.
  • 377: HIV infection Modulates IL-1β Response to LPS Stimulation Through a TLR4-NLRP3 Pathway in Human Liver Macrophages
  • 378: Reducing free cholesterol accumulation specifically in hepatic stellate cells, by using either SREBP2-siRNA-bearing or anti-miR-33a- bearing vitamin A-coupled liposomes, ameliorates liver fibrosis in mice.
  • 379: Exposure of hepatic stellate cells to hepatocyte-derived mitochondrial DAMPs determines susceptibility to liver fibrosis in inbred mouse strains
  • 380: miR-125b targets l-histidine decarboxylase (HDC) and inhibition of HDC decreases biliary proliferation, VEGF signaling and hepatic fibrosis in Mdr2-/- mice
  • 381: A novel small molecule LOXL2 inhibitor PAT-1251 potently suppresses hepatic stellate cell activation and liver fibrosis in mouse models of biliary disease
  • 382: Portal myofibroblasts develop endoplasmic reticulum stress that both decreases their proliferation and increases their pro-angiogenic activity
  • 383: PAT-409, a Novel Inhibitor of Autotaxin, Reduces Fibrosis in Both Mouse and Rat Models of NASH
  • 384: cRel controls epithelial reprogramming to promote hepatic fibrosis and tissue regeneration
  • 385: Development and characterization of a novel in vitro human liver fibrosis model for efficacy testing of anti-fibrotic drugs based on 3D Human Liver Microtissues
  • 386: The role of mechanosensor molecules in HSCs durotaxis
  • 387: Lipid Droplets Are Not Lost During Hepatic Stellate Cell Activation
  • 388: Anti-inflammatory and anti-fibrotic actions of soluble guanylate cyclase stimulation in experimental NASH.
  • 389: Therapeutic proteins in the treatment of liver fibrosis: the antifibrotic potential of a sustained release formulation for a PDGFβ-receptor targeted rho-kinase inhibitor
  • 390: Identification of novel drug combinations with synergistic effects on hepatic fibrosis in vitro and in vivo
  • 391: Hepatic progenitor cells contribute to hepatic fibrosis progression via ductular reaction in carbon tetrachloride/2-acetylaminofluorene-induced fibrosis rat model
  • 392: PBI-4050 Inhibits Hepatic Stellate Cell Proliferation and Activation Via AMPK, and Improves Hepatic Fibrosis in CCl4-Induced Liver Injury Model
  • 393: Periostin cross-reacts with the renin-angiotensin system during liver fibrosis
  • 394: Hedgehog-YAP Signaling Pathway Regulates Glutaminolysis To Control Hepatic Stellate Cell Fate
  • 395: Antifibrotic effects of 8-hydroxydeoxyguanosine through the inhibition of NADPH oxidase derived oxidative stress in vitro and in vivo models of liver fibrosis
  • 396: S-allyl-glutathione improves liver fibrosis by inhibition of excess M1- or M2- polarized macrophage in rats.
  • 397: Inhibition of toll-like receptor 9 by ODN-2088 reduces inflammation in murine precision-cut liver slices
  • 398: Aberrant signaling leads to capillarization of liver sinusoidal endothelial cells (LSECs) in hepatic fibrosis
  • 399: The antiretroviral rilpivirine decreases hepatic inflammation and fibrosis progression in different experimental mice models of fibrosis
  • 400: Global identification and analysis of isozyme-specific substrates crosslinked by transglutaminases in mouse liver fibrosis
  • 401: Lipoxin A4 Improves Ultrastructural View of Liver and Reduces Expression Levels of MKK4 and TGF-β During Thioacetamide (TAA) Induced Fibrosis
  • 402: AB604, an Activin A/Bone Morphogenetic Protein 6 (BMP6) chimera, has potential anti-fibrotic properties.
  • 403: Novel oral plasminogen activator inhibitor-1 inhibitor attenuates hepatic fibrosis via suppression of activated hepatic stellate cell in rat NASH models.
  • 404: Single Nucleotide Polymorphism (SNPs) Related to Stellate Cell Activation: Is there an Association with Lower Risk of Pericellular Fibrosis in Diabetics with Non-alcoholic Fatty Liver Disease (NAFLD)?
  • 405: Opioid growth factor receptor-like 1; an extracellular vesicle-mediated signal between hematopoietic cells and hepatic parenchymal cells that regulates repair and embryonic development of the liver
  • 406: Namodenoson (CF102) Prevents Liver Fibrosis in the CCL4 Model
  • 407: Thyroid hormone (T3) regulates liver progenitor cell response
  • 408: The Anti-Fibrogenic and Liver Protective Effects of Namodenoson (CF102) in a Non-Alcoholic Steatohepatitis model
  • 409: Junction Plakoglobin, an EpCAM Binding Protein, Serves as a Marker to Identify Hepatocytes Derived from Hepatic Stem Cells.
  • 410: Loss of TRPV1 promotes the pro-inflammatory and activation response in hepatic stellate cells
  • 411: ER Stress promotes HSC activation through C/EBPβ-mediated regulation of profibrotic genes

Bile Transport 

  • 412: Intestinal FXR activation by pharmacological inhibition of the organic solute transporter α-β
  • 413: Bile acids and FXR modulate hepatic antioxidant defense by regulating hepatic cysteine and glutathione metabolism in mice
  • 414: Fibroblast Growth Factor 15 Regulates the Priming Phase of Liver Regeneration after Partial Hepatectomy in Mice Independent of Bile Acids
  • 415: Alterations in Bile acid profile in portal venous system across the spectrum of HCV-associated liver disease
  • 416: Nuclear Ca2+ determines bile acid induction of chemokines in mouse hepatocytes
  • 417: Dysregulated bile transporters and liver tight junctions enable chronic liver injury
  • 418: Proof-of-Concept for Positron Emission Tomography of the Enterohepatic Circulation of Conjugated Bile Acids in Rats
  • 419: Zebrafish abcb11b mutant reveals novel strategies to restore bile excretion in bile salt export pump-deficient hepatocytes
  • 420: Suppression of the hepatocyte canalicular sterol transporter ABCG5/8 enhances the inhibitory effects of phytosterols on FXR signaling
  • 421: Milk thistle natural polyphenols increase systemic as well as hepatic concentrations of bilirubin and decrease hepatic lipoperoxidation in mice
  • 422: Early onset gallstone formation due to the variant p.D19H of the sterol transporter ABCG8: analysis of children with gallstones and humanized knock-in mice
  • 423: Laparoscopic versus Open Hepatectomy for Hepatolithiasis: a meta-analysis of literatures

Clinical and Translational Fibrosis Research

  • 424: Hepatocyte exosomes preferentially target fibrotic liver and demonstrate integrin-like and heparin-like binding to hepatocytes and hepatic stellate cells
  • 425: Combination of ASK1 and ACC Inhibitors Increases Efficacy in Rodent Models of NASH
  • 426: Non-invasive markers of fibrosis and risk of liver related-hospitalizations, all-cause hospitalizations and mortality in a community-based population
  • 427: Interleukin-13 Activated Hedgehog Signaling Regulates Pathogen Driven Inflammation and Fibrosis
  • 428: A mouse model with inducible ablation of TGFb receptor type 2 limited to hepatic stellate cells predicts the power of HSC-specific TGFb pathway inhibition
  • 429: Nonclinical proof-of-concept for "hepatic artery infusion of cultured autologous bone marrow mesenchymal stem cells" in a canine liver fibrosis model
  • 430: Targeting liver inflammation using Mincle-targeted liposomes as a novel drug delivery system.
  • 431: Apoptosis Signal-regulating Kinase1-MAPKinase p38 (ASK1-p38) Pathway Associated with IL-10 is Independently Correlated to Higher Percent (%) Collagen in Patients with Non-alcoholic Steatohepatitis (NASH)
  • 432: Clinical Phase 1b/2 Study Results for Safety, Pharmacokinetics, and Efficacy of ND-L02-s0201, a Novel Targeted Lipid Nanoparticle (LNP) Delivering HSP47 siRNA for the Treatment of Patients with Advanced Liver Fibrosis
  • 433: Non-invasive measurement of fibrogenic activity by metabolic labeling of lumican in HCV patients before and after DAA treatment indicates rapid anti-fibrogenic effects after HCV cure
  • 434: Circulating let-7 levels in serum and extracellular vesicles correlate with hepatic fibrosis progression in chronic hepatitis C
  • 435: SOX9 predicts progression of liver fibrosis in patients with chronic hepatitis C
  • 436: Plasma cell-free DNA harbours novel genome-wide methylome signatures associated with advanced fibrosis in non- alcoholic fatty liver disease
  • 437: Comparative evaluation of circulating LOXL-2 and TNC-C in HCV/HIV, HIV and HCV infections, in relation to liver fibrosis severity, and pre and post anti-viral therapy
  • 438: Porphyromonas Gingivalis Is Associated With Disease Severity In Patients With Alcoholic Liver Disease And Increases Hepatic Stellate Cell Activation
  • 439: Serum galectin-9 levels are correlated to liver fibrosis regardless of chronic inflammation or hepatocellular carcinoma complications.
  • 440: Treatment with ND-L02-s0201, a Novel Targeted Lipid Nanoparticle (LNP) Delivering HSP47 siRNA, Results in Fibrosis Resolution in Preclinical Rat Models
  • 441: Non-invasive Biomarkers predictive of fibrotic improvement of liver after Telbivudine Treatment in chronic hepatitis B Patients
  • 442: Refined quantitative assessment of septa to determine the different type of septa in chronic hepatitis B patients.
  • 443: Correlation Between The Phosphodiesterase 4 (PDE4) Family Of Enzymes And Inflammatory And Fibrotic Markers In Human Livers

Complications of Cirrhosis I

  • 444: A Prospective, Randomized Clinical Trial Comparing Blood Product Use, Bleeding Events, and Cost During and After Endoscopic Procedures in Patients with Cirrhosis and Coagulopathy: Rotational Thromboelastrometry (ROTEM) versus Conventional Therapy
  • 445: Hepatic venous pressure gradient (HVPG) predicts clinical disease progression in patients with compensated cirrhosis due to NASH
  • 446: Liver Stiffness Measured By Vibration Controlled Transient Elastography Is An Excellent Surrogate for Identifying Clinically Significant Portal Hypertension In Patients With Compensated NASH Cirrhosis
  • 447: Platelets count performs better than liver and spleen elastography as a predictor for liver related events in compensated chronic hepatitis C cirrhotic patients.
  • 448: Performances of FibroScan® to detect large esophageal varices in chronic liver diseases patients are improved by a novel spleen-dedicated examination
  • 449: Comparison of continuous infusion versus intermittent infusion of terlipressin for the control of acute variceal bleeding in patients with cirrhosis: A prospective randomized control trial
  • 450: Management of hepatitis C-cirrhotic patients with basal large betablocked esophageal varices after sustained virological response
  • 451: Effect of Hepatic Venous Pressure Gradient (HVPG) Changes on Cirrhosis Decompensation in Patients with Clinically-Significant Portal Hypertension (CSPH)
  • 452: A Combination of Albumin-Bilirubin Grade and Platelet Count to Predict Compensated Patients with Hepatocellular Carcinoma Who Do Not Require Endoscopic Screening for Esophageal Varices
  • 453: Is it necessary to screen for varices in cirrhotic patients who are receiving entecavir or tenofovir for chronic hepatitis B?
  • 454: The Sustained Virological Response (SVR) by Direct-acting antivirals agents (DAA) reduces portal hypertension in patients with HCV cirrhosis.
  • 455: Validation of Baveno VI Criteria for Triaging Patients for Screening Endoscopy in Primary Biliary Cholangitis and Primary Sclerosing Cholangitis
  • 456: A pragmatic refinement of non-invasive algorithm in predicting high-risk varices in cirrhosis: Can more esophagogastroduodenoscopies be circumvented while not missing high-risk varices?
  • 457: A simple score model based on liver function tests (LFT) and liver stiffness measurement (LSM) allows noninvasive estimation of hepatic venous pressure gradient (HVPG)
  • 458: Variability in measurement of hepatic venous pressure gradient (HVPG) in patients with compensated cirrhosis due to NASH: Results from a randomized, controlled trial
  • 459: Effectiveness of Beta-Blockers (BB) in primary prevention of Esophageal Varices (EV) bleeding in patients with cirrhosis: a prospective evaluation by Hepatic Venous Pressure Gradient (HPVG) measurement.
  • 460: Efficacy and safety of edoxaban for treatment of portal vein thrombosis following danaparoid sodium in patients with liver cirrhosis
  • 461: Rapidly Rising Burden of Portopulmonary Hypertension in the United States
  • 462: Hemostatic “Re-Balance” In Patients With HCV-Related Liver Cirrhosis After Sustained Virological Response: The Story Is Not Over Yet
  • 463: Role of local endothelial alterations in the pathogenesis of portal vein thrombosis in cirrhosis
  • 464: Identification of Portal Hypertension and Prediction of Clinical Outcomes by Measuring Spleen Stiffness with Acoustic Radiation Force Impulse Imaging in Patients with Liver Cirrhosis
  • 465: Multicenter Study of Portosystemic Shunt Embolization for Persistent Hepatic Encephalopathy: From the Consortium on Liver Disease OUTcomes (CLOUT) Group
  • 466: Antithrombin III Administration for Portal Vein Thrombosis in Patients with Cirrhosis: A Randomized Double-Blind Controlled Trial
  • 467: Sarcopenia in Decompensated Cirrhosis
  • 468: Preoperative Liver Stiffness Predicts an Improvement in Vital Prognosis by Occlusion of Portosystemic Shunts in Portal Hypertensive Patients
  • 469: Multi-modal MRI in Elderly Cirrhotic Patients Reveals a Distinct Brain Response to Aging Compared to Healthy Elderly Subjects
  • 470: Periodontal therapy Improves Oral and Gut Microbiota and Reduces Systemic Inflammation and Endotoxemia in Patients with Cirrhosis
  • 471: Liver volume used as a predictor for mortality in cirrhotic patients
  • 472: Clinical implication of abnormal glucose tolerance in liver cirrhosis
  • 473: Predicting the risk of hepatic encephalopathy in patients with cirrhosis: A risk score including longitudinal data and potential benefit of statins
  • 474: Impact of race/ethnicity and primary admission diagnosis on readmission and mortality rates among patients hospitalized with hepatic encephalopathy
  • 475: Diagnostic Accuracy of CT Angiography-based Virtual Hepatic Venous Pressure Gradient in Patients with Portal Hypertension
  • 476: Diagnostic Accuracy of Radiomics-based Hepatic Venous Pressure Gradient for Clinically Significant Portal Hypertension in Cirrhosis
  • 477: Effects of Balloon-Occluded Retrograde Transvenous Obliteration on Portosystemic Shunt Syndrome in Cirrhotic Patients with Hepatic Encephalopathy
  • 478: Anticoagulation in non-malignant portal vein thrombosis is associated with improved hepatic function
  • 479: Does Liver Stiffness Measurement and Controlled Attenuation Parameter predict portal hypertension, liver related events and overall mortality in individuals with cirrhosis?
  • 480: Changing Trends Of Admissions, Readmissions, Morbidity And Mortality In Cirrhosis: A Hospital Based Study Of 6108 Patients
  • 481: Occurrence and severity of erectile dysfunction in patients with cirrhosis is related to liver dysfunction, reduced libido, age and arterial hypertension
  • 482: Congenital extrahepatic portosystemic shunts (Abernethy malformation): International observational study of clinical manifestations and outcome.
  • 483: Orthotopic liver transplant free survival is significantly lower in patients with cirrhosis and portal vein thrombosis with advanced liver disease with a trend for better prognosis in patients on anticoagulation.
  • 484: The impact of sarcopenia on prognostic value of portal hypertension and MELD in cirrhotic patients
  • 485: Decorin, a Newly Identified Exercise-induced Myokine, was Associated with Sarcopenia in Patients with Liver Cirrhosis
  • 486: Disparity in race, stage of cirrhosis and etiology of cirrhosis in prevalence of Portal Vein Thrombosis and Deep Vein Thrombosis
  • 487: Impact of Rifaximin Monotherapy Versus Rifaximin and Lactulose Combination Therapy on Quality of Life in Patients With a History of Overt Hepatic Encephalopathy (OHE)
  • 488: Mindfulness-Based Stress Reduction Therapy Improves Patient and Caregiver-Reported Outcomes in Cirrhosis
  • 489: Benign Pneumatosis Intestinalis in Cirrhotic Patients, A Potential Link to Lactulose?
  • 490: Risk Factors for Refractory Hepatic Encephalopathy after Elective Transjugular Intrahepatic Shunt Placement
  • 491: The presence and change of sarcopenia are independently associated with the long term mortality of patients with liver cirrhosis
  • 492: Cerebral Complications in Hepatopulmonary Syndrome
  • 493: Glutamine synthetase in endothelial cells of the blood-brain barrier: role in protecting the brain from hyperammonemia-induced neurotoxicity?
  • 494: Decreased Protein C Function Predicts Mortality in Patients with Cirrhosis
  • 495: Circadian rhythm and hepatic encephalopathy in cirrhosis-prospective, descriptive study
  • 496: Cytokine Profile In Patients With Chronic Liver Disease and Sarcopenia.
  • 497: Sarcopenia Worsens Following Liver Transplant
  • 498: Sexual hormones in male patients with cirrhosis are frequently deranged and are independently associated with an increased risk for mortality
  • 499: Geographic Differences for Patients Enrolled in STOP-HE: A Randomized, Phase 2 Study of OCR-002 for Hepatic Encephalopathy
  • 500: Hepatic Involvement In Hereditary Hemorrhagic Telangiectasia (HHT) Rendu-Osler-Weber Syndrome: Cross-Sectional Study At Latin American Reference Center
  • 501: An Open-Label Crossover Study of the Pharmacokinetics of Ornithine Phenylacetate (OCR-002) after IV and Oral Doses in Subjects with Cirrhosi
  • 502: STOP-HE: A Randomized, Double-blind, Placebo-controlled Study of OCR-002 in Patients with Hepatic Encephalopathy
  • 503: Ammonia is an Important Determinant of Mortality in Patients with Acute Deterioration of Cirrhosis
  • 504: Evaluation of potential risk factors and the role of medication regimen in the development of hepatic encephalopathy after transjugular intrahepatic portosystemic shunting in cirrhotic patients
  • 505: Lactulose-induced hypernatremia in patients with hepatic encephalopathy
  • 506: Addition of Sodium to the Model for End Stage Liver Disease (MELD) Score Does Not Improve the Prediction of Outcomes Following Transjugular Intrahepatic Portosystemic Shunt (TIPS) in Patients with Liver Cirrhosis
  • 508: Autotaxin and vascular endothelial growth factor receptor-2 regulate vascular development in chronic viral hepatitis C progression
  • 509: Concurrent treatment with partial splenic embolization and transcatheter hepatic arterial chemoembolization in patients with hepatocellular carcinoma accompanied by thrombocytopenia
  • 510: Rectal or Oral Lactulose in Patients Admitted with Hepatic Encephalopathy
  • 511: Usefulness of Balloon-Occluded Retrograde Transvenous Obliteration as a Procedure to Improve Liver Function in Patients with Decompensated Cirrhosis
  • 512: Serum myostatin in predicting gender-specific sarcopenia and survival in patients HOSPITALIZED WITH DECOMPENSATED advanced chronic liver disease
  • 513: The impact of race/ethnicity on acute on chronic liver failure
  • 514: Common NOD2 risk variants have differential effects on bacterial infections in compensated or decompensated stage of cirrhosis
  • 515: Oxidized plasma albumin present in patients with decompensated cirrhosis triggers the inflammatory response in innate immune cells
  • 516: Branched-chain amino acids suppress lipopolysaccharide binding protein expression resulted in an improvement of survival in chronic liver diseases.
  • 517: Lactate and number of organ failures predict intensive care unit mortality in patients with acute-on-chronic liver failure
  • 518: Presence of IgA isotype F-actin antibody is frequent in patients with cirrhosis and constitutes the risk of progressive disease course
  • 519: Prevalence and Short-term Mortality of Acute-on-Chronic Liver Failure (ACLF) in the Veterans Affairs Hospitals (2004-2014): a National U.S. Cohort.
  • 520: Sepsis-3 criteria and quick SOFA are strong predictors of in-hospital mortality in patients with cirrhosis and bacterial infections
  • 521: Hepatic encephalopathy and ammonia can predict 28 day mortality in acute on chronic liver failure in a dynamic manner- Results of multination study from APASAL-ACLF Research Consortium.
  • 522: The use of proton pump inhibitors is not associated with an increased risk of infections in a cohort of patients with alcoholic cirrhosis from Danish nationwide registers.
  • 523: Diabetes does not increase the risk of infections in patients with cirrhosis and ascites
  • 524: Functional polymorphisms of innate immunity pattern recognition receptors do not constitute the risk of bacterial infections other than spontaneous bacterial peritonitis and also not the progressive disease course in patients with cirrhosis
  • 525: Dynamic AARC-AKI score determines Extrarenal Organ Failures and Bacterial Infection in patients with Acute on Chronic Liver Failure
  • 526: Early prediction of 90-day mortality is improved by C Reactive Protein in acutely decompensated cirrhotic patients
  • 527: Emerging thrombocytopenia associated with organ failures and short-term mortality of HBV-related Acute on Chronic Liver Failure patients
  • 528: Outcome of liver transplant candidates after the first episode of bacterial infection
  • 529: Review of 3rd Generation Cephalosporin as Empiric Treatment of Suspected Spontaneous Bacterial Peritonitis: Single Center Experience in the United States.
  • 530: Invasive Fungal Infections in patients of Acute on Chronic Liver Failure
  • 531: The LIV-4 Score: A Validated Model for Predicting Mortality in Critically Ill Patients with Cirrhosis
  • 532: The impact of obesity in cirrhotic patients with septic shock: a retrospective cohort study
  • 533: In vitro efficacy of pro- and anticoagulant strategies in acutely ill patients with cirrhosis
  • 534: Definition, Characteristics and Prognosis of Hepatitis B Related Pre-Acute-on-Chronic Liver Failure
  • 535: A Deadly Trend: The Rising Incidence of Clostridium difficile in Decompensated Cirrhotic Inpatients
  • 536: Hospital-Acquired Infection is the Strongest Predictor of In-Hospital Mortality in Patients with Alcoholic Hepatitis
  • 537: Admission Neutrophil to Lymphocyte Ratio (NLR) is an Independent Predictor of Mortality in Hospitalized Cirrhotics
  • 538: Evaluation of CLIF Consortium Acute Decompensation score (CLIF-C ADs) as a predictor of short-term acute-on-chronic liver failure (ACLF) development and mortality in patients with decompensated cirrhosis (DC).
  • 539: The bilirubin/prothrombin crossing rule improves the prognostic accuracy of CLIF-C ACLF score in patients with acute-on-chronic liver failure
  • 540: Invasive pulmonary aspergillosis in patients with acute-on-chronic liver failure
  • 541: A Growing Concern: The Interaction and Association of Spontaneous Bacterial Peritonitis and Clostridium difficile infection in Decompensated Cirrhotics
  • 542: Broad-spectrum empiric antibiotic therapy for skin and soft tissue infections in patients with cirrhosis is associated with improved outcomes
  • 543: Impact of diabetes mellitus on the incidence and clinical course of spontaneous bacterial peritonitis in patients with liver cirrhosis and ascites
  • 544: Predictors of Bacterial Infection in Acute on Chronic Liver Failure
  • 545: Efficacy of early empiric antibiotic treatment and its impact on short-term mortality in cirrhotic patients with subsequent identification of the infecting bacteria
  • 546: Liver Insufficiency Is Associated With Mortality In Patients With Cirrhosis And Infectious Endocarditis: A Case Control Study
  • 547: Predictive value of the preoperative neutrophil-to-lymphocyte ratio for the development of hepatocellular carcinoma in HBV-associated cirrhotic patients after splenectomy
  • 548: Prospective evaluation of the Thromboelastrography (ROTEM®) profile in patients with Acute-on-Chronic Liver Failure (ACLF) and decompensated cirrhosis.
  • 549: Decrease of platelet count is a negative indicator of acute-on-chronic liver failure outcome

Genomics and Precision Medicine 

  • 550: A Reverse Metabolomics Approach Identifies Circulating Liver-Specific Biomarkers of the Hepatic NADH/NAD+ Ratio
  • 551: A potential role of cancer testis antigens in hepatocellular carcinoma progression
  • 552: Functional comparison of a novel three-dimensional liver organoid platform compared to 2-D cell culture- a better tool to assess hepatotoxicity?
  • 553: Hepamine - A Liver Disease Microarray Database, Visualization Platform and Data-Mining Resource
  • 554: Hepatic stellate cell-targeted pharmacological EGFR inhibition for HCC chemoprevention
  • 555: An Exonic Variant in the Alkaline Ceramidase 1 (ACER1) Gene has a highly suggestive association with Bridging Fibrosis and Cirrhosis in NAFLD: Results from Exome Chip Analysis
  • 556: DNA methylation induced by liver transplantation in children may predict gene sets associated with acute cellular rejection.
  • 557: Circulating long non-coding RNA TCONS_00016452 as a potential diagnostic marker for nonalcoholic steatohepatitis
  • 558: Recurrences after liver transplantation for unresectable hepatoblastoma associate with novel mutations in the tumor genome landscape.

Health Care Delivery/Access/Quality

  • 559: Incidence rate of hepatitis E in asymptomatic HEV infection proven by screening on blood donation in Hokkaido, Japan
  • 560: Race and Socioeconomic Status Predict Migration for Liver Transplantation in the United States
  • 561: Disparate Access Based on Insurance Status to Highly Effective Direct Acting Antivirals (DAA) for Hepatitis C Virus Treatment in the Post-DAA Era Persists: Alarmingly Impaired Access in Medicaid Recipients
  • 562: Public Health Implications of Geographic NAFLD Belt
  • 563: Lessons for a Definitive Prevalence Study Design and Scalability of Comprehensive HBV-HCV Screening and Access to Care Pathways in Ho Chi Minh City (HCMC), Vietnam
  • 564: Patients with HBV and HCV chronic liver disease under surveillance for HCC have a favorable long-term outcome for pancreatic cancer due to early diagnosis and high resection rate.
  • 565: Disease-related admission, readmission and mortality rates in advanced liver disease compared to congestive heart failure in the U.S. Department of Veterans Affairs
  • 566: Increased utilization of outpatient services and changes in sociodemographic characteristics of hepatitis C patients referred to a tertiary care center in Kentucky
  • 567: A Missing Link: Psychosocial Barriers and Linkage to Care among Chronic Hepatitis C Patients Diagnosed in an Urban Academic Emergency Department
  • 568: Improving Primary Care Training for the Evaluation and Therapy of Hepatitis C in the Community-based Test and Cure of Hepatitis C Program
  • 569: Substance Use Treatment Among Veterans with Liver Disease and Substance Use Disorders in the Veterans Health Administration
  • 570: Adherence to sofosbuvir and ledipasvir-sofosbuvir in British Columbia
  • 571: Knowledge and adoption of HCV screening recommendations for Baby Boomers: A national survey of family physicians
  • 572: Implications of Implementation Strategies for New York State Mandated Hepatitis C Virus Screening in Hospitalized Baby Boomers: Does Care Coordination Improve Inpatient Linkage to Care?
  • 573: A Locally Developed Population Management Application to Understand Veteran Barriers to HCV Treatment
  • 574: Liver Disease Management TeleECHO Improves Provider Knowledge and Care of Patients
  • 575: Time series analysis to estimate when hepatitis C infection will no longer be a major public health problem in prisons in Catalonia (Spain)
  • 576: Screening and treating hepatitis C virus infection in a residential substance use disorder program
  • 577: Advancements in the Cascade of Care for Hepatitis C Virus Infection within the U.S. Department of Veterans Affairs
  • 578: Creating and testing usability of an mHealth tool using targeted messages to affect HCV treatment decisions in HCV+ methadone patients
  • 579: Real-world treatment for hepatitis C in the unrestricted direct-acting antiviral era – comparing liver clinic and community outcomes
  • 580: Impact of a Hepatitis C Virus Screening Alert for Baby Boomers in a Regional Health System
  • 581: Project ECHO in Australia: A novel tele-mentoring service to aid Hepatitis C treatment in difficult to access populations
  • 582: A dedicated hostel-based community liver service for Homeless and Vulnerable Adults: VALID (Vulnerable Adults LIver Disease) Study
  • 583: Evaluation Of Access To NAFLD-Related Care Offered By Primary Providers: Single Center Experience
  • 584: Factors preventing testing for chronic viral hepatitis (CVH) in UK South-Asians - A novel National Institute for Health Research (NIHR) Study in a high risk group
  • 585: Low Rates of Retention into Hepatocellular Carcinoma (HCC) Surveillance Program After Initial HCC Screening Examination
  • 586: The role of race, socioeconomic variables and insurance type in the access of Hepatitis C treatment
  • 587: Socioeconomic Disparities in the Relationship between Serious Psychological Distress and Chronic Liver Disease: Analysis of the 2014-2015 National Health Interview Survey
  • 588: Factors Affecting Awareness of Hepatitis C Virus Infection: National Health and Nutrition Examination Survey 2003- 2012
  • 589: Prevalence and predictors of complementary and alternative medicine modalities in patients with chronic hepatitis B
  • 590: Healthcare Provider and Payer Perceptions of Optimism, Challenges, and Strategies for Achieving National Goals for Hepatitis C Virus Elimination
  • 591: Cirrhosis related diagnostic codes for health services research
  • 592: The fragility of liver related randomized clinical trials
  • 593: The Quality of Transjugular Liver Biopsies is Operator Dependent
  • 594: Nationwide Estimates and Risk Factors of Readmission in Patients with Cirrhosis in the United States
  • 595: The Impact of Nursing Volume on In-hospital Mortality Among Patients with Cirrhosis: A Population-based Study
  • 596: Algorithm for identification of patients at high risk for cirrhosis from administrative data
  • 597: Barriers to Treatment of Chronic Hepatitis C with Direct-Acting Antivirals in an Urban Clinic
  • 598: Epic Babyboomer Reminders Increase Screening by 10 Fold
  • 599: Screening For Subclinical (Minimal) Hepatic Encephalopathy Among Asymptomatic Drivers With Chronic Liver Disease
  • 600: Chronic Liver Disease and Impaired Physical Function: the Role of Gender, Income and their Interaction
  • 601: Antenatal Clinic: The ideal screening platform for alcohol related harm
  • 602: Characteristics and Outcomes of Hepatocellular Carcinoma (HCC) differ in Black versus White patients: a 15-Year Large Transplant Center Experience
  • 603: Being Accompanied to the Post Discharge Visit: An Easy Measure to Identify Potential Liver Transplant Candidates Among Patients Initially Considered Ineligible
  • 604: The Effect of Curative Treatment Delay on Recurrence in Hepatocellular Carcinoma at a Non-Transplant County Hospital Setting
  • 605: Factors that Predict 30 Day Readmission in Patients with Hepatic Hydrothorax
  • 606: Hepatitis C Virus (HCV)-Infected Patients Receiving Opioid Substitution Therapy (OST) Experience Significant Increases in Patient-Reported Outcomes (PROs) Following Treatment with Anti-Viral Regimens
  • 607: Out-of-Pocket Costs for Hepatitis C Virus Treatments
  • 608: Doctors in jails: a proof of concept for tackling hepatitis C in prisons
  • 609: Hepatitis C treatment outcomes in a pharmacist-managed clinic in a rural tribal health system

Imaging and Noninvasive Fibrosis Assessment

  • 610: Bimodal Targeted Near Infrared/Positron Emission Tomography Contrast Agent to Image Liver Fibrogenesis
  • 611: New blood test multi-targeted for liver fibrosis outperforms elastometry for most outcomes
  • 612: Multi-Biomarker Validation of MRI-PDFF- and MRE-Derived Treatment Response With BMS-986036 (peg-FGF21): A Secondary Analysis of a Multi-center Clinical Trial in Non-Alcoholic Steatohepatitis (NASH)
  • 613: Assessment of non invasive markers of fibrosis against collagen quantitation and NASH-CRN scoring in liver biopsies of NAFLD patients
  • 614: Is liver biopsy still necessary in evaluating HCV infected kidney transplant candidate?
  • 615: Obesity predicts discordancy between magnetic resonance elastography and transient elastography for the stage of fibrosis in patients with nonalcoholic fatty liver disease
  • 616: Optimization of 99mTc Sulfur Colloid SPECT for the Functional Liver Assessment in Patients with Decompensated Cirrhosis: Correlation with Indocyanine Green and Clinical Scores.
  • 617: Non-viral Liver Disease Burden in HIV Mono-infected Individuals: A Prospective Cohort Study
  • 618: Multiparametric magnetic resonance imaging can quantitatively assess fibroinflammatory response to direct acting antiviral treatment of hepatitis C virus.
  • 619: Analysis of biomarkers predictive of fibrosis progression in patients with Fontan associated liver disease
  • 620: Pattern recognition and quantification of hepatic fibrosis in NASH preclinical models using deep-learning based image analysis
  • 621: Quantification of fibrosis staging and collagen proportionate area in NASH pre-clinical models using a fully automated deep-learning approach
  • 622: Real time two-dimensional shear wave elastography in patients with acute hepatitis
  • 623: Transient Elastography Changes During Hepatitis C Treatment with Novel Agents
  • 624: Evaluation of the Liver’s Function and Physiology Using HepQuant SHUNT to Potentially Differentiate Irreversible from Reversible Hepatic Impairment in Patients with Chronic Passive Hepatic Congestion Secondary to Fontan Circulation
  • 625: Reduced hepatocyte uptake of Gd-EOB-DTPA in chronic liver disease is not related to lowered expression of hepatocyte transporters: a radio-pathologic study.
  • 626: Quantitative Non-invasive Assessment of Liver Disease in Preclinical Models Using Multiparametric MR Imaging: A Feasibility Study
  • 627: Quantitative characterization of liver fibrosis in a mouse model of infection by Schistosoma mansoni using molecular MR imaging
  • 628: Transient Elastography with Controlled Attenuation Parameter (CAP) a tool for liver disease screening in type II diabetes mellitius patients
  • 629: Evaluation of blood perfusion in liver cirrhosis by dynamic contrast enhanced computed tomography
  • 630: The impact of liver stiffness measured by MR elastography to predict liver related events after eradication of hepatitis C virus
  • 631: Optimal threshold of controlled attenuation parameter with MRI-PDFF as the gold standard for the detection of hepatic steatosis
  • 632: Evaluation of liver disease severity by transient elastography in patients with short bowel syndrome (SBS) receiving long-term parenteral nutrition
  • 633: Improvement of fibrosis is associated with the decrease of collagen III formation biomarker Pro-C3 in patients with non-alcoholic steatohepatitis
  • 634: Comparison of YKL-40, FIB-4, APRI against Shear Wave Elastography to assess the stage of liver fibrosis in chronic Hepatitis C and chronic Hepatitis B patients
  • 635: Computed tomography-measured liver volume predicts stage of hepatic fibrosis
  • 636: Liver stiffness measurement with Fibroscan: Use the right probe in the right condition!
  • 637: Evaluation of liver stiffness, APRI and FIB-4 scores in end-stage renal disease patients with chronic hepatitis B viral infection
  • 638: Influence of intense exercise on hepatic stiffness values as measured by transient elastography.
  • 639: Portal-systemic Shunt Fraction measured by the HepQuant-SHUNT Test Correlates with the Hepatic Venous Pressure Gradient (HVPG)
  • 640: Practicality of Using Vibration Controlled Transient Elastography (VCTE) in Outpatient Hepatology Clinic – Number of Attempts and Time Needed to Obtain Reliable Liver Stiffness Measurement
  • 641: Assessment of liver fibrosis in non-viral liver disease patients using acoustic radiation force impulse elastography
  • 642: Impact of vitamin D supplements on liver stiffness and aminotransferase activities in patients with chronic liver diseases

Innate Immunity

  • 643: Effects of Acute-Phase Proteins in Mediating Hepatic FXR’s Protection of Mice from NASH Development
  • 644: EpCAM-high liver cancer stem cells resist natural killer cell-mediated cytotoxicity by upregulation of cell surface CEACAM1 in hepatocellular carcinoma
  • 645: Overexpression of FoxM1 transcription factor in murine hepatocytes results in hepatocyte death and liver inflammation.
  • 646: Female hormone enhances hepatic innate and autoimmune responses against double-stranded RNA
  • 647: Systemic Neutrophils of Non-alcoholic steatohepatitis (NASH) patients inhibit T cell response
  • 648: Alpha-1 Antitrypsin improves engraftment in a rat model of hepatocyte transplantation through inhibition of the innate immune system
  • 649: A Novel inhibitory NK cell subpopulation is expanded in Cirrhosis
  • 650: Immunological Changes In Portal And Systemic Blood In Compensated HCV Associated Chronic Liver Disease
  • 651: Plasmacytoid dendritic cells are a cellular target of chronic alcohol-induced immune dysregulation.
  • 652: Myeloid PTEN Deficiency Promotes Akt/Stat1/IDO signaling and Alleviates Acetaminophen-Induced Liver Injury
  • 653: Role of miR-301b in arsenic-altered macrophage polarization: Potential insight into impact of arsenic exposure on innate immune response
  • 654: Circulating Natural Killer cells in Hepatocellular Carcinoma are hypofunctional with an exhausted phenotype
  • 655: Increased frequency of myeloid-derived suppressor cells in patients with non-alcoholic fatty liver disease
  • 656: Mapping the heterogeneity of circulating neutrophils in Hepatocellular Carcinoma.
  • 657: Macrophages from NLRP3 and Caspase-1 null mice exhibit reduced inflammasome activation, altered expression of M1/M2 markers and oxidative stress, ER stress and autophagy genes in response to iron: Role for NLRP3 inflammasome in iron-mediated liver injury.
  • 658: The week 1/week 0 Frequency Ratio of Peripheral CD1d+ NKT cell can be Biomarker for Steroid Therapy in Patients with Severe Alcoholic Hepatitis.
  • 659: A novel hepatic stellate cells ligand β-neurexin in NAFLD liver biopsy as a potential NK cell therapy
  • 660: Effects of pituitary adenylate cyclase-activating polypeptide (PACAP) on the hepatic macrophages in septic peritonitis in mice.
  • 661: Monocyte HLADR expression and Neutrophil based Sepsis Index in patients with and without Spontaneous bacterial peritonitis (SBP)
  • 662: The frequencies of total mucosal associated invariant T (MAIT) cells are significantly altered both in blood and liver of patients with primary sclerosing cholangitis
  • 663: Evaluation of dextran-based nanoparticles for hepatic macrophage repolarization in liver cancer
  • 665: Fibrinogen-Like Protein 2 Inhibits IL-12 Production By Peritoneal Macrophages
  • 666: Nod-like receptor family, pyrin domain containing 6 (NLRP6) correlated with the progression and therapeutic outcome of hepatocellular carcinoma

Mechanisms of Injury

  • 667: RIP3-MLKL-mediated Necroptosis in Hepatic Ischemia and Reperfusion Injury of Steatotic Livers
  • 668: Alcohol binge induces neutrophil extracellular traps and impairs stimulation-induced NET formation and macrophage efferocytosis in severe sepsis in mice
  • 669: Acute adipocyte death causes liver inflammation and injury via the activation of macrophages: insight from a novel model of specific adipocyte death
  • 670: Neutrophil extracellular trap mediate mitochondrial biogenesis in cancer cells to promote growth of metastases
  • 671: Progressive Impairment of Immune Reserves in Different Stages of Cirrhosis And in Sepsis
  • 672: The Interrelationships between PNPLA3 Variants, BMI, Liver-Related Apoptosis and Oxidative Stress in HIV+ Adults from the (Miami Adults Studies in HIV) MASH Cohort
  • 673: Extracellular vesicles induce renal tubular cells apoptosis, oxidative stress and functional abnormalities in patients with an acute decompensation of cirrhosis
  • 674: Alcohol consumption suppresses T cell response in ALDH2-deficient individuals: Roles of corticosterone and acetaldehyde
  • 675: Tumor Necrosis Factor-producing Regulatory T Cells are Associated With Severe Liver Injury in Patients With Acute Hepatitis A
  • 676: Liver immune microenvironment in the pathogenesis of chronic HBV and HCV infection: Th17/Treg interplay related to fibrosis

Molecular and Stem Cell Biology

  • 677: Long-Term Disease Correction and Reduced Liver Tumorigenesis Using Hybrid Recombinant AAV-Piggybac Transposon Mediated Gene Therapy in the Progressive Familial Intrahepatic Cholestasis Type 3 (PFIC3) Mouse Model in vivo
  • 678: Development of mouse models for hepatocellular carcinoma and intrahepatic cholangiocarcinoma induced by activated TAZ.
  • 679: Hepatocyte-derived Osteopontin drives the development of Hepatocellular Carcinoma
  • 680: microRNA mediated interaction of TGF-β/RECK signaling pathway in hepatic stellate cells during alcoholic liver injury
  • 681: Dissection of genomic and transcriptomic profiles of patient-derived liver cancer cells enables therapeutic target identification
  • 682: CRISPR/Cas9-mediated genetic correction of Familial Hypercholesterolemia type IIA patient-specific induced pluripotent stem cells restores LDLR functionality and promotes productive hepatitis C virus (HCV) infection after hepatocytic differentiation
  • 683: Long-term Gene Expression and Effective Prevention of Liver Fibrosis by Liver-Specific Delivery of Oligonucleotide Therapeutics
  • 684: MDM2 inhibition for non-genotoxic activation of TP53 – a novel strategy for the treatment of hepatocellular carcinoma (HCC)
  • 685: The AMPK-related kinase SNARK inhibitor disulfiram exhibits anti-HCV/HCC properties
  • 686: Prohibitin 1 Regulates Interleukin-8 Expression in Multiple Human Cancers
  • 687: Regulation of cellular senescence by long non-coding RNA transcribed from an ultraconserved region during alcoholic liver injury
  • 688: Pericentral hepatocytes produce IGF-2 to promote liver regeneration during special injuries
  • 689: Aberrant unfolded protein response (UPRMT) reflects premature hepatocyte senescence in cirrhotic liver and ClpP overexpression attenuates senescence
  • 690: Anti-miR-32-5p therapy reverses multidrug resistance in hepatocellular carcinoma through inhibiting the PI3K/Akt pathway.
  • 691: Hepatitis E virus infection induces mitochondrial fusion to facilitate viral replication
  • 692: Human and Baculovirus-Insect Manufacturing Platforms Generate Chemically and Functionally Distinct AAV Vectors with Sexually Dimorphic Liver Transduction.
  • 693: Human Homologue of Maid contributes to DNA damage response pathway in HCC.
  • 694: Alterations in the NO-cGMP pathway may contribute to the development of portal hypertension: Results of a study in rats with liver fibrosis/cirrhosis
  • 695: Dysregulation and functional roles of microRNA-133b in hepatocellular carcinoma
  • 696: Rescue of the Epigenetically Silenced microRNA miR-493-5p Inhibits Liver Cancer Progression
  • 697: Temporal adaptations and transcriptional reprogramming in mice liver after systemic deletion of c-MET
  • 698: Inducible Knockdown of c-Jun N-terminal Kinase-2 (Jnk2) in hepatocytes has a stage dependent effect on disease progression.
  • 699: New insights on the role of endoplasmic reticulum stress response in development of hepatocellular carcinoma
  • 700: Pten Deletion in SOX9+ Hybrid Periportal Hepatocytes (HybHP) Leads to the Development of Cholangiocarcinoma (CC)
  • 701: Lack of β-catenin in Hepatocytes Impairs Proliferation and Promotes Liver Progenitor Cell-Mediated Repair in Response to the Choline-Deficient Ethionine-Supplemented Diet
  • 702: Generation of functional human hepatocyte-like cells from Bone Marrow Mesenchymal Stem Cells by defined factors
  • 703: Gene Expression Profile of Chaperones in ATTR-derived Hepatocyte-like Cells
  • 704: Loss of trefoil factor 1 inhibits biliary regeneration but accelerates the differentiation of hepatic progenitors into hepatocytes in mice
  • 705: Engineering Advanced Biliary Organoids with Mesenchymal Niche from Human Induced Pluripotent Stem Cells
  • 706: Fn14 and Wnt Signaling Pathway Crosstalk Controls Liver Progenitor Expansion in 3D Organoid Culture
  • 707: Synergistic effects of simvastatin and bone marrow-derived mesenchymal stem cells on hepatic fibrosis
  • 708: Hedgehog agonist HhAg1.5 mediated reprogramming breaks the quiescence of non-injured liver stem cells for rescuing liver failure
  • 709: Interleukin-27 / WSX-1 axis: A potential prognostic factor for Hepatocellular carcinoma

Organ Preservation and Cell Transplantation

  • 710: Biliary fibrosis promotes multi-lineage differentiation of ectopically transplanted fetal liver cells
  • 711: Lymphopenia in Waitlist Treatment Naïve HCC Patients is Associated with Increased Myeloid-Derived Suppressor Cell Expansion and Decreased Tumor Response to Doxorubicin-Eluting Bead Transarterial Chemoembolization
  • 712: Towards Long-Term Vascular Patency of Tissue Engineered Liver Grafts, a Large Animal Study
  • 713: Targeting Kupffer Cell Polarization as Strategy to Ameliorate Liver Ischemia-Reperfusion Injury in a Mouse Model
  • 714: Proof-of-concept demonstration of the hepatoprotective effect of small-molecule cyclophilin inhibitors mediated by inhibition of mitochondrial permeability transition pore opening in the context of hepatic ischemia-reperfusion injury
  • 715: Histone Deacetylase Inhibition Mitigates Liver Ischemia/Reperfusion Injury in Mice
  • 716: The delivery of stem cell therapy to extended criteria donor human livers using normothermic machine perfusion
  • 717: Allogeneic transplantation of MUSE cell ameliorates liver regenerations in large animal models of chronic liver injury.

Patient Centered Outcomes Research

  • 718: Colder and Darker Climates Increase the Weight of Alcohol As A Cause of Cirrhosis Both in the United States and Worldwide
  • 719: Gender Disparities in Liver Transplant Candidates with Non-Alcoholic Steatohepatitis.
  • 720: Seroprevalence of HEV infection in patients on maintenance hemodialysis: A systematic review and meta-analysis of observational studies
  • 721: Relationship between Neurocognitive Performance (NCP) and Patient-Reported Outcomes (PROs) in Patients with Genotype 1 (GT1) Hepatitis C Virus (HCV) With or Without Viremia
  • 722: Modified NUTRIC Score Guided Aggressive Nutrition Therapy Significantly Decreased 15 Day Mortality in Critically ill patients in Liver Intensive Care Unit
  • 723: Low Calorie High Protein Diet and Brisk Walking Results in Fat Loss but Maintains Muscle Mass in Obese Cirrhotics
  • 724: Bioelectrical Impedance Analysis is in Close Agreement with Computed Tomography for the Assessment of Muscle Mass, Total Body Fat and Visceral Fat in Obese Cirrhotics
  • 725: The CT Scan as Crystal Ball: Analytic Morphomics Predicts Mortality in Patients with Chronic Liver Disease
  • 726: French Hepatitis C (HCV) Patients Treated with Anti-viral Combinations Containing Pegylated Interferon (IFN), Ribavirin (RBV), Sofosbuvir (SOF), Ledipasvir (LDV), Velpatasvir (VEL) and/or Voxilaprevir (VOX): The Impact of Treatment on Patient-Reported Outcomes (PROs)
  • 727: Food Insecurity in Nonalcoholic Steatohepatitis (NASH): Results of Community Survey
  • 728: Polypharmacy is Associated with High-Risk Medication-Related Problems in People with Decompensated Cirrhosis
  • 729: Risk factors for 30-day readmission for cirrhosis in the National Readmission Database (NRD)
  • 730: Mental and physical health-related quality of life in patients with Hepatitis C is related to baseline co-morbidities and improve only marginally with hepatitis C cure
  • 731: The Effects of Multiple Chronic Comorbidities on the Health Status of US Adults with Chronic Liver Disease: Results from the 2014-2015 National Health Interview Survey
  • 732: Establishing an Alcohol Liaison Service (ALS): Provision of tailored care and Improvement in Clinical Outcomes
  • 733: Hospitalization In Hepatology Dedicated Wards Is Associated With Lower Rates Of Readmission
  • 734: A novel digital medicine offering to assess and optimize adherence for oral hepatitis C treatment
  • 735: Patient Reported Outcomes Assessment improves Quality of Life in Patients with Cirrhosis
  • 736: Racial Disparities in the Association between Illness Related Work Limitations and Chronic Liver Disease: A population Based Study of US Adults
  • 737: Health-Related Quality of Life (HRQL) in East Asian Patients with Hepatitis C Virus (HCV) Infection: The Impact of Treatment and Sustained Virologic Response (SVR)
  • 738: The Use of Metformin Reduces the Burden Of Chronic Liver Diseases in Hispanic Veterans with Type 2 Diabetes
  • 739: National Drug Overdose Epidemic is a Significant Contributor to Deceased Donor Liver Organ Pool
  • 740: Is an Active Search Program for HCV useful to increase the rate of treatment?
  • 741: Assessing Patient Preferences for and Relative Importance of Features of New Direct Acting Antiviral (DAA) Treatments for Chronic Hepatitis C Virus (HCV) Infections
  • 742: Outcome of the implementation of an electronic alert-system for HBV and HCV screening prior to chemotherapy: results from a prospective study.
  • 743: Combined Elimination of Met and EGFR Signaling Attenuates Hepatomegaly and Hepatocyte Proliferation Induced by TCPOBOP (1,4-Bis [2-(3,5-Dichloropyridyloxy)] Benzene) in Mice
  • 744: Ammonia induces an oxygen-independent stabilization of hypoxia inducible factor-1α (HIF1α) and its consequent signaling responses via mTORC1
  • 745: Identifying a novel function for hepatic Fxr-Shp axis in regulating glycosylation
  • 746: Nuclear expression of Chibby is associated with prognosis in hepatocellular carcinoma patients with β-catenin nuclear accumulation
  • 747: Serum Cytokine Profiles Predict Survival Benefits in Patients with Advanced Hepatocellular Carcinoma Treated with Sorafenib: a Retrospective Cohort Study
  • 748: Epidermal growth factor receptor inhibition is a conserved mechanism for environmental pollutants in nonalcoholic fatty liver disease
  • 749: Prescription of FuZheng JieDu Xiaoji influence the progression of HCC by regulating PKB-P21/P27 pathway.
  • 750: Loss of tumor suppressor PDCD4 induced cellular senescence in human hepatoma cells
  • 751: Serum tricarboxylic acid cycle intermediates: potential biomarker for hyperammonemic metabolic dysregulation in human cirrhosis
  • 752: Dichloroacetic Acid Promotes Hepatocellular Carcinoma Cell Apoptosis via Reactive Oxygen Species Production
  • 753: Nuclear receptor coactivator 5 promotes HCC cell apoptosis by targeting IL6/STAT3 pathway
  • 754: Androgen Enhances the Activity of E26 transformation specific sequence 1 (ETS-1) and Promotes the Proliferation of HCC Cells
  • 755: Cerium oxide nanoparticles improve liver repair after acetaminophen treatment and two-thirds partial hepatectomy in rats

Training and Education

  • 756: Entrustable Professional Activities (EPAs) for Transplant Hepatology
  • 757: Authorship Gender Disparity in Hepatology Medical Literature: Why Are Women Silent?
  • 758: Can We Accurately Assess the Spectrum of Hepatic Encephalopathy (HE) Stages? A Multi-Center Initiative using Standardized Simulated Patients.
  • 759: Spanish Women Hepatologists: Breaking The Glass Ceiling?

Poster Session II: Saturday, October 21, 2-7 pm

Presentation time 5:30–7:00 pm

Cost-Effectiveness and Economics of Care; Health Economics and Cost-effectiveness of Viral Hepatitis

  • 760: Role of HEV antigen detection for diagnosis of acute hepatitis E
  • 761: Network Meta-Analysis of Treatments for Unresectable Hepatocellular Carcinoma
  • 762: Cirrhotic patients with acute respiratory illness in the United States encounter substantial hospital charge burden
  • 763: Cost-effectiveness of HCV Treatment Models for People Who Inject Drugs in Opioid Agonist Treatment Programs
  • 764: Health Outcomes And Costs Associated With The Implementation Of A National Treatment Plan For Hepatitis C In Spain
  • 765: The Cost-effectiveness of General Population HCV Screening in India
  • 766: Multidimensional burden of disease in chronic liver disease patients
  • 767: Cirrhosis Related Hospitalizations Are Mostly Due To Chronic Hepatitis C Virus and Largely Paid For By Medicare and Medicaid: An Analysis of 2007-2013 Nationwide Inpatient Sample Data
  • 768: HCV Treatment with Direct-Acting Antivirals in India is Cost-Saving
  • 769: Changes in HCV presentation and the new unmet need challenge

Drug Induced Liver Toxicity 

  • 770: The diurnal variation of acetaminophen induced hepatotoxicity is dependent on the gut microbiota in mice
  • 771: Innate Lymphoid Cells Type 1 and 2 are Expanded in Early Stages of Hepatocellular Carcinoma In A Novel Murine Model Close to Human Hepatocarcinogenesis
  • 772: Vinyl Chloride exacerbates liver injury induced by high-fat diet via causing ALDH2 dysfunction in mice
  • 773: Human circRNA-0046367 prevents hepatoxicity of lipid peroxidation: an inhibitory role against hepatic steatosis via miR-34a-5p/PPARα signaling
  • 774: Alcohol Exacerbates HIV Infection In Liver Cells: Possible Mechanisms
  • 775: Evaluation of CXCL-8 in patients with alcoholic liver disease
  • 776: Vinyl chloride inhalation causes mitochondrial dysfunction and exacerbates experimental fatty liver disease in mice.
  • 777: “Jacked” or Jaundiced: Is it worth it?
  • 778: Different diagnostic criteria for inactive HBsAg carriers (IC) in patients with HBeAg-negative chronic hepatitis B virus (HBV) infection:correlation to Liver histological features and diagnosis
  • 779: Case Report: Pembrolizumab Induced Hepatotoxicity Attenuated by Low Dose External-Beam Radiation

Genetic and Metabolic Liver Disease 

  • 780: Double Deletion of Pink1 and Parkin Eliminates Compensatory Effects of a Single deletion of Pink1 or Parkin on Acetaminophen-Induced Mitophagy and Liver Injury
  • 781: IL-22 Alleviates Acetaminophen Induced Liver Injury by promoting autophagy through AMPK in mice
  • 782: MCU, the Core Protein of the Electrogenic Mitochondrial Calcium Uniporter, is Required for Iron Translocation from Cytosol into Mitochondria But Not for Activation of c-Jun N-Terminal Kinase (JNK) during Acetaminophen Hepatotoxicity
  • 783: Hepascore predicts liver cirrhosis and total mortality in long-term methotrexate users
  • 784: Magnetic resonance imaging findings in the patients with pyrrolizidine alkaloids-induced Hepatic Sinusoidal Obstruction Syndrome
  • 785: Role of Pregnane X receptor in binge ethanol-induced steatosis and hepatotoxicity
  • 786: Profiling the endogenous and xenobiotic metabolome in a porcine model of acetaminophen induced acute liver failure
  • 787: Novel Oxysterol Sulfates Alleviate Injured Liver Function and Decrease Mortality in Mouse Models
  • 788: Zoledronic Acid suppresses tumour associated macrophages and myeloid derived suppressor cells boosting immune modulating therapies against murine HCC
  • 789: Plasma cytokeratin-18 (CK18-M65) and circulating APOA1 mRNA are novel biomarkers of liver damage that define human-specific toxicity in humanized liver mouse models
  • 790: Immunosuppressive Therapy Using Prednisone and Azathioprine Promoted Disease Remission in Patients with Drug-induced Liver Injury, Whose Liver Biopsy Showing Bridging or Multi-acinus Necrosis
  • 791: Combined treatment with Rapamycin and Zoledronic Acid strongly inhibits growth of murine hepatocellular carcinoma via activation of the immune microenvironment
  • 792: CTAE and Verbascoside Protect Against Hepatotoxicity and Ameliorates Hypercholesterolemia in db/db Mice
  • 793: Prevalence of hepatitis E markers in Spanish patients with suspected drug-induced liver injury
  • 794: Prediction of Cholestatic Hepatotoxicity: Integration of Transporter Inhibition and Interference with the FXR Mediated Adaptive Response to Bile Acids
  • 795: Incidence and Predictors of Acute Kidney Injury following Drug Induced Liver Injury
  • 796: Higher rates and significant disparities in the risk and phenotypes of amoxicillin:clavulanate-related liver injury were observed in the Veterans Health Administration (VHA)
  • 797: Pathological Injury Pattern Is Associated with Clinical Course Better than Clinical Classification Determined by R-value in Patients with Drug-induced Liver Injury
  • 798: The impact of age on phenotype presentation and severity in patients with idiosyncratic drug-induced liver injury (DILI)
  • 799: Development of hepatic steatosis after chemotherapy for non-Hodgkin lymphoma
  • 800: Phase 1, Randomized, Placebo Controlled Study of Givosiran, an Investigational RNA Interference (RNAi) Therapeutic, in Patients with Acute Intermittent Porphyria: Interim study results
  • 801: Heterozygous Carriage of the Alpha1-antitrypsin PiZ Variant Increases the Risk to Develop Liver Fibrosis
  • 802: An Ongoing Extension of a Phase 2 Study of WTX101 in Newly Diagnosed Wilson Disease Patients
  • 803: European Cohort Reveals Liver Fibrosis and Steatosis in Adults with Homozygous Alpha1-antitrypsin Deficiency (PiZZ Genotype)
  • 804: A simple clinical and biological score to promote and enhance Ferroportine disease screening.
  • 805: Long-term performance of implanted bioprinted human liver tissue in a mouse model of human alpha-1 antitrypsin deficiency
  • 806: Non-HFE variation in Chinese patients with primary iron overload: recurrent HJV variants in the signal peptide region
  • 807: Breath Volatile Organic Compounds are Novel Biomarkers to Differentiate Glycogen Storage Disease from Nonalcoholic Fatty Liver Disease
  • 808: Sequence analysis of exon 1 of the ferritin light chain (FTL) gene can reveal the rare but benign diagnosis of ‘hereditary hyperferritinaemia without cataracts’
  • 809: Long-term Benefit of Sebelipase Alfa Over 100 Weeks in Children and Adults With Lysosomal Acid Lipase Deficiency (ARISE study)
  • 810: UK Biobank Study of Liver Iron Overload Shows Variable Penetrance of Different Genotypes
  • 811: Fatty Liver is the Hepatic Manifestation of Spinal and Bulbar Muscular Atrophy (SBMA), a Genetic Disorder of the Androgen Receptor
  • 812: Hepatic involvement in telomere disease increases morbidity and mortality.
  • 813: Bevacizumab (Avastin) Treatment for severe pulmonary Hypertension and High Cardiac Output Failure Secondary to Liver involvement in Patients with Hereditary Hemorrhagic Telangiectasia
  • 814: Epigenetic regulation of thioredoxin system in an animal model and in patients with Wilson disease
  • 815: Risk and risk factors of hepatocellular carcinoma in patients with HFE-related hereditary hemochromatosis
  • 816: Decompensated Wilson’s disease: Advanced Hepatic Encephalopathy and High Bilirubin decide the need for Liver Transplantation. Does the New Wilson’s index help?
  • 817: Long-term Benefit of Sebelipase Alfa Over 96 Weeks in a Diverse Population of Children and Adults With Lysosomal Acid Lipase Deficiency
  • 818: Excretion of WTX101 (bis-choline tetrathiomolybdate) after intravenous administration in rat models
  • 819: Ribosomal Stalling Causes Wilson Disease in Patients with Synonymous ATP7B Variant
  • 820: Screening of Novel Small Molecules Targeting Z Variant Alpha-1-Antitrypsin Polymerization in Hepatocytes, Using In Silico Molecular Docking Technology
  • 821: Activated Phosphoinositide 3 kinase d syndrome (APDS) – exploring liver involvement in a newly discovered disease.
  • 822: Upregulation of miR-34c driven by JNK and FOXO3 in livers expressing mutant Z α1-antitrypsin.
  • 823: Advanced liver fibrosis is uncommon among adults with alpha 1-antitrypsin deficiency and severe pulmonary manifestation, while heterozygosity for the Z allele predisposes for clinically significant portal hypertension
  • 824: Change in Liver Histopathology in a Diverse Population of Children and Adults With Lysosomal Acid Lipase Deficiency After 48 and 96 Weeks of Sebelipase Alfa Therapy
  • 825: Liver function tests and pattern of hepatic injury in glycogenic hepatopathy associated with insulin-dependent diabetes mellitus: A systematic review and analysis of 172 cases
  • 826: 5-Aminolevulinate Dehydratase Porphyria (ADP): Evidence for Hepatic ALAS1 Induction
  • 827: Clinical presentation and outcome of Wilson’s disease patients in a monocentric cohort of liver reference center
  • 828: EXPLORE: A Prospective, Multinational Natural History Study of Patients with Acute Hepatic Porphyria (AHP) with Recurrent Attacks
  • 829: Significant heterogeneity in the diagnosis and management of Wilson Disease (WD): results from a large Spanish Registry.
  • 830: Pertinence of liver stiffness measurement in patients with Wilson's disease for assessment of initial fibrosis and treatment follow-up
  • 831: Factors Protective Against the Formation of Liver Cysts in Autosomal Dominant Polycystic Kidney Disease

Gut Liver Axis and Microbiome

  • 832: Integrated collaboration of intestinal microbiota induces bacterial translocation and Th17 immune response in primary sclerosing cholangitis
  • 833: Altered Gut Microbiota at Hospitalization are Associated with ACLF, type of Organ Failure, and Death in a Multi-Center North American Cohort
  • 834: Commensal gut microbiota modulates susceptibility to acetaminophen-induced hepatotoxicity.
  • 835: Antibiotic Depletion Reveals Multifaceted Protective and Detrimental Effects of Resident Microbiota on Hepatobiliary Inflammation and Fibrosis in a PSC mouse model
  • 836: Gut microbiota-mediated changes in liver bile acids composition elicit mTOR signaling.
  • 837: Eradication of chronic HCV infection is associated with improvement of dysbiosis in the intestinal microbiota
  • 838: Intestinal type I NKT cells migrate to the liver and contribute to hepatocyte apoptosis during alcoholic liver disease
  • 839: Nicotinamide N-methyltransferase regulates hepatic immunity via gut-liver axis
  • 840: Lactobacillus Casei Shirota (LCS; Yakult) vs Placebo in patients with well-compensated cirrhosis: A double-blind, randomized controlled study
  • 841: Gut microbiome of alcoholic hepatitis patients is disparate from those of alcoholic pancreatitis and both being distinct from respective healthy controls
  • 842: Gut dysbiosis and altered plasma short chain fatty acid profile underlie the pathogenesis of nonalcoholic steatohepatitis
  • 843: Impairment of 25-hydroxylation of Vitamin D Promotes Liver Fibrosis through Gut Dysbiosis
  • 844: Gut microbiota-driven IL-17 responses by intrahepatic γδ T cells mediates pathology of cholestatic liver disease
  • 845: Portal LPS Is Associated With Immune And Bile Acid Changes In The Portal Venous Circulation Across The Spectrum Of Chronic HCV-Associated Liver Disease
  • 846: Tauroursodeoxycholic acid modulates gut microbiota to inhibit intestinal inflammationin NAFLD mice
  • 847: The Role of Intestinal Reg3 lectins for Non-Alcoholic-Steatohepatitis
  • 848: Aldose Reductase Gene Shapes the Gut Microbiome and Contributes to Dietary Glucose Induced Hepatic Steatosis: Effect of Environment-host Genetics Interaction on the Pathogenesis of Hepatic Steatosis
  • 849: Intestinal Hypoxia-Inducible Factor 1α Depletion Exacerbates Acute Alcohol-Induced Liver Injury In DSS-Treated Mice Through CRAMP-Mediated Signaling
  • 850: Microbial Translocation in the Contexts of Hepatitis B Infection and Hepatitis D Infection
  • 851: A novel combined Gut Fungal and Bacterial metric, Bacteroidetes/Ascomycota ratio, is independently Associated with Hospitalization Risk in Cirrhotic Patients
  • 852: Gut microbiota hampers T cells immunity via the IFN-IL-10 axis during liver cirrhosis.
  • 853: DNA and RNA analysis of Gut microbiota in Cirrhosis Demonstrate Different profiles which can Predict Hospitalizations Independently
  • 854: Different intestinal microbiota profile in alcoholic pancreatitis as compared to alcoholic hepatitis
  • 855: Intestinal Microbiota Transplantation From HFD-fed and Quercetin Treated Donors Results in a Complex Metabolic Phenotype Transfer that Modulates Obesity-Related NAFLD in Germ Free Mice
  • 856: Effect of probiotics (Lactobacillus rhamnosus R0011 and Lactobacillus acidophilus R0052) on modulation of gut microbiota in the treatment of mild alcoholic liver disease
  • 857: Accumulation of free fatty acids in portal serum with elevated direct portal pressure in chronic HCV associated liver disease
  • 858: Alcohol-primed Hepatic Stellate Cell for Porphyromonas gingivalis Infection
  • 859: Gut microbiome influences clinical events and severity in patients with alcoholic hepatitis
  • 860: Epithelial Cell Junction miRNA Network in Metabolic Syndrome and Hepatic Steatosis

Hepatitis C: Virology, Pathogenesis, Immunology

  • 861: Identification of TACSTD2 as a novel host cofactor for hepatitis C virus entry
  • 862: The mechanism of lncRNA-IFI6 regulation of HCV infection
  • 863: mRNA for selenoprotein P, a hepatokine, binds RIG-I protein and inhibits the RIG-I-mediated type I interferon response
  • 864: Development of hepatocellular carcinoma after treatment with direct acting antivirals in hepatitis C virus-associated chronic liver diseases.
  • 865: MicroRNA-10a is associated with the impaired liver functions in patients with advanced stage of chronic hepatitis C
  • 866: CCR5+T cells homing to the liver exhibit Inflammatory and profibrogenic signatures in chronic HCV infected patients
  • 867: Characterization of Telomerase Mitochondrial Response to Oxidative Stress after HCV Infection
  • 868: Third-generation sequencing unveils the evolution of multi-drug resistant hepatitis C virus clones during direct-acting antiviral therapy.
  • 869: Pathogenic IgM memory B cells in hepatitis C-induced cryoglobulinemia vasculitis
  • 870: Osteopontin regulates IFN signaling and HCV replication in cancer stem cells
  • 871: Characteristic and prevalence of NS3, NS5A and NS5B resistance associated substitutions in DAA-naive and DAA-failed HCV-3 patients in Italy
  • 872: Is Hepatitis C virus infection associated with increased rate of malignancy other than B-cell lymphoma and HCC
  • 873: Induction of neutralization E2 antibody by immunization of recombinant E2 proteins
  • 874: Comprehensive study of macrophage populations in the liver and periphery upon hepatitis C virus clearance with interferon (IFN)-free direct-acting antiviral (DAA) therapy
  • 875: Chronic kidney disease and hepatitis C mutually advance liver and renal disease progression: real-world evidence from the United States
  • 876: Innate immune signaling is modulated by cellular microRNAs that are differentially regulated during DAA therapy in patients with chronic hepatitis C infection (HCV)
  • 877: Identification of Novel Variants in HLA Class II Region Related to HLA DPB1 Expression and Disease Progression in Patients with Chronic Hepatitis C
  • 878: DAA treatment failure is associated with Gt 3 HCV cirrhosis and the selection of NS5A resistance sequences (RAS) – implications for salvage therapy
  • 879: Different metabolic fingerprints between HCV and HBV patients: a possible interference of the two major hepatitis viruses in basal metabolism pathways.
  • 880: Interactive influences of polymorphic IFNλ genes on HCV immunity are determined by affinity-based effects of KIR on NK cell licensing and tuning
  • 881: Dynamic changes in IFNa and IFN-sensitive cytokines/chemokines vs. TH1/TH2 cytokines are different during hepatitis C virus (HCV) resolution with direct-acting antivirals (DAAs)
  • 882: IFN-free DAA therapy does not fully re-constitute the altered phenotype and function of HCV-specific CD8+ T cells but immune check-point inhibitions can selectively re-invigorate the functionality during chronic HCV.
  • 883: HCV And Alcohol-Induced Hepatocyte Apoptosis As A Trigger Of Liver Inflammation And Fibrosis
  • 884: CD4+ regulatory T cells in hepatocellular carcinoma with different etiologies
  • 885: Functional and structural constraints restrict the evolutionary space of hepatitis C virus NS3 protease variants
  • 886: Regulation of Hepatitis C Virus Infection by Long Non-Coding RNA
  • 887: Establishment of novel hepatitis C virus cell culture system using a genotype 2a strain with minimum modifications
  • 888: Antioxidant HDL function improves after sustained virological response in chronic HCV infected patients: Dysfunctional HDL as possible new mechanism for HCV-associated high cardiovascular risk.
  • 889: Estimating the contamination level that caused an outbreak of acute hepatitis C (AHC) transmitted by IV injection of contrast material during computerized tomography
  • 890: Inhibitory 3-Domain KIR (but not IL28B) interact with inhibitory 2-Domain KIR in HCV-associated cirrhosis development in a VA hepatitis C cohort
  • 891: Hepatitis C virus infection and risk of Parkinson disease: A Systematic review and Meta-analysis
  • 892: Changes in serum lipid profiles caused by three regimens of interferon-free direct-acting antivirals for patients infected with hepatitis C virus.
  • 893: IFN-λ3 induces dendritic cell maturation independently of type I IFN
  • 894: HCV-infected hepatocytes inhibit autophagic flux and suppress HCV replication through up-regulation of Rubicon expression.
  • 895: Circulating Kynurenic Acid Correlates with Improvement in the Fatigue Component of the FACIT Questionnaire in Chronic CH-C Patients Undergoing Treatment.
  • 896: Early and Late Changes in Natural Killer cells in Response to Ledipasvir/Sofosbuvir Treatment
  • 897: Hepatitis C Resistance-Associated Substitutions Among People Who Inject Drugs Treated With Direct-Acting Antiviral-Containing Regimens in the PREVAIL Study
  • 898: Multi-Target DAA Therapy is associated with resolution of T cell suppression marked by reduced T regulatory cells and Myeloid derived suppressor cells in HIV/HCV Co-Infected Patients
  • 899: Antiviral therapy in HCV infected patients prevents relapse of diffuse Large B cell Lymphoma
  • 900: The analysis of NS5A Resistance-Associated Substitutions (RAS): In vitro study of NS5A recombinant hepatitis C in infectious cell culture system for various RAS detected after treatment failure in chronic hepatitis C patients
  • 901: Telomere length in chronic hepatitis C infection is not associated with severity of liver disease.
  • 902: Impact of productive hepatitis C virus (HCV) infection and long-term exposure to alcohol, alone and in combination, on the unfolded protein response (UPR) in primary human hepatocytes
  • 903: HCV eradication still difficult for genotype 4r

Hepatitis B: New and Approved Treatment

  • 904: Improved Bone and Renal Safety at 1 Year after Switching from Tenofovir Disoproxil Fumarate (TDF) to Tenofovir Alafenamide (TAF): Results from 2 Phase 3 Studies in HBeAg-positive and HBeAg-negative Patients with Chronic Hepatitis B (CHB)
  • 905: Effect of Tenofovir Disoproxyl (TDF) on Hepatocellular Carcinoma (HCC) Incidence in Patients with Chronic Hepatitis B (CHB) compared to Untreated Patients: a Multicenter Study with Propensity Score Matching (PSM)
  • 906: Phase 1b clinical trial of TG1050 a novel HBV-targeted immunotherapy in NUC suppressed chronic hepatitis B (CHB) patients: safety and early immunological data following single administration
  • 907: Independent and Combinational Anti-HBV Effects of CRV431 and TXL in the HBV Transgenic Mouse Model
  • 908: Identification of a new class of HBV and HDV entry inhibitor, proanthocyanidin
  • 909: Hepatocellular Carcinoma in Patients with Hepatitis B Virus-Related Cirrhosis Treated with Entecavir vs Tenofovir
  • 910: The combination of entecavir and peginterferon alfa-2a in HBeAg-positive immune tolerant (IT) adults with chronic hepatitis B virus (HBV) infection: Results of the HBRN IT Trial
  • 911: Quantitative anti-HBc level is a robust predictor of relapse in chronic hepatitis B patients who discontinued nucleos(t)ide analogue treatment: a prospective study
  • 912: Peg-interferon alpha induces CD56bright natural killer cell mediated reduction of HBsAg in entecavir treated chronic Hepatitis B patients
  • 913: Kinetics of serum HBsAg and interferon inducible protein-10 (IP10) levels in non-cirrhotic HBeAg-negative chronic hepatitis B (CHBe-) patients who discontinue entecavir (ETV) or tenofovir (TDF) therapy: results from the prospective DARING-B study.
  • 914: Efficacy and Safety of Tenofovir Alafenamide (TAF) at 96 Weeks in Chronic HBV (CHB) Patients with Risk Factors for Use of Tenofovir Disoproxil Fumarate (TDF)
  • 915: Cytokines Induced by GS-9688, a Toll-Like Receptor 8 Agonist, Inhibit HBV RNA, DNA and Antigen Levels in Primary Human Hepatocytes
  • 916: Functional Activation of NK and CD8+ T Cells In Vitro by the Toll-Like Receptor 8 Agonist GS-9688
  • 917: Single Dose Safety, Tolerability, and Pharmacokinetics of AB-423 in Healthy Volunteers from the ongoing Single and Multiple Ascending Dose Study AB-423-001
  • 918: Safety, Tolerability and Pharmacokinetics of GSK3389404, an Antisense Oligonucleotide for the Treatment of Chronic Hepatitis B (CHB) Infection: A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation, First Time in Human Study
  • 919: AL-034 (or TQ-A3334), a Selective Toll-like Receptor 7 Agonists for the Oral Treatment of Chronic Hepatitis B Virus Infection
  • 920: Multiple Dose Study of GLS4JHS, Interfering With The Assembly Of HBV core particles, in Patients Infected with Hepatitis B Virus
  • 921: DARING-B: Discontinuation of effective entecavir (ETV) or tenofovir (TDF) therapy in non-cirrhotic HBeAg-negative chronic hepatitis B (CHBe-) patients: final results of a prospective Greek study
  • 922: Preclinical Profile of Potent Second Generation CpAMs Capable of Inhibiting the Generation of HBsAg, HBeAg, pgRNA and cccDNA in HBV Infected Cells
  • 923: Identification and characterization of HBV RNA destabilizers in vitro and in vivo
  • 924: Tenofovir Disoproxil Fumarate (TDF) Significantly Decreases Serum Lipoprotein Levels Compared to Entecavir (ETV) Nucleos(t)ide Analog Therapy in Chronic Hepatitis B Carriers
  • 925: Chronic kidney disease stage progression in 4,458 patients on nucleos(t)ide analogues for chronic hepatitis B – a propensity-score-matched cohort study
  • 926: Phase 1a Safety and Pharmacokinetics (PK) of ABI-H0731, a Novel Core Protein Allosteric Modifier (CpAM) For The Treatment of Chronic HBV Infection
  • 927: A Phase 2 Randomized Clinical Trial to Evaluate the Safety and Efficacy of Pegylated Interferon Lambda Monotherapy in Patients with Chronic Hepatitis Delta Virus Infection. Interim Results From the LIMT HDV Study
  • 928: CRV431 Blocks NTCP-Mediated Uptake of HBV and HDV Independently of Effects on Bile Acid Transport
  • 929: In Vivo Study of a LNP siRNA Investigational Agent Applied Sequentially with Immunomodulatory Treatments for Chronic Hepatitis B Infection
  • 930: Safety and Efficacy of Vesatolimod (GS-9620) in Patients with Chronic Hepatitis B (CHB) Who Are Not Currently on Antiviral Treatment
  • 931: Sequential combination therapy with IFN, rhIL-2 and therapeutic vaccine enhanced HBsAg loss and led to partial immune restoration in entecavir-suppressed CHB patients (the Endeavor study)
  • 932: Comparison of the incidences of HBsAg loss and hepatocellular carcinoma development between HBeAg-negative patients who discontinued or continued entecavir therapy
  • 933: A controlled clinical study of sequential combination therapy of interferon and lamivudine in children with immune-tolerant chronic hepatitis B
  • 934: Cessation of Nucleos(t)ide Analogue treatment after HBeAg seroconversion is associated with a 4-fold increased risk of relapse in cirrhotic compared to non-cirrhotic patients
  • 935: Regulation of antiviral CD8 T cell response by MMP mediated soluble CD100 releasing in HBV infection
  • 936: Persistence and adherence to nucleos(t)ide analogue treatment in chronic hepatitis B: a multi-center cohort study from the Greek national e-prescription database.
  • 937: Heteroaryldihydropyrimidine compound GLS4 regulates both assembly and disassembly of HBV capsids to inhibit cccDNA formation
  • 938: Long-term follow-up of peginterferon α treatment of HBeAg-positive chronic hepatitis B patients in phase III study of peginterferon α-2b (40kD, Y Shape) (Pegberon)
  • 939: Evaluation of Factors Associated with Differences in ALT Normalization between Virally Suppressed TAF- and TDF-treated CHB Patients
  • 940: The HBV capsid assembly modulator JNJ-379 is a potent inhibitor of viral replication across full length genotype A-H clinical isolates in vitro
  • 941: Higher Risk of Liver Cancer and Death in Immune-Tolerant Phase than Treated Immune-Active Phase of Chronic Hepatitis B
  • 942: Interaction of nucleic acid polymers with the large and small forms of the hepatitis delta antigen protein
  • 943: Pharmacokinetics, Safety and Antiviral Activity of Tenofovir exalidex(TXL), a Novel Prodrug of Tenofovir, Administered as Ascending Multiple Doses to HBV-Infected Subjects: A 28 Day Study Final Analyses
  • 944: HBV rtL180M+A181C+M204V mutations may lead to entecavir resistance in real-life clinical practice
  • 945: Usefulness of Stopping Rule and Clinical Predictors for Relapse after Cessation of Nucleoside Analogues in Chronic Hepatitis B Patients
  • 946: Mean week 24 HBsAg declines predict subsequent rate of HBsAg clearance and could be a valuable endpoint for early development HBV trials
  • 947: On-treatment higher levels of alpha-fetoprotein and M2BPGi are associated with development of hepatocellular carcinoma during nucleos(t)ide analog therapy in patients with HBV chronic infection
  • 948: Real World Applicability of Tenofovir Alafenamide in Chronic Hepatitis B
  • 949: Incidence and predictors for HBsAg seroclearance after cessation of Nuc therapy in HBeAg negative chronic hepatitis B patients
  • 950: A combined therapeutic vaccine for chronic HBV and HDV infections raising broadly crossreactive and neutralizing antibodies and genotype specific T cells
  • 951: Response-guided route map therapy can obviously elevate response for pegylated interferon alfa-directed therapy in chronic HBeAg-positive CHB patients
  • 952: Sequential PEG-IFNa-2a and TDF+PEG-IFNa-2a combination therapy after long-term nucleic acid analog treatment effectively reduce hepatitis B surface antigen levels
  • 953: Antiviral characterization of a next generation chemical series of HBV capsid inhibitors in vitro and in vivo
  • 954: The safety, immunogenicity and efficacy of TVGV-HB, a therapeutic HBV vaccine, in immunocompetent HBV mouse models
  • 955: Correlations of baseline and early changes in bone and renal tubular biomarkers with BMD changes on TAF/ TDF treatment
  • 956: Rebound of HBV DNA after cessation of nucleos/tide analogues in chronic hepatitis B patients with undetectable cccDNA
  • 957: Structural determinants of the post-entry antiviral effects of nucleic acid polymers against HBV infection in vitro
  • 958: Reduced hepatitis B and D viral entry using clinically applied drugs as novel inhibitors of the bile acid transporter NTCP
  • 959: Serum HBV RNA is a Predictor of the Genetic Resistant Mutations with Entecavir Treatment in Chronic Hepatitis B Patients
  • 960: Cessation of Nucleos(t)ide Analogue therapy after HBeAg seroconversion does not lead to increased HBsAg loss rates: an international, multi-ethnic cohort study
  • 961: REST-B Study: Long-term safety and efficacy of Tenofovir Disoproxil Fumarate in Chronic Hepatitis B (CHB): A multicenter real life cohort
  • 962: Screening for microRNAs to suppress hepatitis B virus replication
  • 963: Treatment efficacy and safety of tenofovir disoproxil fumarate (TDF) in naïve chronic hepatitis B for 144 weeks: a Real Life multicenter cohort study in Korea
  • 964: The possible association between hepatic steatosis and decreased treatment efficacy in patients receiving sequential therapy for hepatitis B virus
  • 965: Is antiviral treatment for chronic hepatitis B (CHB) in Asian patients associated with osteopenia/osteoporosis? A comparison study of tenofovir (TDF), entecavir (ETV) and untreated (UTx) patients
  • 966: The 144-week efficacy of Entecavir in HBeAg-positive patients with chronic hepatitis B: a prospective repeat liver biopsy study
  • 967: Real-world Single Center Experience with entecavir and tenofovir in treatment naive and experienced of Chronic Hepatitis B Patients
  • 968: GalXC Technology Enables Potent and Durable RNAi-Mediated Inhibition of Hepatitis B Virus in Preclinical Models

Hepatitis C: Diagnostics, Epidemiology, and Natural History

  • 969: Long-Term Follow Up of Patients with Chronic HCV and No or Minimal Fibrosis Shows Low Risk for Liver-Related Morbidity and Mortality After Achieving SVR with DAA-Based Therapy: Results from the Gilead SVR Registry
  • 970: Risk of end stage renal disease in hepatitis C patients following completion of direct-acting antiviral therapy: a retrospective cohort study
  • 971: Pathological characteristics of patients who develop primary hepatocellular carcinoma after achieving sustained virologic response for hepatitis C virus infection
  • 972: Risk of Parkinson’s disease in hepatitis C patients following exposure to direct-acting antiviral treatment: an analysis of US administrative claims data
  • 973: Investigating the association of TLL1 variant with development of hepatocellular carcinoma after eradication of hepatitis C virus by interferon-free regimens
  • 974: HCV Clearance Is Associated with an Increase in Cardiovascular Risk
  • 975: “Diagnostic Burn-out” for Hepatitis C: when will countries run out of diagnosed people to treat with DAAs?
  • 976: Epidemiologic impact of expanding chronic hepatitis C (CHC) treatment in people who inject drug (PWID) in the United States (US): a mathematical model using data from the C-EDGE CO-STAR Study
  • 977: Reflex viral load testing following positive screening for HCV leads to improved patient follow up and virologic responses.
  • 978: Similar rates of HCV recurrence in HCV/HIV co-infected and HCV mono-infected patients who achieved SVR after DAA treatment: interim results from the ACTG A5320 Viral Hepatitis C Infection Long-term Cohort Study (V-HICS).
  • 979: The development of liver disease in childhood acquired hepatitis C infection in the UK
  • 980: VirA+EmiC project: universal Hepatitis C and B screening with integrated linkage to care in an urban London emergency department - interim results
  • 981: Does Hepatitis C eradication lead to improved glucose metabolism, renal and cardiovascular outcomes in diabetic patients?
  • 982: Liver disease monitoring after hepatitis C cure in underserved patients with advanced liver fibrosis
  • 983: Hepatitis C (HCV) in Patients Without Fibrosis or with Minimal Fibrosis: The Impact of Treatment and Sustained Virologic Response (SVR) on Patient-Reported Outcomes (PROs)
  • 984: Expression of Growth Hormone Receptor Is Associated to Prognosis and Overall Survival in Hepatitis C Virus-related Hepatocellular Carcinoma
  • 985: Declining Rate of Acute Graft Failure in Liver Transplant Recipients with Hepatitis C
  • 986: An Observational, Prospective Epidemiological Registry in Australia of HCV Liver Disease (OPERA-C)
  • 988: Short-term risk of de novo hepatocellular carcinoma in cirrhotic patients treated with DAAs compared to untreated cirrhotic patients
  • 989: Updated Prevalence of Hepatitis C in the United States: Results from a Simulation Model including the non-NHANES population
  • 990: Prevalence and screening of chronic hepatitis C virus infection in patients with hematologic malignancies: A call for universal screening
  • 991: Cross-sectional Assessment of HCV NS5A Resistance-Associated Variants in Over 30,000 Samples Submitted for Drug Resistance Testing in the US
  • 992: Impact of Sustained Virological Response on Incidence of Type 2 Diabetes in Hepatitis C Patients
  • 993: HIV testing in patients starting HCV treatment and factors associated with adherence to AASLD-IDSA Guidelines.
  • 994: Project ITTREAT (Integrated Community Based Test – stage-TREAT HCV Service) for People who Inject Drugs: Year 3 Results
  • 995: Direct and Indirect Cost Analysis of Strategies to Control the Disease Burden of Chronic Hepatitis C Virus (HCV) Infection in Mexico
  • 996: Genotype 6 Hepatitis C virus (HCV) infection is associated with lower odds of cirrhosis compared to genotype 1 HCV infection
  • 997: Increase in Hepatocellular carcinoma (HCC) in Hepatitis C (HCV) patients without cirrhosis
  • 998: Impact of HCV treatment on long term mortality in patients ≥ 70 years at the time of HCV infection diagnosis
  • 999: Sexually-acquired HCV Infections Emerging Among HIV-uninfected Men Who Have Sex with Men on Pre-exposure Prophylaxis Against HIV
  • 1000: Understanding Women’s Preferences Regarding Treatment of Hepatitis C During Pregnancy
  • 1001: Short-term histological evaluations after achieving a sustained virological response to direct-acting antiviral treatment for chronic hepatitis C
  • 1002: Prospective assessment of the impact of successful DAAs treatment on liver fibrosis stage and predictors of fibrosis regression in patients with chronic hepatitis C and advanced fibrosis stage
  • 1004: Variation of the lipid profile of patients with hepatitis C after treatment with direct action antivirals. Statins modifying effect
  • 1005: Utilization of an Electronic Medical Record to Evaluate the Hepatitis C Care Cascade in a Large, Urban Health System, 2004--2016
  • 1006: What is Killing People with HCV infection? Analysis of population based cohort in Canada
  • 1007: Liver elasticity change in chronic hepatitis C patients who achieved sustained virological response by direct-acting antivirals
  • 1008: Economic Burden Of Chronic Hepatitis C (CHC) In Medicaid And Commercially Insured Patients In The United States
  • 1009: Impact of an Electronic Medical Record Alert on Increasing Hepatitis C Screening and Curative Treatment for Baby Boomers in Primary Care Clinics
  • 1010: Implementation and Evaluation of a Care Coordination Program for Patients with Hepatitis C Following Release from Jail
  • 1011: Efficient and sensitive HCV RNA extraction and amplification on silicon microchip technology
  • 1012: Use of APRI to exclude cirrhosis in correctional services: minimizing need for Fibroscan
  • 1013: Association of different types of chronic liver diseases with hepatocellular carcinoma in the United States
  • 1014: A risk-based approach to HCV Screening among non-birth cohort emergency department patients: Testing the CDC recommendations
  • 1015: Low liver cancer surveillance rates among patients with advanced liver disease cured of HCV with direct acting antiviral therapy.
  • 1016: Cost Outcomes and Efficiency Gains from Streamlining the Hepatitis C Screening and Linkage to Care Cascade in Emergency Departments, Substance Use Programs, and Federally Qualified Health Centers
  • 1017: Hepatitis C Screening Rates in a Large US Insured Population, 2010-2016: Slow Progress Among Baby Boomers
  • 1018: Significantly Higher Rates of Cirrhosis and Cirrhosis Related Complications Among Hispanic and Asian HCV Patients Hospitalized in the U.S.
  • 1019: Hepatitis B virus reactivation in patients with active or resolved HBV infection treated with direct acting antivirals for chronic hepatitis C: a systematic review and meta-analysis
  • 1020: Real life clinical outcomes in DAA-treated and untreated patients with HCV advanced liver disease. Interim one year data from the ongoing PITER cohort
  • 1021: An analysis of features of subjects with unawareness of HCV infection in community
  • 1022: HCV Screening and linkage to care of baby boomers at community hospital emergency department using streamlined EHR ordering
  • 1023: The Prevalence of Plasma Cell Dyscrasia in Hepatitis C Patients
  • 1024: How should kidney function be measured in patients with hepatitis C treated with antivirals without interferon?
  • 1025: A Prognostic Model for Liver Transplant Candidates with Hepatitis C – A Decision Aid for Antiviral Therapy
  • 1026: Return on Investment (ROI) on Vibration-Controlled Transient Elastography (FibroScan®)Return on Investment (ROI) on Vibration-Controlled Transient Elastography (FibroScan®)
  • 1027: HCV Infection: A New Risk Factor For Osteoporosis?
  • 1028: Ferritin As a Biomarker for Detecting Early Recurrence of HCC After IFN-free DAAs: An Observational Study
  • 1029: HepFree: A large cluster randomised controlled cross sectional trial to assess screening and treating first and second generation migrants from ‘At Risk’ countries with chronic viral hepatitis
  • 1030: Presence of Genotype 3 predicts cirrhosis in Chronic Hepatitis C patients
  • 1031: Fast-track HCV check-up enhances possibility of sustained virological response in HCV infected patients
  • 1032: Linkage to HCV-related care and treatment among patients at an urban health network in Philadelphia, PA
  • 1033: Regression of Fibrosis after Hepatitis C Treatment - A Step Towards Discharge?
  • 1034: Characterization of Hepatitis C Virus Recombinants Identified during Routine Drug Resistance Testing
  • 1035: Overall Linkage to Care for Hepatitis C is Improving but not in those Younger than 40
  • 1036: Prediction of hepatocellular carcinoma following direct-acting antiviral treatment for chronic hepatitis C
  • 1037: Changes in fibrotic markers in chronic hepatitis C patients treated with direct antiviral agents and the enhanced liver fibrosis score as a predictor of hepatocellular carcinoma
  • 1038: Improved HCV Care Cascade Outcomes Among Urban Baby Boomers Identified Through A Screening Program In the All-Oral DAA Era
  • 1039: Evaluation of Wisteria floribunda agglutinin-positive Mac-2 binding protein glycosylation isomer during the course of antiviral treatment
  • 1040: Increasing incidence of MELD exception applications for hepatocellular cancer among hepatitis C patients waiting for transplant in the era of direct acting antivirals
  • 1041: Lower sustained virologic response in patients with hepatocellular carcinoma treated for hepatitis C with direct acting antivirals
  • 1042: Liver volume is an independent predictor of hepatocellular carcinoma risk in chronic hepatitis C patients
  • 1043: Detectable HCV Viral Load at Week 8 May Predict Higher Risk of Relapse in INF-free Treated Patients.
  • 1044: Seroprevalence of HCV and Transient Elastography in a Correctional Setting
  • 1045: Evaluation of Socioeconomic Factors and Achievement of Sustained Virologic Response (SVR) in the Treatment of Hepatitis C Virus (HCV)
  • 1046: Health outcomes among surveyed patients infected with hepatitis C in the Chronic Hepatitis Cohort Study (CHeCS)
  • 1047: Hospital Wide Automated Birth Year Order Entry of HCV Testing Combined with Patient Navigator (PN) Mediated Linkage to Care (LTC)
  • 1048: Economic impact of HCV treatment – Japan, 2015-2030
  • 1049: Risk of hepatocellular carcinoma in patients with chronic hepatitis C treated with direct-acting antivirals
  • 1050: Can HCV be eliminated among HIV-infected MSM in Berlin? Modeling a setting with increasing incidence and high treatment rates.
  • 1051: Characteristics of Hepatitis B and C prevalence in key populations in South Africa
  • 1052: Improving Cascade of Hepatitis C Care through Linkage to C Care Program [LTC] in the PWID population
  • 1053: Improving Cascade of Hepatitis C Care through Linkage to C Care Program [LTC]
  • 1054: Dynamics of hepatic steatosis in the treatment for chronic hepatitis C with direct acting antivirals
  • 1055: Hepatocellular carcinoma development in Japanese patients with HCV genotype 1 infection who achieved sustained virologic response by ledipasvir/sofosbuvir and protease inhibitor with peginterferon plus ribavirin
  • 1056: Flow Cytometric Assessment Of B-Lymphocyte In Response To SVR After DAAs In HCV-Infected Patients With Or Without Lymphom
  • 1057: Lessons Learned from HIV Screening: Routine HCV Screening and linkage to care in an Urban Emergency Department in Chicago, IL
  • 1058: Higher prevalence of autoantibodies among 40 years old women in chronic hepatitis C and more discreasing titer after DAA treatment compared with IFN treatment
  • 1059: Geomapping HCV in a Large Healthcare System: An Analysis of Gaps in HCV Care Utilization
  • 1060: Elastography findings in mono-infected HCV prison inmates: demographics and baseline characteristics from HIPPOCRATES study (Hepatitis C In-Prison Program fOr enhancing Cure RATES)
  • 1061: HCV-infected persons in the USA: Identification, current treatment needs, and obstacles to care
  • 1062: New York City Hospitals’ Capacity to Support the Elimination of Hepatitis C: A Follow-up Survey
  • 1063: Hepatitis C Screening and Linkage to Care is Infrequent in Safety-Net Health Systems
  • 1064: Perceived barriers related to the management of HCV infection among physicians prescribing opioid agonist therapy: The C-SCOPE Study
  • 1065: Baseline Transmission Risk Behaviors and Opioid Agonist Therapy Interest in People Who Inject Drugs with HCV
  • 1066: Impact of National Screening Guidelines on HCV Testing at an Urban Tertiary Care Medical Center: Differences emerging in the outpatient (OP) versus inpatient (IP) settings
  • 1067: Severity and Correlates of Liver Fibrosis Assessed by Elastography are Different Between Hepatitis C-infected People Who Inject Drugs and Patients Infected by Other Routes.
  • 1068: Screening HCV genotype-specific epitope peptides based on conservation assessment and B-cell epitope prediction in HCV E2 region

Hepatitis C: Therapeutics - Approved Agents I

  • 1069: Sofosbuvir/Velpatasvir for 12 Weeks in Genotype 1-4 HCV-Infected Liver Transplant Recipients
  • 1070: Prolonged abnormal ALT and AFP following SVR and advanced liver fibrosis were associated with hepatocellular carcinoma development in chronic hepatitis C patients who achieved SVR by IFN-free direct-acting antiviral agents.
  • 1071: HCV resistance-associated substitutions in patients with HCV genotype 4 and failure to DAA combination therapies and implications for a retreatment
  • 1072: Predictive features of clinical improvement or deterioration for patients with decompensated hepatitis C cirrhosis after direct acting antiviral therapy
  • 1073: High SVR-12 rates in patients with and without opioid substitution therapy (OST) in daily practice after SOF-based therapy regimens despite cannabis and alcohol consumption in both groups
  • 1074: Shortened therapy of 8 weeks duration with paritaprevir/ritonavir/ombitasvir and dasabuvir is highly effective in people with acute and recent genotype 1 HCV infection: The TARGET3D Study
  • 1075: Resistance guided retreatment of patients failing NS5A inhibitors in Spain: real life data from the GEHEP004 cohort
  • 1076: Real-World Safety and Efficacy of Ribavirin –free regimen of Ombitasvir/Paritaprevir/Ritonavir for dialysis patients infected with HCV
  • 1077: An analysis of potential elimination strategies for hepatitis C using a budget optimization model for the UK
  • 1078: Bioequivalent pharmacokinetics for generic and originator Hepatitis C Direct Acting Antivirals
  • 1079: Evaluation of cardiac function by global longitudinal strain before and after treatment with sofosbuvir-based regimens in HCV infected patients
  • 1080: Unexpected Enhancement of Replication Capacity by Simeprevir for Simeprevir-Resistant Variants in Genotype 1a Hepatitis C Virus
  • 1081: Predictive factors of treatment outcome among patients included in hepatitis C elimination program in Georgia
  • 1082: Real world experience of re-treatment by Ledipasvir/Sofosbuvir for patients who failed previous Daclatasvir plus Asunaprevir therapy: interim analysis from large scale nation-wide study
  • 1083: Declines in HBsAg Levels Observed during Treatment with Ledipasvir/Sofosbuvir (LDV/SOF) in Patients with Chronic Hepatitis B Virus (HBV) and Hepatitis C Virus (HCV) Infection
  • 1084: Effect of DAA combination therapy on glucose intolerance improvements in HCV infection
  • 1085: Interferon-free therapies for hepatitis C: efficacy and discontinuation of treatment in inmates vs. non-inmates
  • 1086: SVR after all-oral DAA regimens reduces the risk of hepatocellular carcinoma in HIV/HCV-coinfected patients with cirrhosis
  • 1087: Safety and efficacy of the combination Sofosbuvir-Ledipasvir in HCV mono-infected patients from the French Cohort ANRS CO22 HEPATHER
  • 1088: Real-world efficacy and safety of Elbasvir and Grazoprevir in HCV genotype 1 or 4 infected patients with severe chronic kidney disease stage 4/5 or hemodialyzed
  • 1089: Safety, efficacy and tolerance of half-dose sofosbuvir plus daclatasvir in treatment of acute hepatitis C infection in patients with end-stage renal disease on hemodialysis: a prospective, single-center, open-label study
  • 1090: NS5B-A218S Mutation Locating Along with the NTP Tunnel as a Factor Involved in Virologic Failure after Sofosbuvir/Ledipasvir Therapy in Patients with Genotype 1b HCV: Evaluation by Bioinformatics and Molecular Dynamics
  • 1091: DAA Hepatitis C treatment in low socioeconomic population at a Federally Qualified Health Center [FQHC]
  • 1092: Effect of interferon free antiviral therapy on glomerular and tubular kidney involvement in HCV Child-A cirrhosis
  • 1093: Real-world patterns of therapy utilization and outcomes in 7098 genotype 1-6 HCV patients: data from the TRIO network.
  • 1094: Safety and Efficacy of Sofosbuvir/Velpatasvir in a Genotype 1-6 HCV Infected Population from Singapore, Malaysia, Thailand, and Vietnam: Results from a Phase 3, Clinical Trial
  • 1095: Higher occurrence of HCC in DAAs therapy than in Peg-IFN based therapy in patient with chronic hepatitis C related cirrhosis
  • 1096: Safety and Efficacy of Velpatasvir and Sofosbuvir-based Regimens for the Treatment of HCV Genotype 1-6: Results of the HCV-TARGET Study
  • 1097: Direct Acting Antiviral Therapy for Waitlist Candidates with Hepatocellular Cancer: Influence on Locoregional Therapy en route to Transplant and Explant Pathology
  • 1098: Baseline resistance does not impact hepatitis C sustained response rates using approved direct acting antivirals (DAAs) in a real world setting
  • 1099: Ledipasvir / Sofosbuvir plus Ribavirin as highly effective regimen for recombinant strain RF1_2k/1b patients within Georgian national hepatitis C elimination program
  • 1100: Efficacy and safety of new direct antiviral agents in HCV infected patients with Diffuse Large B Cell Non-Hodgkin Lymphoma
  • 1101: Liver volume as a predictor of functional improvement post DAA treatment
  • 1102: Directly observed therapy with sofosbuvir/ledipasvir for 8 weeks is highly effective in treatment-naive, non-cirrhotic genotype 1 patients with borderline compliance receiving opioid agonist therapy
  • 1103: Real-World Effectiveness of Sofosbuvir-based Regimens for Hepatitis C Treatment among People Who Inject Drugs and those in Opioid Substitution Therapy in Canada
  • 1104: Comparison of Efficacy and Tolerability of Direct Acting Antiviral Agents in Patients with End Stage Renal Disease before vs. after Renal Transplant: A Multi-Center Experience
  • 1105: Effectiveness And Safety Of Elbasvir/Grazoprevir Treatment For HCV Patients In Real-Life Clinical Practice: Results From Spanish Hepa-C Cohort
  • 1106: Safety and Efficacy of Direct Acting Antivirals: UK Real World Experience from a Large Well Characterised Predominantly Cirrhotic HCV Cohort
  • 1107: Drivers of Therapy Choice in Genotype 1 HCV: Analyses of real-world data from the TRIO Network.
  • 1108: Measures of Adherence to HCV Therapy in a Specialty Pharmacy Setting and Association with NON-SVR
  • 1109: Insulin resistance in hepatitis C virus infection: relative contribution from liver vs. extrahepatic sites
  • 1110: Electronically-monitored adherence to a once-daily single-tablet regimen in inner-city patients with chronic hepatitis C infection treated in a primary care setting
  • 1111: HCV Treatment Failure in the era of direct-acting antivirals (DAAs): Analyses of real-world data from the TRIO Network.
  • 1112: Real Life Effectiveness of Direct-Acting Antivirals (DAAs) in Asian Patients with Chronic Hepatitis C Genotype 1: Systematic Review and Meta-analysis of 33 Published Articles and 7942 patients
  • 1113: Effectiveness of Elbasvir/Grazoprevir in patients with Chronic Hepatitis C and Chronic Kidney Disease: Results from the Veterans Affairs system
  • 1114: Risk of developing “de novo” liver cancer after achieving sustained virologic response (SVR) after direct antiviral (DAA) regimens in patients with chronic hepatitis C virus (HCV) infection: a 21,4 months follow up study cohort.
  • 1115: Cure denied and cure delayed in Chronic Hepatitis C; monitoring non-start rates and increased time to start using real-world data from the TRIO Network.
  • 1116: Long-Term Follow-Up of Patient-Reported Outcomes (PROs) in Chronic Hepatitis C (HCV) Patients with Compensated and Decompensated Cirrhosis with Sustained Virologic Response (SVR)
  • 1117: Race/Ethnicity Disparities in Access to Hepatitis C Virus Treatment Before and After Availability of Direct-Acting Antivirals (DAA): Data From 3 Safety Net Hospital Systems
  • 1118: Changes in Serum Neurotransmitters (NTs) and Patient-reported Outcomes (PROs) and Neurocognitive Performance (NCP) after Viral Eradication of Hepatitis C Virus (HCV)-Genotype 1 (GT1)
  • 1119: High Efficacy of Generic and Original Direct Acting Antivirals in Treatment of Chronic HCV Genotype 4: Real-Life Single Center Experience
  • 1120: Cost-effectiveness analysis of Daclatasvir/Sofosbuvir (DCV/SOF) for the treatment of the HCV patients failed after the first line with second generation of DAA in Italy.
  • 1121: The characteristics of patients in whom Sofosbuvir and Ledipasvir therapy failed to eradicate HCV
  • 1122: Fibrosis Progression and Incidence of Cirrhosis and Hepatic Decompensation in Persons Treated with Paritaprevir/Ritonavir/Ombitasvir/Dasabuvir: Results from ERCHIVES
  • 1123: Changes in the use of direct acting antiviral(s) (DAA) in the treatment of chronic hepatitis C (CHC) patients in clinical practice. HERACLIS: a Hellenic multicenter real-life cohort clinical study
  • 1124: A Pragmatic Approach to Optimizing the Efficacy of Elbasvir/Grazoprevir Using Baseline Viral Load in Participants With Hepatitis C Virus (HCV) Genotype (GT)1a Infection: A Post Hoc Analysis of 11 Clinical Trials
  • 1125: Efficacy and safety of ledipasvir/sofosbuvir in treatment-naïve and –experienced patients with hepatitis C virus genotype 6 infection
  • 1126: Hepatitis B reactivation during DAA therapy for Hepatitis C - does it affect clinical outcomes?
  • 1127: Effectiveness and safety of direct-acting antiviral therapy in patients with chronic hepatitis C and severe fibrosis/cirrhosis from "real world" in Argentina: a multicenter, observational study.
  • 1128: Impact of treatment duration and ribavirin (RBV) addition on real-world effectiveness of elbasvir/grazoprevir (EBR/GZR) in select patient subgroups with Genotype 1 (GT1) Chronic Hepatitis C (HCV): Retrospective data analyses from the Trio Network.
  • 1129: Expanding HCV Treatment Access: Training Primary Care Providers in the U.S. using the ECHO Model
  • 1130: Early emergence of opportunistic infections after starting direct acting antiviral drugs in HIV/HCV coinfected patients
  • 1131: Real World Effectiveness of 8 vs 12 Weeks of Ledipasvir/Sofosbuvir (LDV/SOF) in Blacks with HCV: A Comparative Analysis of Clinical Trials with Real World Cohorts
  • 1132: A state-wide, nurse-led model of care for HCV in the prison: high SVR12 rates that are equivalent to the specialist liver clinic
  • 1133: Minimally Elevated End-of-Treatment Alpha-fetoprotein Levels Are an Indipendent Predictor of Hepatocellular Carcinoma in Cirrhotic Patients Treated with Direct Antiviral Agents for HCV Infection
  • 1134: Baseline Characteristics and Patient-Reported Outcomes (PROs) from PROP UP: A Large US Multi-site Observational Study of Patients with Chronic Hepatitis C (HCV) Initiating Direct Acting Antiviral Therapy (DAA)
  • 1135: Increased Intensity of Testing and Treatment for Elimination of Hepatitis C. Real World Experience from the Treatment as Prevention (TraP HepC) Program in Iceland
  • 1136: Treatment of HCV-infected Vulnerable Populations with All-Oral Regimens; Updated Real-World Data
  • 1137: Early development of hepatocellular carcinoma after hepatitis C virus eradication in interferon-free direct-acting antiviral treatment: Results from a real-life, multicenter study
  • 1138: Improvement of clinical symptoms and patient-reported outcomes after HCV-therapy with interferon-free sofosbuvir-based regimens: Real-world results from the DHC-R
  • 1139: Treatment of HCV-Induced Cryoglobulinemic Vasculitis with New Direct Acting Antiviral (DAA) Regimens
  • 1140: SVR12 Outcomes for approved HCV DAAs in Black subjects with HCV Genotype (GT) 1 Infection.
  • 1141: Improvement in Glycemic Control of Type II Diabetes after Successful Treatment of Hepatitis C Virus With Direct-Acting Antivirals
  • 1142: Low dose sofosbuvir is safe and effective in treating chronic hepatitis C in patients with severe renal impairment or end stage renal disease.
  • 1143: Influence of DAA therapy in the arterial distensibility of patients with chronic hepatitis C.
  • 1144: High Rates of Rapid Virologic Response for Chronic Hepatitis C Infection Treated with Ledipasvir/Sofosbuvir in Rwanda: Preliminary Results from the SHARED Study
  • 1145: HCV therapy as part of an interdisciplinary low-threshold harm reduction strategy in HCV infected injection drug users
  • 1146: Pre-treatment hepatic volume does not predict clinical improvement in HCV patients treated with DAAs and decompensated liver disease.
  • 1147: The Majority of Patients that Achieve Sustained Virologic Response after DAA Treatment Continue to Require Long-Term Monitoring: Real-World Experience from a Large Viral Treatment Center
  • 1148: Factors Associated with Direct Acting Antiviral Treatment Failures in the Treatment of Chronic Hepatitis C in a Real World Population
  • 1149: Severe adverse events and direct acting antivirals in the French cohort ANRS CO22 HEPATHER
  • 1150: Efficacy of Generic Oral Directly Acting Agents in Patients with Hepatitis C Virus Infection
  • 1151: Regression of liver stiffness following therapy with direct acting antiviral(s) in chronic hepatitis C patients. Results from HERACLIS: a Hellenic multicenter real-life cohort clinical study.
  • 1152: Long term retrospective study on hepatitis C patients treated with ledipasvir/sofosbuvir in a large health maintenance organization
  • 1153: Risk of HBV Reactivation with DAA Therapy for HCV in those with evidence of Past HBV Exposure
  • 1154: SVR with Ultra Short Duration DAA Therapy is Associated with Increased Peripheral PD-1+ T Cells Co-expressing Activation/Exhaustion Markers
  • 1155: Real-World Cost-Effectiveness Of Elbasvir/Grazoprevir (EBR/GZR) In Treatment-Naive (TN) Patients With Chronic Hepatitis C (CHC) Virus Genotype 1 (GT1) In The United States (US)
  • 1156: Two years follow-up after treatment with Ombitasvir/Paritaprevir/ritonavir ±Dasabuvir ±Ribavirin, an interim analysis of CE-long study following the AMBER – real world experience study.
  • 1157: Prediction Of Hepatocellular Carcinoma Occurrence After Treatment With Direct Acting Antivirals
  • 1158: Significant HbA1C Lowering with Sustained Virologic Response in Patients with Type 2 Diabetes
  • 1159: Effects of IFN-free treatment on the virological, clinical, immunological, and quality- of- life in patients with HCV-related mixed cryoglobulinemia: a prospective and controlled study
  • 1160: Elder patients in the DAA era: real-life report on 7.746 patients from the Lombardy HCV network
  • 1161: Treatment of Hepatitis C Infection in an Office-Based Opiate Treatment (OBOT) Clinic
  • 1162: Telemedicine-based Hepatitis C Virus (HCV) Management for Individuals on Opioid Agonist Treatment (OAT)
  • 1163: Efficacy and Safety of Direct-Acting Antivirals in Hepatitis C Virus-Infected Patients Taking Proton Pump Inhibitors
  • 1164: The effect of interferon-free Direct-Acting Antivirals combination therapy on innate immune responses (NK cell activity and frequency of CD56dim and CD56bright NK cell subset in peripheral blood) in chronic hepatitis C patients
  • 1165: Long-term Effect of Antiviral Treatment on the Development of Hepatocellular Carcinoma in Patients with Chronic Hepatitis C
  • 1166: Analysis of the Association between Serum Proprotein Convertase Subtilisin/kexin Type 9 Level and the Progression of Liver Fibrosis in Patients with Chronic Hepatitis C genotype 1b
  • 1167: Real-world effectiveness of sofosbuvir and ledipasvir/sofosbuvir based regimens in hepatitis C virus genotype 3 infection within national hepatitis C elimination program in the country of Georgia
  • 1168: Effect of DAAs therapy for chronic hepatitis C on lipid levels

Hepatitis C: Therapeutics Pre-Clinical and Early Clinical Development

  • 1169: Post-treatment Serum Wisteria floribunda Agglutinin-positive Mac-2-binding Protein Levels Predict the Risk of Hepatocellular Carcinoma Development after Hepatitis C Virus Eradication
  • 1170: Hepatocellular carcinoma development in hepatitis C virus patients who achieved sustained viral response by interferon therapy and direct anti-viral agents therapy
  • 1171: Aberrant expression and altered zonal distribution of hepatic organic anion transporting polypeptide 1B3 in chronic hepatitis C infection
  • 1172: Modeling in humanized mice and patients suggests that antihistamine chlorcyclizine HCl not only blocks HCV infection/entry but also viral production
  • 1173: Pretreatment NAFLD activity score significantly predicts fibrosis regression in hepatitis C patients receiving antiviral therapy
  • 1174: Single-Dose Bioequivalence Study comparing Fixed Dose Combination of Daclatasvir and Sofosbuvir Film-Coated Tablets (60 mg/400 mg) with individual reference products in Healthy Adult Volunteers

Hepatitis C: Therapeutics: New Agents (Not Approved, Phase 2-3)

  • 1175: C-BREEZE 1: Efficacy and Safety of Ruzasvir 60 mg Plus Uprifosbuvir 450 mg for 12 Weeks in Adults With Chronic Hepatitis C Virus (HCV) Genotype (GT)1, 2, 3, 4, or 6 Infection
  • 1176: Susceptibility to Voxilaprevir of NS3 Resistance-Associated Substitutions and of Clinical Isolates from Direct Acting Antiviral-Experienced and-Naive Patients
  • 1177: Pan-genotypic hepatitis C treatment with glecaprevir + pibrentasvir resulted in improvement in cardiovascular and metabolic extrahepatic manifestations and stable renal function: Results from phase 3 clinical trials
  • 1178: SOF/VEL/VOX for 12 Weeks in NS5A-Inhibitor Experienced HCV-Infected Patients: Results of the Deferred Treatment Group in the Phase 3 POLARIS-1Study
  • 1179: Efficacy and Safety of Glecaprevir/Pibrentasvir in Patients Infected with HCV GT1-3 by Renal Impairment Status: A Pooled Analysis of Two Phase 3 Japanese Trials
  • 1180: Sofosbuvir with NS5A Inhibitors in Hepatitis C Virus Infected Patients with Severe Renal Insufficiency
  • 1181: Health Outcomes Associated with Sofosbuvir-based Single-Tablet Regimens for Initial and Re-treatment of Chronic Hepatitis C in the US
  • 1182: Safety and Efficacy of Glecaprevir/Pibrentasvir in Patients With Chronic Hepatitis C Genotypes 1–6 and Recent Drug Use
  • 1183: Virology analyses from HCV-infected patients treated with the combination of AL-335 and odalasvir, with and without simeprevir in Phase II studies
  • 1184: Ledipasvir/Sofosbuvir in the Treatment of Japanese Patients with Chronic HCV Genotype 2 Infection
  • 1185: Exposure-Response Analyses of Virologic Response to Glecaprevir and Pibrentasvir in HCV Subjects from Phase 2 and 3 Studies
  • 1186: Safety and Efficacy of Sofosbuvir/Velpatasvir in a Genotype 1-3 HCV Infected Russian and Swedish Population: Results from a Phase 3, Prospective Trial
  • 1187: Impact of hepatitis C treatment with glecaprevir + pibrentasvir on patient`s health related quality of life: Results from phase 3 CERTAIN trials
  • 1188: Safety and Efficacy of Glecaprevir/Pibrentasvir in Patients Aged 65 Years or Older With Chronic Hepatitis C: A Pooled Analysis of Phase 2 and 3 Clinical Trials
  • 1189: Exposure-Safety Response Relationship for Glecapravir and Pibrentasvir in Hepatitis C Virus-Infected Subjects in Phase 2 and 3 Studies
  • 1190: Glecaprevir and Pibrentasvir Exposures in Hepatitis C Virus-Infected Subjects in Phase 2 and 3 Studies
  • 1191: Safety and Efficacy of Ledipasvir/Sofosbuvir in a Genotype 1 HCV Infected Chinese Population: Results from a Phase 3, Clinical Trial
  • 1192: Pharmacokinetics and dose selection of the 2- and 3-direct acting antiviral combination of AL-335 and odalasvir with/without simeprevir in hepatitis C virus-infected patients
  • 1193: Treatment with Glecaprevir/Pibrentasvir (G/P)-based regimens of patients with difficult to treat HCV infection. A compassionate use study.

Pediatric Liver Disease

  • 1194: Congenitally dysregulated mannose metabolism stimulates hepatic fibrogenesis
  • 1195: Predictive value of intrahepatic hepatitis B virus covalently closed DNA and serum HBsAg in children with chronic hepatitis B treated with interferon
  • 1196: Serum HBsAg quantification to predict the HBeAg serum conversion in children with chronic hepatitis B treated with interferon
  • 1197: Transcription Factor GATA4 promotes EMT in Human Hepatoblastoma Cells
  • 1198: Characterisation of a novel space in neonatal and adult extrahepatic bile duct
  • 1199: MMP7 and relevant chemokines in NASH
  • 1200: The ileal bile acid transport inhibitor A4250 reduced pruritus and serum bile acid levels in children with cholestatic liver disease and pruritus: final results from a multiple-dose, open-label, multinational study
  • 1201: Neurocognitive status in Alagille Syndrome: Results of a Multi-Center Prospective Observational Study
  • 1202: Sex disparity in response of murine sclerosing cholangitis to short-term FXR agonist treatment
  • 1203: Implications of a Limited Immunoglobulin Repertoire in Biliary Atresia
  • 1204: Validating the Mayo model of primary sclerosing cholangitis outcomes in children: data from the Pediatric PSC Consortium
  • 1205: Correlation of Immune Markers with Short-term Outcomes in Biliary Atresia following IVIg Treatment
  • 1206: CD71+ erythroblasts are novel regulators of bile duct Injury and the phenotype in experimental biliary atresia
  • 1207: Post-natal development of the biliary glycocalyx and biliary epithelial barrier
  • 1208: Biliatresone, a toxin causing biliary atresia, leads to increased mRNA and protein expression of CX3CL1, a leukocyte adhesion ligand, in mouse cholangiocytes and organoids
  • 1209: Transient elastography predicts transplant free survival in biliary atresia patients
  • 1210: Unraveling the Relationship between Itching, Scratch Scales and Biomarkers in Children with Alagille Syndrome
  • 1211: Some Considerations About FibroScan In Extrahepatic Cholestatic Liver Disease
  • 1212: Homozygous CYP7B1 mutations in Taiwanese patients with oxysterol 7a-hydroxylase deficiency: a rare disease possibly underdiagnosed
  • 1213: Use of a Comprehensive 66 Gene Panel to Diagnose the Causes of Cholestasis in >700 Individuals
  • 1214: Pregnant Women Tenofovir Disoproxil Fumarate Treatment Prevents Mother- to-Infant Transmission of Hepatitis B Virus by Decreasing Neonatal Viral Exposure
  • 1215: Early HBeAg Seroconversion in Childhood and Hepatocellular Carcinoma
  • 1216: Long-Term Safety of Maternal Tenofovir Disoproxil Fumarate Treatment during Pregnancy for Hepatitis B Virus Infected Mothers: a Follow-up Study of Mothers and Children
  • 1217: Analysis of the efficacy and safety of sequential therapy using Pegylated Interferon and nucleos(t)ide analogue versus standard therapy for treatment of immunotolerant and immunoclearance cases of chronic hepatitis B infection in children
  • 1218: Predictors of Response to Immunosuppressive Therapy in Pediatric Onset Autoimmune Hepatitis
  • 1219: Evaluating for human herpesvirus-6 in children with liver failure of unknown etiology
  • 1220: Non-invasive assessment of Paediatric Liver Disease with Multi-Parametric MRI
  • 1221: Marked Elevation of Serum Transaminase Levels >1,000 IU/ml in Children- Causes and Outcome
  • 1222: Epidemiology of new HCV infections among children
  • 1223: The Role of Kinase Fusion DNAJB1-PRKACA in Fibrolamellar Hepatocellular Carcinoma
  • 1224: Spectrum of Clinical Presentation and Genetic Causes of Mitochondrial Hepatopathies
  • 1225: Transient elastography and controlled attenuation parameter assessment of liver disease in children and young adults with Cystic fibrosis: a 3 year longitudinal study
  • 1226: Hepatic Parenchymal Injury in Crigler-Najjar Syndrome
  • 1227: Risk Factors for Hepatic Steatosis in Cystic Fibrosis Are Distinct from Risk Factors for Cystic Fibrosis Liver Disease
  • 1228: Predisposing Conditions to Pediatric Hepatocellular Carcinoma
  • 1229: Treating Obstructive Sleep Apnea and Chronic Intermittent Nocturnal Hypoxia with CPAP Improves Severity of Non-Alcoholic Fatty Liver Disease (NAFLD) in Obese Pediatric Patients
  • 1230: Visceral and subcutaneous adipose tissue measurements associate with increased metabolic risk for NAFLD in pre-pubertal obese children
  • 1231: RNA-seq analysis reveals evidence for novel pathways regulating cystogenesis, fibrosis, and inflammation in congenital hepatic fibrosis.
  • 1232: YKL-40 as a Potential Marker of Fibrotic Complications in Gaucher Disease
  • 1233: Hepatic Venous Outflow Tract Obstruction in Children: Etiology, Clinical profile and outcome following radiological interventions
  • 1234: Noninvasive hepatic fibrosis scores developed in adults had poor performance in diagnosing fibrosis in Chinese children with NASH
  • 1235: Prevalence of Fatty Liver in Adolescents Attending Primary Care Clinic
  • 1236: Quality of Life in Young Adults Who Received Liver Transplants as Children
  • 1237: High Prevalence of Hepatitis B Antibody Loss and De Novo Hepatitis B Virus (HBV) Infection in a Child with Living-Donor Liver Transplantation
  • 1238: Immunosuppression Induction with delayed use of Rabbit Antithymocyte Globulin and Rituximab in Pediatric Liver Transplantation
  • 1239: Body composition and risk for cardio-metabolic dysregulation in youth post-liver transplantation (LTx).

Poster Session III: Sunday, October 22, 8 am-5:30 pm

Presentation time 12:30 pm – 2:00 pm

Acute Liver Failure and Liver Support

  • 1240: Technetium-99m-GSA Scintigraphy Obtained Within Three Days of Admission as an Early Predictor of Outcome in Acute Liver Failure and Severe Acute Hepatitis
  • 1241: Identifying Herpes Simplex Virus (HSV)-Related Acute Liver Failure (ALF)
  • 1242: Thrombospondin-1 Exacerbates Azoxymethane-Induced Acute Liver Injury and Hepatic Encephalopathy by Activating Transforming Growth Factor Beta 1 and Promoting Inflammation
  • 1243: Suppression of cholesterol accumulation in the brain protects against the cognitive impairment observed during acute liver failure
  • 1244: Extracorporeal Albumin Dialysis using microparticle charcoal for albumin recycling is superior to using MARS macroparticle Adsorbents in removing albumin bound toxins (ABT)
  • 1245: Lille Score Predicts Outcome in a Clinical Study of an Extracorporeal Human Allogeneic Cellular Liver Treatment (ELAD) for Severe Alcoholic Hepatitis (sAH)
  • 1246: Serum Caspase-1 Level as a Diagnostic and Prognostic Biomarker for HBV-Related Acute-on-chronic Liver Failure
  • 1247: ADAMTS13 deficiency exacerbates acute liver failure with enhanced VWF accumulation and hepatic inflammation in mice.
  • 1248: The role of ulinastatin in the treatment of liver failure
  • 1249: Drug- Induced Acute Liver Failure in 128 Patients Including Children: Implicated Drugs, Outcome, Predictors of Mortality - Results From a Single-Center Drug-induced Liver Injury Registry
  • 1250: Multi-platform metabonomics reveals a distinct metabolic phenotype of acute-on-chronic liver failure
  • 1251: Impact of plasmapheresis on outcomes in patients with Acute liver Failure fulfilling King’s College Criteria
  • 1252: Ethanol-Induced Oxidative Stress in Primary Human Hepatocytes is Suppressed by VTL C3A Cell-Secreted Factors
  • 1253: Promising effects of thymosin α1 treatment for rats with acute liver failure
  • 1254: Serotonin facilitates the concanavalin A induced acute liver injury in mice
  • 1255: Hospital Teaching Status on the Mortality, Length of Stay and Cost Amongst Patients with Acute Liver Failure in the U.S.
  • 1256: MicroRNA-181c potentially relieved fulminant viral hepatitis by targeting TNF-α in mice
  • 1257: Plasma lipidomics identifies novel biomarkers in patients with hepatitis B virus-related acute-on-chronic liver failure
  • 1258: Palmitoleate protects 3-hydroxy fatty acid-induced hepatocyte lipoapoptosis
  • 1259: Triggering factors for acute liver failure in patients with first manifestation of autoimmune hepatitis: a single center experience of 501 patients.
  • 1260: Interference with novel gene KCTD9 ameliorates fulminant liver failure in mice
  • 1261: Significant lung injury and its prognostic significance in acute liver failure
  • 1262: Hepatic Cell Microencapsulation for External Bioartificial Liver : Performance of Spheroids versus Isolated Cells
  • 1263: Validation of TPPM Score in predicting short-term survival in HBV-ACLF patients: a multinational study from APASL ACLF Research Consortium (AARC)
  • 1264: Multicenter Survey for Patients with Acute-on-Chronic Liver Failure in Japan
  • 1265: Direct comparison of two mouse models of Type A hepatic encephalopathy.
  • 1266: Modification of the MELD Score with Serological Fibrosis Markers Reflecting Extracellular Matrix Remodeling Improves Prediction of Outcomes in Non-acetaminophen-associated Acute Liver Failure
  • 1267: G-CSF administration attenuates liver injury by inhibiting hepatocyte apoptosis through Akt/Bcl2 pathway
  • 1268: Nationwide Survey for Acute Liver Failure and Late-Onset Hepatic Failure in Japan
  • 1269: Sexual dimorphism in liver ischemia and reperfusion injury in mice: Role of male-specific gene SRY
  • 1270: Serial Procalcitonin Levels in Patients with Acute Liver Failure

Adaptive Immunity

  • 1271: Imbalance of Treg/Th17 correlates with poor prognosis of autoimmune hepatitis
  • 1272: Evaluation of viral specific T-cell response in chronic hepatitis B may be improved by immune clustering strategy
  • 1273: Disease activity of human autoimmune hepatitis is associated with type-II interferon signaling and cytotoxic effector lymphocyte gene signature in the liver
  • 1274: PD-1 expression in the peripheral blood and the liver of patients with alcoholic hepatitis is impaired and may contribute to disease pathogenesis.
  • 1275: Attenuation of Antibody Response and Elevation of CD4+CD25+Foxp3+ Treg cell Frequency During Chronic Liver Fibrosis
  • 1276: Usefulness of follicular helper T cell subset frequencies in the diagnosis of autoimmune hepatitis

Alcoholic Liver Disease

  • 1277: Mice With Endogenously Elevated ω-3 Polyunsaturated Fatty Acids Have Attenuated Liver Injury Induced By Chronic Alcohol Administration
  • 1278: Immature myeloid cells have an important role of gut bacteria-associated infection in alcoholics
  • 1279: Systems-Wide Characterization of Alcoholic Hepatitis using proteomics of PBMCs
  • 1280: Chronic alcohol consumption upregulates ceramide synthase 6 in hepatic lipid droplets and zone 3 hepatocytes of mice and humans
  • 1281: Liver-brain axis in alcoholic liver disease: Chronic alcohol induces recruitment of peripheral macrophages with different inflammatory gene expression profile into the liver and brain
  • 1282: Impact of metabolic risk factors in non-cirrhotic patients with alcoholic liver disease
  • 1283: Molecular Mechanisms of Recovery from Ethanol-Induced Steatosis after Ethanol Withdrawal
  • 1284: Genomic and transcriptomic analysis reveal a driving role of TGF-β signaling in suppressing alcohol induced liver injury and HCC
  • 1285: PDE4 Inhibitor Attenuates Liver Injury In Alcoholic Hepatitis Model: Use Of Novel Drug Carrier System For Targeted Delivery
  • 1286: Impaired TFEB-Mediated Lysosomal Biogenesis Contributes to Acute-on-Chronic Alcohol-Induced Liver Injury in Mice
  • 1287: Dynamin related protein-1 inhibition drives megamitochondria formation and protects from alcohol-induced liver toxicity.
  • 1288: Ethanol reduces skeletal muscle protein synthesis via novel non-canonical β-catenin-cMYC mediated impaired ribosomal biogenesis
  • 1289: LncRNA AK054921 and AK128652 are potential serum biomarkers and predictors of patient survival with alcoholic cirrhosis
  • 1290: Resolvin D1 Markedly Attenuated Ethanol And LPS-Induced Liver Injury By Reducing The Hepatic Pro-Inflammatory Response In Mice
  • 1291: Dual role of FOXO3 in regulating the evolution of the macrophage inflammatory phenotype in response to alcohol
  • 1292: Quantitative immunohistochemical labeling (IHC) of phospho-p38 (p-p38) and clinical correlations in subjects with alcoholic hepatitis (AH) compared to nonalcoholic steatohepatitis (NASH)
  • 1293: Alcohol-induced microtubule hyperacetylation impairs lipid droplet dynamics
  • 1294: Alcohol exposure promotes epigenetic changes leading to loss of HNF4α
  • 1295: Acute-On-Chronic Alcohol Induces Adipose Tissue Atrophy, Hepatic Steatosis and Liver Injury via Inhibition of mTOC1 in Adipose Tissue in Mice
  • 1296: Metabolic Reprogramming In Patients With Alcoholic Hepatitis: Identification Of The Polyol Pathway As Potential Target For Therapy
  • 1297: Targeted liver metabolomics reveals a role for CCL2 in arginine metabolism and glutathione generation in a model of alcoholic liver injury
  • 1298: Hepatocyte apoptosis is linked to decreased TET1 and 5-hydroxymethylcytosine in rat alcoholic liver disease
  • 1299: Identification and novel mechanisms of elevated CYP2E1 and other P450 isoforms in circulating extracellular vesicles from alcoholic patients and alcohol-exposed rodents through increased oxidative and ER stress
  • 1300: Ethanol induced hepatic exosomes mediate impaired skeletal muscle signaling responses in myotubes and contribute to sarcopenia in alcoholic liver disease.
  • 1301: Worldwide Lack of Early Referral of Patients with Alcoholic Liver Disease: Final Results of the Global Alcoholic Liver Disease Survey (GLADIS)
  • 1302: Phosphoprotein Profiling Indicates Markers of Hepatic DNA Damage and ATM Pathway Activation Separate Hepatic Injury in NASH from Fatty Liver
  • 1303: Comparisons of infectious complications in severe alcoholic hepatitis and decompensated alcoholic cirrhosis
  • 1304: Peripheral blood CD4+ T helper cells (Th1, Th2, Th17, Th22) are increased in severe alcoholic hepatitis
  • 1305: External Validation of Lille Score Calculated at Day 4 (Lille-4) as a Predictor of Survival in Severe Alcoholic Hepatitis
  • 1306: Relationship between alcohol treatment and transcriptome in mouse model of acute-on-chronic alcoholic liver injury
  • 1307: Lactobacillus rhamnosus GG supplementation decreases liver steatosis in a zebrafish model of alcoholic liver disease
  • 1308: The changing epidemiology of alcoholic hepatitis: increasing incidence in the young, white, and women
  • 1309: Mitochondrial DNA Enriched Microparticles Promote Acute-on-chronic Alcoholic Neutrophilia And Hepatotoxicity
  • 1310: Good relationship between RIPK3-mediated necroptosis with neutrophil-mediated alcoholic liver inflammation and the prognosis
  • 1311: Transcriptomics of liver tissue, PBMCs, and monocytes in alcoholic hepatitis
  • 1312: Single cell gene expression analysis identifies a chronic alcohol-mediated shift in the distribution of hepatocyte molecular states after partial hepatectomy
  • 1313: Role of 13C-Octanoate Breath Test for non-invasive evaluation of Alcoholic Steatohepatitis
  • 1314: Mice with myeloid-specific deletion of StARD1 develop acute-on-chronic alcoholic steatohepatitis
  • 1315: Ethanol Induces ATM-mediated DNA Damage Response along with Additional Oxidative DNA Damage and Mitochondrial Injury that is Amenable to Receptor-mediated Therapeutics
  • 1316: Alcohol Liver Disease is now the most rapidly rising Indication for Liver Transplant Waitlist Registration in the United States
  • 1317: Role of Serum Zinc And Polyunsaturated Fatty Acids In The Exacerbation Of Liver Injury In Treatment Naïve HIV-Infected Alcohol Dependent Patients
  • 1318: The Impact of Strength of Social Support on Alcohol Use Behaviors in Patients with Alcohol Related Cirrhosis
  • 1319: “You Gotta Want It”: Misconceptions, Preferences, and Barriers to Alcohol Use Treatment in Alcoholic Liver Disease
  • 1320: Errors and Misconceptions about Alcohol Use are Common Among Patients with Alcoholic Liver Disease
  • 1321: Prognostic Value of Liver Histology in "Low-Risk" Alcoholic Liver Disease (Maddrey Score <32)
  • 1322: The Role Of The Il-8 Signaling Pathway In The Infiltration Of The Liver By Granulocytes In Alcoholic Hepatitis
  • 1323: Ethanol impairs mitochondrial function and ATP synthesis in skeletal muscle in alcoholic liver disease
  • 1324: Lipolysis in hepatocytes is regulated by β-adrenergic induction and attenuated by alcohol.
  • 1325: The characteristic features of Japanese patients with alcoholic liver disease from the view of complicated obesity or sarcopenia

Cell Structure and Function

  • 1326: Altered biliary differentiation of human iPSC lines relevant to biliary atresia
  • 1327: A Novel and Direct Interaction Between Large and Small GTPases Mediates Autophagic Lipid Droplet Breakdown in Hepatocytes
  • 1328: Caspase 1-dependent cleavage of the Rab7 trafficking adaptor RILP links inflammasome activation to increased exosome secretion in inflammatory liver diseases
  • 1329: Yap1 Activation Induces TGF-β Signaling and Epithelial-to-Mesenchymal Transition (EMT) in Regenerating Hepatocytes After Partial Hepatectomy
  • 1330: Lipid droplet homeostasis is crucial for the establishment of polarity in collagen sandwich-cultured hepatocytes.
  • 1331: Co-Transplantation of Liver Sinusoidal Endothelial Cells, Kupffer Cells and Hepatocytes Improved Cell Engraftment and Repopulation in the Mouse Liver
  • 1332: Modulation of KATP Channel by Blockade of the Sulfonylurea Receptor Subunit Enhanced Engraftment and Proliferation of Transplanted Hepatocytes by Improving Mitochondrial Functionality
  • 1333: Age-dependent effects of intracellular ATZ protein globules on hepatocyte proliferation and ploidy in alpha-1 antitrypsin deficiency
  • 1334: Inhibition of hypoxia inducible factor via upregulation of von Hippel-Lindau protein induces 'Angiogenic switch off' in a mouse hepatoma model
  • 1335: A simple method for long term cultures of primary human hepatocytes
  • 1336: Activin A is a prominent autocrine regulator of multiple molecular and biological functions in hepatocytes, especially growth control and metabolic homeostasis
  • 1337: STARD11-mediated Ceramide Transport is Necessary for Release of Lipotoxic Extracellular Vesicles
  • 1338: STAT3 deficiency prevents hepatocarcinogenesis and promotes transdifferentiation of hepatocytes into biliary cells in chronic liver injury of mice.
  • 1339: The effects of aging on polarization and lipid droplets in hepatocytes.
  • 1340: Reduction of Organelle Motility by Removal of Potassium and Other Solutes
  • 1341: MAL2 overexpression promotes collective cell migration, a feature of metastatic epithelial-derived cancer cells
  • 1342: State of activation of Hepatic Stellate Cells determines their role in Hepatocellular Carcinoma progression or arrest
  • 1343: The divergent roles of matriptase and HAI-1 in human hepatocyte and biliary duct epithelium
  • 1344: Hepatic Stellate Cell-Induced Cytotoxicity in Liver Cancer Cells: Special Role of Apoptosis Inducing Factor (AIF)
  • 1345: Rab1a Binds to and Recruits the Minus-end-directed Kinesin, KifC1, to Early Endocytic Vesicles
  • 1346: The Cytoskeletal Protein β-Actin Mediates T Cell Apoptosis during Acute Liver Allograft Rejection in a Rat Model
  • 1347: Cold storage of porcine hepatocytes

Clinical Liver Cancer

  • 1348: Aspirin and the Risk of Hepatocellular Carcinoma Development in Patients with Compensated Alcoholic Cirrhosis
  • 1349: Trial Design: Phase I study to evaluate safety and anti-tumor activity of autologous T cells with alpha-feto protein (AFPc332T) receptor in patients with advanced hepatocellular carcinoma (HCC)
  • 1350: Identification of serum cold inducible RNA-binding protein as a novel biomarker that predicts survival in patients with resectable hepatitis B-related hepatocellular carcinoma
  • 1351: Development and Validation of a Primary Sclerosing Cholangitis Patient-Reported Outcome (PSC-PRO) Instrument
  • 1352: GNS561 a new quinoline derivative inhibits the growth of hepatocellular carcinoma in a cirrhotic rat and human PDX orthotopic mouse models
  • 1353: High expression of miR-196a is associated with progression of hepatocellular carcinoma
  • 1354: Time course of treatment-emergent adverse events (TEAEs) in the randomized, controlled phase 3 RESORCE trial of regorafenib for patients with hepatocellular carcinoma progressing on sorafenib treatment
  • 1355: A phenotypic map of disseminated hepatocellular carcinoma (HCC) shows clonal constrains in metastatic sites: a morphological study of 88 HCC autopsies.
  • 1356: Healthcare Delivery System is Associated with Curative Treatment Receipt and Overall Survival in Patients with Hepatocellular Carcinoma
  • 1357: Circulating Tumour Cell (CTC) biomarkers and the stratification of therapy for patients with hepatocellular carcinoma
  • 1359: Cancer surveillance in primary sclerosing cholangitis is associated with improved clinical outcomes.
  • 1360: Sorafenib versus transarterial chemoembolization plus external beam radiotherapy in patients with hepatocellular carcinoma with major vascular invasion (START): a randomized phase 2 trial
  • 1361: Direct Acting Antiviral Therapy is Associated with Shorter Time to HCC Recurrence but not Increased Risk of Recurrence
  • 1362: Hepatocellular Carcinoma Surveillance using Ultrasound and AFP Improves Early Detection and Survival in Patients with Cirrhosis
  • 1363: Natural course and clinical implications of hypovascular lesions on dynamic CT and/or Gd-EOB-DTPA-enhanced MRI detected during the diagnosis of hepatocellular carcinoma
  • 1364: Serum Wisteria Floribunda Agglutinin-Positive Sialylated Mucin 1 as a Biomarker of Hepatic Progenitor Cell/Biliary Features in Hepatocellular Carcinoma and of Prognosis
  • 1365: Multicenter, Randomized Pilot Study of the Effect of Sorafenib Dosing Schedule on Tolerability and Drug Delivery
  • 1366: A Prognostic Impact of Fibroblast-derived Cytokine, IL-34 in Non-hepatitis B virus-, Non-hepatitis C virus-related Hepatocellular Carcinoma Patients with Chronic Liver Disease
  • 1367: Comparison of Determinants for Hispanic-White and Black-White Disparities in Hepatocellular Carcinoma Prognosis
  • 1368: Differences in the Prevalence of Cancer Stem Cells and Features of Intrahepatic versus Ductal Cholangiocarcinoma Cell Lines
  • 1369: Health-related Quality of Life (HRQOL) and Disease Symptoms in Patients with Unresectable Hepatocellular Carcinoma (HCC) Treated with Lenvatinib (LEN) or Sorafenib (SOR)
  • 1370: IFN-free DAA treatment of cirrhotic HCV patients with or without history of HCC: a multicenter prospective trial in Italy
  • 1371: Pre-treatment alpha-fetoprotein slope is an independent predictor for overall survival of hepatocellular carcinomas.
  • 1372: Low serum zinc concentration is a risk for development of hepatocellular carcinoma and oral zinc supplementation decreases its risk in patients with HCV eradication by direct-acting antivirals
  • 1373: Autophagy in tumors and the liver microenvironment strongly predict hepatocellular carcinoma recurrence after curative resection
  • 1374: Non-tumor portal vein thrombosis (PVT) increases with number of local regional therapies (LRT) and waitlist time in liver transplant (LT) candidates with hepatocellular carcinoma (HCC)
  • 1375: The Association Between Tumour Size and Overall Survival in Surgically Resected Patients with Intrahepatic Cholangiocarcinoma: A Population-based Study.
  • 1376: Sarcopenia measured by psoas muscle index is an independent factor for mortality in Korean patients with hepatocellular carcinoma who underwent curative hepatic resection
  • 1377: Predictive microenvironment factors in hepatic tissue are key in the development of de novo occurrence or recurrent HCCs after DAAs
  • 1378: HCC-derived lncRNA CRNDE Inhibits T Lymphocyte Activation and Impairs Host Immunity Leading to Immune Evasion and HCC Progression
  • 1379: Clusterin and its’ related NR index could serve as an early predictor of sorafenib response.
  • 1380: Lack of evidence for increased rates of hepatocellular carcinoma following treatment with direct acting antivirals: a systematic review and meta-analysis.
  • 1381: Gene expression of the NOX family members and their clinical significance in hepatocellular carcinoma
  • 1382: Efficacy and Safety of Lenvatinib for Unresectable Hepatocellular Carcinoma in Patients with Baseline Hepatitis B Virus (HBV)
  • 1383: Efficacy and safety of vitamin K + sorafenib combination treatment against hepatocellular carcinoma-Open label, randomized, phase 2 study.
  • 1384: Predicting the risk of hepatocellular carcinoma in 116,404 cirrhotic patients according to etiology of cirrhosis.
  • 1385: Risk of hepatocellular carcinoma in patients with chronic hepatitis C who achieve sustained virologic response with interferon-free versus interferon-based therapy in Japan
  • 1386: Does Interferon-free Direct-acting Antiviral Therapy for Hepatitis C Lead to Unexpected Recurrences of Hepatocellular Carcinoma ? Real-World Nation-Wide Multicenter Study by the Japanese Red Cross Hospital Liver Study Group
  • 1387: Comparison with Child-Pugh, liver damage and newly proposed ALBI-grade for assessment of hepatic function and predicting prognosis of Japanese patients with hepatocellular carcinoma
  • 1388: High-quality diets are associated with reduced risk of hepatocellular carcinoma: diet quality index analyses in the Multiethnic Cohort
  • 1389: Comparison of Repeated Surgical Resection and Radiofrequency Ablation for Small Recurrent Hepatocellular Carcinoma after Primary Resection
  • 1390: Hepatocellular Carcinoma (HCC) Incidence in Hispanics Overtakes Asians to become the Ethnic Group with the Highest HCC Incidence in the U.S.: An Updated Analysis of 2000-2014 Surveillance Epidemiology and End Results Cancer Registry
  • 1391: Is the incidence of liver cancer increased after DAA treatment of chronic hepatitis C?
  • 1392: Using Nomogram of the Barcelona Clinic Liver Cancer System for Treatment Selection in Patients with Stage C Hepatocellular Carcinoma
  • 1393: Transarterial chemoembolization shows no superiority to bland embolization as the adjuvant therapy after curative hepatectomy for hepatocellular carcinoma: a retrospective cohort study
  • 1394: Tumor burden improves prognosis prediction for patients with terminal hepatocellular carcinoma: a nomogram study
  • 1395: Application of the Albumin Bilirubin (ALBI) Grade improves the prognostic ability of the Barcelona Clinic Liver Cancer (BCLC) Staging system and helps to guide therapy.
  • 1396: Effects of an adjuvant direct-acting antiviral drug therapy-induced sustained virological response after hepatic resection for hepatitis C virus-related solitary hepatocellular carcinoma
  • 1397: The impact of thyroid hormones on patients with hepatocellular carcinoma
  • 1398: Nearly One in Five Hepatocellular Carcinoma (HCC) Patients in the U.S. are of Hispanic Ethnicity, But less than 40% had HCC Within Milan Criteria at Time of Diagnosis
  • 1399: Nonalcoholic Steatohepatitis Remains the Fastest Growing Indication for Liver Transplantation in Patients with Hepatocellular Carcinoma in the United States
  • 1400: The Association of Nonalcoholic Steatohepatitis and Hepatocellular Carcinoma
  • 1401: A Proposal for Modification of Barcelona Clinic Liver Cancer System for Hepatocellular Carcinoma Staging Based on Korean Multicenter Registry Database
  • 1402: No-touch radiofrequency ablation is an ideal method to prevent intrahepatic metastasis of hepatocellular carcinoma
  • 1403: Quality of life assessment increases the accuracy of survival prediction in HCC patient
  • 1404: Risk factors for hepatocellular carcinoma development in patients with chronic HBV infection during nucleos(t)ide analogues therapy: a result of 10-year follow up
  • 1405: A simple scoring system incorporating ALBI grade predicts survival in patients with hepatocellular carcinoma – a study of 1,270 patients
  • 1406: MicroRNA-125b expression levels and intrahepatic metastasis are predictors for early recurrence after hepatocellular carcinoma resection
  • 1407: Osteopontin predicts the prognosis of patients with single nodule or early-stage hepatocellular carcinoma and should be associated with the microenvironment of background liver
  • 1408: Treatment Patterns and Healthcare Costs by Lines of Therapy in Patients with Advanced Hepatocellular Carcinoma Treated with Systemic Cancer Therapy
  • 1409: Phase 3 biomarker study for HCC surveillance using AFP, AFP-L3 and DCP: A prospective collection with retrospective blinded evaluation
  • 1410: Serum Biomarkers Improve Prognostic Ability of BCLC Staging System
  • 1411: Impact of Hepatocellular Carcinoma (HCC) and Tumor Treatment on Sustained Virologic Response (SVR) Rates with Direct-Acting Antiviral (DAA) Therapy for Hepatitis C: HCV-TARGET Results
  • 1412: Unexpected Hepatocellular Carcinoma (HCC) following treatment-induced HCV clearance in a VA cohort.
  • 1413: Tumor biomarkers and regorafenib (REG) efficacy in patients with hepatocellular carcinoma (HCC) in the RESORCE trial
  • 1414: Intratumoral Expression of Tregs Predicts Prognosis in Patients with Hepatocellular Carcinoma
  • 1415: Prediction of Hepatocellular Carcinoma in Non Alcoholic Fatty Liver Disease in a Screening Cohort
  • 1416: Higher levels of AFP, AFP-L3, and PIVKA-II in hepatocellular carcinoma recurrence in patients with chronic hepatitis C who achieved sustained virologic response with interferon-free compared with interferon-based therapy
  • 1417: A simple clinical score to predict survival in patients with hepatocellular carcinoma
  • 1418: Direct acting antiviral therapy after curative treatment of hepatocellular carcinoma improved recurrence free survival rate
  • 1419: Diabetes, duration of diabetes, use of anti-diabetic medications, and risk of hepatocellular carcinoma
  • 1420: Effect of Statins on the Risk of Extrahepatic Cholangiocarcinoma
  • 1421: Hepatocellular carcinoma recurrence after curative treatments in patients with chronic hepatitis C who underwent direct-acting antiviral therapy
  • 1422: Evolution Of Prognosis And Characteristics Of Patients With Hepatocellular Carcinoma Over Last Decades
  • 1423: Liver Resection for BCLC 0-A Stage Hepatocellular Carcinoma Does Time to Surgery Impact Outcomes?
  • 1424: Immunohistochemical detection of markers for hepatic adenoma in steatohepatitic hepatocellular carcinoma
  • 1425: A Novel Prognostic Algorithm for Patients with NAFLD-related Hepatocellular Carcinoma: A Nationwide Data-mining Analysis by Japan Study Group of NAFLD
  • 1426: Serum HMGB1 concentrations is a useful predictor of extreme poor prognosis for advanced hepatocellular carcinoma treated with sorafenib and hepatic arterial infusion chemotherapy
  • 1427: Impact of HIV and Chronic HCV Status on Advanced HCC Stage in Veterans
  • 1428: Prognosis of Patients with Non-hepatitis B virus-, Non-hepatitis C virus-related Hepatocellular Carcinoma: A Comparison with Hepatitis C virus-related Hepatocellular Carcinoma Patients
  • 1429: Transarterial chemoembolization within first 3 months of sorafenib initiation improves overall survival in intermediate to advanced stage hepatocellular carcinoma: A retrospective, multi-institutional study with propensity matching
  • 1430: Robust efficacy of hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with macroscopic vascular invasion: a comparative study with sorafenib
  • 1431: Hypothyroidism is associated with poorer survival in hepatocellular carcinoma patients after liver transplantation
  • 1432: Hepatocellular Carcinoma Screening Rates in Diverse Patients with Chronic Hepatitis B Infection
  • 1433: Clinical outcomes of localized concurrent chemoradiotherapy for advanced hepatocellular carcinoma with major portal vein invasion: A single center experience
  • 1434: sCTLA-4 is a predictor for recurrence in hepatocellular carcinoma patients treated with curative radiofrequency ablation
  • 1435: Evolution Of Cirrhotic Patients With Hepatitis C Virus Treated With Direct Acting Antivirals
  • 1436: Dynamic Change of Skeletal Muscle Index as a Novel Prognostic Predictor in Patients with Intermediate Stage Hepatocellular Carcinoma Treated with Transarterial Chemoembolization
  • 1437: Treatment and Prognosis of locally advanced HCC with main portal vein invasion
  • 1438: Role of Hepatic STAMP2 Overexpression in Human Hepatocellular Carcinoma
  • 1439: FIB-4 Index, the Easy Liver Fibrosis Test, and Prediction of Hepatocellular Carcinoma Development in Patients with Compensated Alcoholic Liver Cirrhosis
  • 1440: Clinical impact of globulin albumin score on outcome after surgery for patients with hepatocellular carcinoma.
  • 1441: Incidentally detected Hepato-cellular carcinoma: Silent, larger, aggresive !!
  • 1442: Conditional survival estimates improve over time for patients with hepatocellular carcinoma: An analysis for nationwide Korea cancer registry database
  • 1443: Assessing Hong Kong Liver Cancer classification in a Western cohort: results from South America
  • 1444: Pre-transplant BALAD and BALAD-2 score to predict recurrence and survival of patients with hepatocellular carcinoma who underwent liver transplant
  • 1445: Phase angle (and NOT BMI) correlates with Child Pugh class and BCLC stage among HCC patients: may it improve after nutritional support? Preliminary results.
  • 1446: Hepatocellular Carcinoma in Baby Boomers is associated with High Rates of Inpatient Morbidty and Mortality
  • 1447: Hepatocellular Carcinoma results in Highest Number of Malignancy-related Hospitalizations in Baby Boomers
  • 1448: Epirubicin-Eluting Superabsorbent Microsphere Embolization: An Alternative Option for Advanced Hepatocellular Carcinoma Refractory to Conventional Transcatheter Chemoembolization
  • 1449: Increased oxidative stress in leukocytes of patients with very early/early hepatocellular carcinoma
  • 1450: Recent Changes of Time-Trends in Clinical Features, Treatment, and Survival from Korean Patients with Hepatocellular Carcinoma
  • 1451: Risk Assessment of Hepatocellular Carcinoma in Patients with Hepatitis C in China and the United States
  • 1452: Surgery versus locoregional treatment in BCLC stage 0 HCC patients
  • 1453: Treatment and Prognosis of advanced HCC with distant metastasis
  • 1454: Soluble Programmed Death-1 as a Serum Marker of Poor Liver Function for Hepatocellular Carcinoma Patients
  • 1455: Long-term Outcome After Radiofrequency Ablation for Hepatocellular Carcinoma With Special Interest to Anti-viral Therapy
  • 1456: Baseline ALBI grade and its time course are predictive factors of prognosis and Child-Pugh grade worsening in patients who underwent initial TACE
  • 1457: Demographic and Clinical Outcomes of Patients with Hepatocellular Carcinoma(HCC) NOS compared with Clear Cell Hepatocellular Carcinoma(HCC): A United States Population Based Analysis (SEER 1973-2013)
  • 1458: Serum and bile squamous cell carcinoma antigen 1 (SCCA1) detection: a new diagnostic approach in patients with perihilar cholangiocarcinoma (pCCA)
  • 1459: The incidence of Denovo HCC or aggressive recurrence of HCC in patients with HCV infection receiving DAA therapy.
  • 1460: Hepatocellular Carcinoma Impacts In-Hospital Mortality among Cirrhotic Patients
  • 1461: Hepatocellular carcinoma (HCC) in multitransfused patients (pts) with thalassemia major (TM) Risk factors, characteristics and therapeutic approaches
  • 1462: Incidence Rates of Hepatocellular Carcinoma in the United States have now Plateaued Except in Hispanic Women

Hepatitis B: Virology, Immunology and Pathogensis

  • 1463: The combination effects of CRISPR/Cas9 and APOBEC3B editing on HBV cccDNA formation
  • 1464: Clonal expansion of hepatitis B virus with S gene escape mutations in the process of reactivation from resolved HBV infection
  • 1465: Pathophysiological role of Receptor Interacting protein kinase 3 derived necroptosis in the acute on chronic liver failure related with Hepatitis B virus independently of NKT/NK cells
  • 1466: Identification of a Triple Mutation that Confers Tenofovir Resistance in Chronic Hepatitis B Patients
  • 1467: HBV infection promotes autophagy by ULK-1 activation leading to increase of HBV replication
  • 1468: TARDBP regulates HBV transcription and replication through interaction with the core promoter
  • 1469: Pilot study of HBsAg turnover rate in patients with chronic HBV infection
  • 1470: Hepatitis B core-related antigen (HBcrAg) correlated with HBV serum viral markers and intrahepatic indicators in treatment-naïve patients with acute and chronic HBV
  • 1471: Characterizing the early immune response to hepatitis B virus infection using the human hepatocyte chimeric mouse model
  • 1472: Analysis of polyploidy of human hepatocytes isolated from hepatitis B virus-infected chimeric mice with humanized liver
  • 1473: The role of IL-21 in the process of HBsAg clearance in the invitro and in vivo study
  • 1474: HBV-specific T cell immunity in inactive carrier patients is independent of Hepatitis B surface antigen load.
  • 1475: Discovery of A Highly Potent and Selective Capsid Assembly Inhibitor (WX-066) For the Treatment of Chronic HBV Infection
  • 1476: How does concomitant positive HBsAg affect the risk of hepatic metastasis- a retrospective clinical study in consecutive 4033 cases of newly-diagnosed colorectal cancer
  • 1477: Persistent Loss of HBV Markers in Serum without Cellular Immunity by Combination of PEG-IFN Plus ETV Therapy in Humanized Mice
  • 1478: Perlecan inhibition efficiently decreases HBV susceptibility of PHHs possibly via NTCP downregulation.
  • 1479: HCV and HBV infection promote liver fibrogenesis through the TGFβ1 induced OCT4/Nanog pathway
  • 1480: HBV different viral load infection model reveals interaction between HBV and molecular signature of host hepatocytes isolated from chimeric mouse with humanized liver
  • 1481: Discovery of an HBeAg-like antigen in hepatitis E
  • 1482: Inhibitory effect of acyclic retinoid on hepatitis B virus replication
  • 1483: Comprehensive molecular characterization of hepatitis B virus-associated acute liver failure
  • 1484: Genetic Polymorphisms and Decreased Expression of Human Leukocyte Antigen (HLA) class II DP Genes are Associated with Hepatitis B Virus (HBV) Reactivation in Patients Treated with Immunomodulatory Agents
  • 1485: Longitudinal deep sequencing reveals effect of TDF treatment on HBV diversity in adolescents
  • 1486: Antigenicity reduction contributes mostly to poor HBsAg detectability of clinically isolated HBV S-gene mutants
  • 1487: Single-Nucleotide-Level Analysis of Evolution and Compartmentalization of Complete Hepadnavirus Genome during Virus Passage in Hosts Developing Chronic Hepatitis and Hpatocellular Carcinoma
  • 1488: Intracellular HBV degradation is associated with Notch signaling inhibition via ITCH in a ubiquitin proteasome–dependent manner
  • 1489: PDCD1 methylation status predicts Hepatitis B Surface antigen seroclearance in HBV reactivation
  • 1490: MX1 variants differentially regulate HBV replication
  • 1491: Rab5B determines HBV release pathways by promoting transport of LHBs from ER to MVB
  • 1492: HLA-DRB1-DQB1 haplotypes and BTNL2 gene associate with response to a hepatitis B vaccine
  • 1493: High rates of osteopenia and osteoporosis in chronic hepatitis B caucasian patients untreated and treated with tenofovir disoproxil fumarate (TDF): a 4-year longitudinal cohort study
  • 1494: The expression of serum miR-125b-5p may serve as a new biomarker of the HBV-infected hepatitis progression
  • 1495: HBV induced overexpression of glucose-regulated protein 78 regulates hepatocyte apoptosis: possible correlation to hepatocarcinogenesis
  • 1496: Nucleos(t)ide analogues and interferon affect intranuclear HBV genome in vitro via Notch signaling modification, independent of the ubiquitin-proteasome system
  • 1497: Accumulation of the Large Hepatitis B Surface Antigen Predisposes Hepatocytes to IFNα Mediated Cell Death.
  • 1499: Kinetics of HBsAg and HBV-DNA in patients undergoing DAAs therapy for chronic hepatitis C
  • 1500: Liver fibrosis is associated with subclinical atherosclerosis in patients with chronic hepatitis B: Results from a prospective multicentre study.
  • 1501: Hepatitis B virus up-regulates IL8 expression via endoplasmic reticulum stress and leads to suppress interferon responsiveness
  • 1502: The Balance of Type 1 and Type 2 Immune Responses in the Contexts of Hepatitis B Infection and Hepatitis D Infection
  • 1503: Rapid Turnover of cccDNA in Chronic Hepatitis B Patients Who Have Failed Nucleoside Treatment Due to Emerging Resistance
  • 1504: A liver-derived secretory protein, LECT2, activates plasmacytoid dendritic cells and protects hepatocytes from HBV infection
  • 1505: Identification of novel HLA- A*2402-restricted endogenous CTL epitopes derived from HBV genotype C
  • 1506: Fusion HBx from HBV integrant might be implicated in hepatocarcinogenesis through dysregulation of ER stress response
  • 1507: Change in T cell cytokines and Tregs as markers of HBV reactivation in patients with hepatocellular carcinoma
  • 1508: Clinics features of HBeAg-positive treatment-naïve chronic hepatitis B patients with precore and/or basal core promoter mutations
  • 1509: Characterization of Hepatitis B Virus (HBV)-Specific T-Cell Dysfunction in Korean patients with chronic HBV infection
  • 1510: Novel non-canonical genetic rearrangements termed “complex structural variations” in HBV genome
  • 1511: Hepatitis B Virus-specific T Cell Responses Are Regulated by Type I Interferon Signaling and Correlated with Intrahepatic Antigen Expression
  • 1512: Detection of hyper-conserved regions in the hepatitis B virus X gene in chronic hepatitis B patients, potentially useful for targeted gene therapy
  • 1513: Critical adaptive immune regulators are differentially regulated in kidney transplant recipients with or without chronic hepatitis B.
  • 1514: Differential Genotype-Dependent Induction Of Cellular Epigenetic Changes By HBV X Protein Expression In Hepatoma Cell Line

Hepatitis C: Therapeutics - Approved Agents II

  • 1515: High sustained virological response with direct-acting antiviral in patients with chronic hepatitis C and inherited blood disorders: a real-life experience
  • 1516: HCV RNA in peripheral blood mononuclear cells may predict sustained virological response to DAAs therapy in HCV patients
  • 1517: Effectiveness and safety of Sofosbuvir-based therapy in patients with chronic hepatitis C virus infection: results from the prospective French multicenter real-world cohort (HELIOS)
  • 1518: First Real World Data of Treatment Outcomes with Direct Acting Antivirals in HIV-HCV co-infected patients from Manipur, India
  • 1519: Risk and outcome of hepatitis B virus (HBV) reactivation during chronic hepatitis C treatment with direct-acting antivirals (DAAs) in patients with HCV-related advanced fibrosis: a single-center experience
  • 1520: Real-World Effectiveness of Sofosbuvir-based Regimens for Treatment of Hepatitis C Genotypes 1-3: BC Hepatitis Testers Cohort (BC-HTC)
  • 1521: Real-world Effectiveness (RWE) of Sofosbuvir+Ribavirin (SOF+RBV) Chronic Hepatitis C Genotype 2 (CHC GT 2) in Asia: A Systemic Review and Meta-analysis of Pooled SVR12
  • 1522: Safety and Efficacy of Elbasvir/Grazoprevir in Asian Participants with Hepatitis C Virus Genotypes 1 and 4 Infection: An Integrated Analysis of Data from 11 Phase 2/3 Trials
  • 1523: Sustained Virological Response 12 Weeks after Therapy (SVR12) with Direct-Acting Antivirals (DAA) in Select Asian Populations with Chronic Hepatitis C Genotype 1 (HCV GT 1): A Meta-Analysis of Real-World Effectiveness from Asia
  • 1524: Efficacy and safety of treatment with direct acting antiviral(s) in Chronic Hepatitis C (CHC) patients with compensated advanced liver disease and signs of portal hypertension. HERACLIS: a Hellenic multicenter real-life cohort clinical study
  • 1525: Efficacy and safety of direct acting antivirals (DAA) in elderly patients with cirrhosis and high comorbidity index
  • 1526: Treatment of hepatitis C patients in a public health care setting with sofosbuvir-based treatment regimens: Efficacy and safety in real-life in Punjab, India
  • 1527: High efficacy of the currently recommended regimens of 2 Direct Acting Antivirals (DAAs) + Ribavirin (R) in HCV genotype 4 (GT4) patients (pts) with advanced fibrosis or cirrhosis in HERACLIS real world cohort
  • 1528: High virological efficacy of sofosbuvir/daclatasvir plus flat dose ribavirin in genotype 3 cirrhotic patients: a real life study
  • 1529: Cardiovascular Risk Evolution After Hepatitis C Treatment With DAA In- HCV/HIV Coinfected Patients
  • 1530: Real-Word Effectiveness of Sofosbuvir/Velpatasvir (SOF/VEL)-Based Therapy for Hepatitis C Virus (HCV) Genotype (GT) 2 and 3: Analysis in a Large North American Integrated Health Care System
  • 1531: Long term outcomes of liver transplantation in the direct-acting antiviral era
  • 1532: Regression of liver stiffness (LS) after direct acting anti-viral (DAA) therapy for hepatitis C in the country of Georgia
  • 1533: Real World Treatment Outcomes with Direct Acting Antivirals: Collated Multicentre Data from India
  • 1534: Comparison of Original and Generic DAA’s in Treatment of Chronic Hepatitis C Patients: Real Life Data from Latvia
  • 1535: Direct-Acting Antivirals (DAAs) treatment Improves Hepatitis C Virus (HCV)-Associated Mixed Cryoglobulinemia Symptoms.
  • 1536: Real World Hepatitis B Virus Screening Rates in Hepatitis C patients treated with Direct-Acting Antiviral Agents
  • 1537: Safety and Efficacy of 8-weeks Ledipasvir/Sofosbuvir Combination in Chronic Hepatitis C Genotype 4–Infected Patients
  • 1538: From Diagnosis to Cure: An Integrated Health System Baby Boomer HCV Screening and Therapy Management Program
  • 1539: Roles of designated hepatologists on treatment of chronic hepatitis C patients with directly-acting antivirals: Evidences based on nation-wide, real-world database in Japan
  • 1540: The Real-World Israeli Experience of Treating Chronic Hepatitis C (CHC), Genotype 1 (GT1) and Genotype 4 (GT4) Patients with Advanced Fibrosis with Elbasvir\ Grazoprevir: A Large Multi-Center Cohort.
  • 1541: Quality of life in HCV patients treated with Ombitasvir/Paritaprevir/r ± Dasabuvir ± Ribavirin under real-life conditions - data from the German observational study LIFE-C
  • 1542: Patient-Reported Quality of Life Improves After Treatment of Hepatitis C with Direct-Acting Anti-Virals: A Real-World Experience
  • 1543: The real-world efficacy, changes in liver stiffness values and fibrosis markers, and the safety of daclatasvir plus asunaprevir used to treat patients with HCV genotype 1b infection
  • 1544: Efficacy and safety of retreatment with Elbasvir/Grazoprevir associated to Sofosbuvir +/- Ribavirin in HCV infected patients with a previous failure to therapy with direct-acting antiviral drugs
  • 1545: Cost-effectiveness of ledipasvir/sofosbuvir in elderly patients with genotype 1b chronic hepatitis C: An analysis with real-world outcomes from a multicenter cohort in Japan
  • 1546: Co-morbidities and clinically relevant drug-drug interactions (DDIs) in patients undergoing treatment of chronic HCV genotype 1 (GT1) infection with elbasvir (EBR)/grazoprevir (GZR): results from the German Hepatitis C Registry (DHC-R)
  • 1547: High sustained virological response rates in genotype 4 patients with advanced liver disease treated with 12 weeks of ombitasvir/paritaprevir-ritonavir plus ribavirin: a single center real-life study
  • 1548: Occult hepatitis C virus infection in patients treated with direct-acting antiviral agents: does this phenomenon exist and is it the driving force for tumorigenesis?
  • 1549: Efficacy and safety of sofosbuvir and daclatasvir for 8 weeks in treatment-naïve non-cirrhotic patients with chronic HCV Genotype 3 Infection
  • 1550: Evaluation of a diverse patient population’s sustained virologic response rates after hepatitis C virus treatment at an urban academic medical center with an interdisciplinary team including a clinical pharmacist
  • 1551: Hepatitis C (HCV) Treatment and SVR12: The Gap Between Clinical Trials and Community Practice with DAA Therap
  • 1552: Receiving directly acting antivirals (DAAs) for hepatitis C improves renal function in patients with CKD regardless of SVR
  • 1553: Direct Acting Antivirals in Hepatitis C Virus Genotype 3 and Advanced Cirrhosis
  • 1554: Occurrence of new of hepatocellular carcinoma in patients with hepatitis C treated with all oral direct-acting anti-virals
  • 1555: Effectiveness, Safety and Clinical Outcomes of Paritaprevir/Ombitasvir/r + Dasabuvir 8 Weeks: Results from a Spanish Real World Cohort (Hepa-C)
  • 1556: Weight based ribavirin with sofosbuvir and daclatasvir for 12 weeks for patients with Genotype 3 Hepatitis C and cirrhosis: An analysis of efficacy and long-term clinical outcomes.
  • 1557: Population pharmacokinetic analysis of ledipasvir in patients with decompensated cirrhosis – results from the UK Expanded Access programme.
  • 1558: SOF/LDV treatment in patients with transfusion-dependent thalassemia major and HCV genotype 1 or 4 infection: follow-up data on liver stiffness, ferritin and liver iron concentration
  • 1559: Prevalence and Factors Associated with Detectable Viral Load at End of Treatment in Direct-Acting Antiviral (DAA)-Treated Patients: Implications for Guidance on HCV RNA Monitoring During Treatment
  • 1560: Treatment of chronic HCV following renal transplantation: A US Experience
  • 1561: Gadoxetic Acid-Enhanced MR Imaging to Predict Paritaprevir-Induced Hyperbilirubinemia During Treatment of Hepatitis C
  • 1562: Multiple Comorbidities and Significant Pill Burden in Hepatitis C Patients in a Large US Insured Population
  • 1563: Successful Hepatitis C Treatment with DAAs Improves Hepatic fibrosis.
  • 1564: Real life experience with Sofosbuvir plus Daclatasvir With or Without Ribavirin for Treatment of Chronic hepatitis C Genotype 4 Patients.
  • 1565: The clinicopathological characteristics of newly diagnosed hepatocellular carcinoma shortly after IFN-Free-DAA therapy
  • 1566: Real Life Data of Daclatasvir and Asunaprevir Combination Therapy for Korean Patients Infected with HCV G1b without NS5A Resistance: Retrospective Multicenter Study
  • 1567: Regression of liver stiffness in patients with HCV-related compensated cirrhosis after viral eradication by DAAs
  • 1568: Utilization and Effectiveness of Elbasvir/Grazoprevir (EBR/GZR) in Treatment Naïve (TN) Genotype 1a (G1a) Chronic Hepatitis C Virus (HCV) Patients with/without Baseline NS5A resistance-associated substitutions (RASs)
  • 1569: On-treatment HCV RNA kinetics do not predict SVR in patients treated for 12 weeks with sofosbuvir plus an NS5A inhibitor
  • 1570: The impact of direct acting antivirals (DAAs) in patients with decompensated liver disease (DLD) due to chronic hepatitis C (CHC). HERACLIS - a multicenter Greek real world study
  • 1571: Direct Acting Antiviral HCV Treatment Influence Lactate and Glucose Levels
  • 1572: Safety and effectiveness of treatment of hepatitis C virus with direct acting antivirals in patients with solid organ transplantation
  • 1573: Evolution of thrombocytopenia in patients with hepatitis C virus infection and advanced fibrosis after treatment with direct antiviral agents.
  • 1574: Real-World Experiences with Direct-Acting Antivirals for Hepatitis C Treatment
  • 1575: Optimising the impact of direct-acting antiviral treatment in Hepatitis C: Lessons from a universal access, real-world cohort
  • 1576: Eradication Of Chronic Hepatitis C Infection With Direct Acting Antivirals Is Associated With Reduction In Fibrosis By Transient Elastography (FibroScan)
  • 1577: Does age matter? Direct-acting antiviral therapy for hepatitis C in a real-life cohort of elderly patients: pretreatment drug-drug interactions, tolerability and efficacy of current treatment regimens.
  • 1578: Pan-genotypic hepatitis C treatment with glecaprevir/pibrentasvir achieves greatest improvements in quality-adjusted life-years and lifetime risk reductions in liver-related morbidity and mortality vs standards of care: a cost-utility analysis
  • 1579: Effects of IFN-free therapy for hepatitis C virus after hepatocellular carcinoma treatment on early HCC recurrence compared to IFN-based therapy
  • 1580: Comparative Analysis of SVR and Side-Effects of Branded and Generic SOF/LED Treatment of Real-Life Patients with Chronic Hepatitis C Infection in Mongolia
  • 1581: Neutrophil-to-lymphocyte ratio and decreased liver volume indicate increased hepatocellular carcinoma risk after hepatitis C cure
  • 1582: High Cure Rate of Hepatitis C in a Primary Care Clinic for People Who Have Limited Access to Specialty Care
  • 1583: Hepatitis C Direct-Acting Anti-Viral treatment options in patients with epilepsy. A drug-drug interaction dilemma in Hepatitis C infection
  • 1584: Elbasvir, Grazoprevir; with or without Ribavirin and its Effectiveness with Sofosbuvir resulting SVR in chronic hepatitis C genotype 1 prior experienced co-infected individuals. A randomized open label clinical prospective trial: EGRESS - C
  • 1585: Comparing Direct Acting Antivirals-Based Regimens Plus Ribavirin in Treatment-Experienced Hepatitis C Virus Genotype 3 Patients: A Systematic Review and Meta-Analysis
  • 1586: Long-term improvement of liver function parameters after IFN-free therapy of advanced HCV- associated liver cirrhosis - Results from the German Hepatitis C-Registry (DHC-R)
  • 1587: Safety and Efficacy of Treatment with Once-Daily Ledipasvir/Sofosbuvir (90/400 mg) for 12 Weeks in Genotype 1 HCV-Infected Patients with Severe Renal Impairment
  • 1588: Treatment-failure to direct antiviral regimens in real world: frequency, patient characteristics and rescue therapy - Results from the German Hepatitis C-Registry (DHC-R)
  • 1589: Safety and Efficacy of Elbasvir (EBR)/Grazoprevir (GZR) in Hepatitis C Virus (HCV) GT1- and GT4-infected Participants 65 Years and Older: An Integrated Analysis of Twelve Clinical Trials
  • 1590: A past history of HCC is not associated to worst SVR in HCV cirrhotic patients treated with DAAs: a prospective multicenter Italian study.
  • 1591: Treatment of HCV with DAAs in cirrhosis: Risk of early de novo hepatocellular carcinoma (HCC) and impact of HCC on SVR.
  • 1592: Impact of Comorbidities and Comedications on the Effectiveness of Ombitasvir/Paritaprevir/Ritonavir ± Dasabuvir ± Ribavirin in Clinical Practice: Real-World Evidence From a Multicountry Postmarketing Observational Study
  • 1593: Safety and Effectiveness of Ombitasvir/Paritaprevir/Ritonavir ± Dasabuvir ± Ribavirin in HCV Genotype 1- and 4-Infected Patients Treated for 12 Weeks: Real-World Evidence From a Global Multicountry Postmarketing Observational Study
  • 1594: Barriers in Treatment of Hepatitis C in Somali Patients: The Epoch of the Direct Acting Antivirals.
  • 1595: Improving Hepatitis C Treatment Engagement: Getting at the What and How of Patient Information Needs and Preferences
  • 1596: Efficacy And Safety Of Elbasvir/Grazoprevir In Chronic C Hepatitis: Prospective And Observational Study In Real-World
  • 1597: Hepatitis C Direct-Acting Antiviral Treatment Failures: Clinical Characteristics, Outcomes And Resistance Testing From A ‘Real-World’ Setting.
  • 1598: Effectiveness of ledipasvir/sofosbuvir in hepatitis C virus genotype 1, 2 and 3 infection: real-world data from Georgian hepatitis C elimination program
  • 1599: Re-treatment of hepatitis C virus infected patients with relapse after 3D direct antiviral therapy
  • 1600: Real-world effectiveness and cost per svr of sofosbuvir/velpatasvir chronic hepatitis c treatment
  • 1601: Cost-effectiveness of sofosbuvir/ribavirin in patients with genotype 2 chronic hepatitis C: An analysis with real-world outcomes from a multicenter cohort in Japan
  • 1602: Real-world Effectiveness (RWE) and Adverse Events with Sofosbuvir plus Ribavirin (SOF+RBV) Based Therapies in Chronic Hepatitis C Genotype 3 (CHC GT 3) Patients in Asia- A Systematic Review of 8 Studies and 3510 Patient
  • 1603: Hepatitis C treatment with Simeprevir and Sofosbuvir in low socioeconomic population in a Federally Qualified Health Center [FQHC]
  • 1604: Care Cascade for Persons with Chronic Hepatitis C Infection: A Single Center Data from Mongolia
  • 1605: Failure to multiple Interferon-free direct antiviral therapies: could chronic hepatitis C become incurable?
  • 1606: A prospective, open-label, Multi-center study to evaluate efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir ± Ribavirin in genotype 1 patients with previous protease inhibitors failure: interim analysis (The Emerald study)
  • 1607: Feasibility and safety of concomitant antiviral therapy with DAAs and chemotherapy in patients with HCV chronic hepatitis and aggressive B-cell non-Hodgkin lymphomas
  • 1608: Title: Fighting hepatitis C virus genotype 3. Are we satisfied yet?
  • 1609: Comparison of IFN-based and DAA-based treatment on hepatocellular carcinoma recurrence in patients with curative treatment – a propensity score matching study
  • 1610: Grazoprevir/Elbasvir plus Sofosbuvir in HCV Genotype 1, 4 Infection after failure of sofosbuvir-based therapy
  • 1611: Smartphone Based Artificial Intelligence Platform Demonstrates High Rates of Adherence and Viral Outcome in Patients Receiving Fixed-Dose Ledipasvir and Sofosbuvir: A Pilot Study

Liver Cancer Diagnostics and Imaging

  • 1612: Predicting the response to sorafenib treatment for patients with hepatocellular carcinoma using 18F-fluorodexoyglucose positron emission tomography
  • 1613: A N-glycan based model may predict hepatitis B virus related hepatocellular carcinoma
  • 1614: Enhanced patterns by intraoperative contrast-enhanced ultrasonography predicts the outcomes in patients with hepatocellular carcinoma after curative liver resection.
  • 1615: Performance of liver biopsy and imaging in the diagnosis of Hepatocholangiocarcinoma: a preliminary study
  • 1616: Serum extracellular vesicles contain protein biomarkers for primary sclerosing cholangitis (PSC), cholangiocarcinoma (CCA) and hepatocellular carcinoma (HCC)
  • 1617: Utility of a new function in 3D Sim-Navigator: electric field, which indicates the predicted ablative area
  • 1618: Are we done with the immunohistochemical classification of hepatocellular adenoma?
  • 1619: Diagnosis of asymptomatic hepatocellular carcinoma by screening offers survival advantages compared to the symptom driven diagnosis
  • 1620: Serum Wisteria floribunda agglutinin-positive sialylated Mucin 1 as a meaningful prognostic biomarker after hepatic resection for HCV-positive patients with hepatocellular carcinoma
  • 1621: Developing A New Iodine Contrast Agent, Which Achieve Hepato-biliary Phase in CT imaging Through Hepatocyte Specific Transporters
  • 1622: Serum WFA+-M2BP Level as a Diagnostic Marker of Hepatitis B Virus-related Hepatocellular Carcinoma
  • 1623: Prognostic histological factors in resected colorectal liver metastasis with preoperative treatment.
  • 1624: Hepatocellular Carcinoma Surveillance: Benefit of Serum Alpha-fetoprotein in Real World Practice
  • 1625: Comparison of Acoustic Radiation Force Impulse Elastography and Transient Elastography for the Prediction of Hepatocellular Carcinoma Recurrence after Radiofrequency Ablation
  • 1626: Use of GALAD in HCC diagnosis: its relation to LI-RADS and tumor staging
  • 1627: The use of immunostains as a risk assessment tool in patients with hepatic adenomatosis
  • 1628: Circulating Hepatocytes: A Liquid Liver Biopsy for Chronic Liver Disease
  • 1629: Serum lysyl oxidase-like 2 as a potential biomarker for diagnosis and treatment response in hepatocellular carcinoma
  • 1630: High glypican-3 expression: an independent unfavorable prognostic factor of surgically-resected hepatocellular carcinoma

Liver Transplantation

  • 1633: No evidence of hepatitis B virus reactivation among liver transplant recipients treated with interferon-free regimens for hepatitis C virus recurrence (ANRS CO23 CUPILT Cohort)
  • 1634: Molecular Characterization of Three Human Hepatitis E Virus (HEV) isolated in France
  • 1635: Longitudinal Analysis of Hepatitis E Virus (HEV) in a U.S. Cohort of HIV-Infected Liver and Kidney Transplant Recipients
  • 1636: Direct-Acting Antiviral Regimens are Safe and Effective in the Treatment of Hepatitis C in Simultaneous Liver-Kidney Transplant Recipients
  • 1637: Outcome of liver transplant for HBV related acute-on-chronic liver failure in the era of more potent antiviral agents
  • 1638: DAAs Therapy Before Liver Transplant In Patients With Hepatocellular Carcinoma And HCV Liver Disease
  • 1639: Impact of direct-acting antiviral therapy on the need for liver transplantation related to hepatitis C in Germany
  • 1640: Risk Factors for Acute Cellular Rejection During Direct Acting Antiviral Therapy for Hepatitis C Recurrence in the Allograft
  • 1641: Influence of DAA treatment on waitlisting and transplant rate (TR) for HCV related liver disease: preliminary results of a single center experience.
  • 1642: Retrospective Review of Liver Transplantation of UNOS-Defined Hepatitis C Positive Donors into Hepatitis C Naïve Recipients
  • 1643: The effects of SVR and early HCV treatment on metabolic risk factors in patients post-liver transplantation.
  • 1644: Is Telbivudine-Induced Polyneuropathy/Myopathy Reversible in Liver Transplant Recipients?

Liver Transplantation: Donor Factors and Allocation

  • 1645: Differences in waitlist mortality for adult women versus others may be eliminated by a minor change to pediatric donor allocation policies
  • 1646: Prognosis after non-curative resection for hepatocellular carcinoma: an analysis using nationwide survey data in Japan
  • 1647: Poor Post-Transplant Survival in Donation after Cardiac Death (DCD)-related Liver Transplant Recipients with Severe Hepatic Decompensation
  • 1648: Variability in acceptance of organ offers by pediatric liver transplant centers and its impact on waitlist mortality
  • 1649: Shock Livers and the Opioid Epidemic: An Underutilized Resource in a Growing Population of Donors
  • 1650: Implementation of Share 35 Policy has Improved Survival following Liver Transplantation
  • 1651: Outcomes Of Liver Transplantation After Downstaging For Hepatocellular Carcinoma Beyond Milan Criteria
  • 1652: Stent or no stent? A randomized controlled trial comparing the incidence of biliary complications after liver transplantation, interim analysis
  • 1653: Directed Sharing to Improve Organ Allocation in the United States
  • 1654: Diminished Survival Following Liver Transplantation For Hepatocellular Carcinoma In Patients Within Milan Criteria But Outside Total Tumor Volume/Alpha-fetoprotein Criteria
  • 1655: HCC 6-Month Delay: Comparison of LSAM to Observed
  • 1656: Underlying protective mechanisms of high-mobility group box 1 against the deleterious effects of brain death in steatotic liver transplantation
  • 1657: Donor Age and Allograft Survival in Recipients with Hepatitis C Virus in the Direct-Acting Antiviral Era
  • 1658: Need to Improve Organs Transplanted Per Donor Despite the Rising Utilization of Hepatitis C Virus-Positive Donors in the United States
  • 1659: A simple set of recipient factors predicts futility after SLKT
  • 1660: The Pediatric End-Stage Liver Disease (PELD) Score Underestimates Pretransplant Mortality in Pediatric Liver Transplant Candidates
  • 1661: Donor-recipient height differences up to 20 centimeters are associated with favorable allograft and patient outcomes: a benefit to women of small stature
  • 1662: Surgical outcomes of minimally invasive repeat liver resection for recurrent primary and metastatic liver cancers
  • 1663: Offer Patterns of Livers Offered to ABO Non-Identical Liver Transplant (LT) Candidates
  • 1664: The New Event of Portal Vein Thrombosis Following Adult-to-Adult Living Donor Liver Transplantation does not Affect Long-Term Outcomes
  • 1665: Impact of “Rescue Allocated” Livers On Outcomes After Liver Transplantation: A Propensity Score Matching Analysis.
  • 1666: Significance of surgical margin in patients with single hepatocellular carcinoma undergoing curative hepatic resection: an analysis using nationwide survey data in Japan
  • 1667: Living Related Liver Transplantation (LRLT) for Progressive Familial Intrahepatic Cholestasis Type III (PFIC III) Children: A Single Center Experience
  • 1668: Preoperative erythropoietin treatment improves overall survival after major hepatic resection in cirrhotic rat models
  • 1669: Role of Cardio-pulmonary Exercise Test Parameters in the Assessment of Liver Transplantation Candidates- An Australian Study
  • 1670: Using Grafts with 2 or more than 2 Bile Ducts for Living Donor Liver Transplantation – Does it affect Patient Outcome?
  • 1671: Roman Liver Tx Allocation: Results at 48 months of an innovative regional allocation model based on MELDNa and Donor-to-Recipient Match
  • 1672: Demographics and Clinical Characteristics of Hepatitis C Virus-Positive Donors and Recipients
  • 1673: Impact of Pre-Transplant Non-Compliance on Clinical Outcomes after Liver Transplantation: Stratification of a High-Risk Population
  • 1674: A novel management algorithm for Bile duct strictures(BDS) complicating Living Donor Liver transplantation (LDLT)

Liver Transplantation: Outcomes 

  • 1675: Use of rifaximin or spontaneous bacterial peritonitis prophylaxis does not increase the risk of early multi-drug resistant infections after liver transplant
  • 1676: Low Subcutaneous Adipose Tissue Index (SATI) is Associated with Increased Waitlist Mortality Risk in Patients with End-Stage Liver Disease. From the Fitness, Life Enhancement, and Exercise in Liver Transplantation (FLEXIT) Consortium
  • 1677: Impact of Direct Acting Antiviral (DAA) for HCV Treatment on Liver Transplant Outcomes: A Multicenter 15-year Experience.
  • 1678: The impact of tumor necrosis on tumor free survival in patients undergoing liver transplant with hepatocellular carcinoma: an analysis using the UNOS liver recipient explant pathology form.
  • 1679: Coronary Artery Calcium Score for Cardiac Risk Stratification: A Retrospective Analysis of Liver Transplant Recipients
  • 1680: Increased rejection-risk measured with allospecific T-cells is associated with delayed immunosuppression minimization in children with liver transplantation.
  • 1681: Long-term clinical outcomes evaluation of everolimus in liver transplant patients with autoimmune liver diseases: Pooled analysis from the H2304 and PROTECT trials
  • 1682: Liver Transplantation (LT) for Cryptogenic Cirrhosis (CC) and Non-alcoholic Steatohepatitis (NASH) Cirrhosis: Twenty-Two Years Data from the Scientific Registry of Transplant Recipients (SRTR)
  • 1683: Recurrence-Free Survival in Liver Transplant Recipients with Non-Alcoholic Fatty Liver Disease-Related Hepatocellular Carcinoma: Results from the US Multicenter HCC Transplant Consortium
  • 1684: Safety and Efficacy Profile of Everolimus With Reduced Tacrolimus in Living Donor Liver Transplant Recipients – 12-month Results From the Pivotal H2307 Study
  • 1685: Everolimus plus Sorafenib as a treatment option for hepatocellular carcinoma recurrence after liver transplantation.
  • 1686: Role of Liver Transplantation in Selected Older Recipients: A Large Center Cohort.
  • 1687: Alcohol Relapse in Patients Transplanted for Alcoholic Liver Disease: A Single Center Experience
  • 1688: The impact of comorbid renal insufficiency in patients with hepatocellular carcinoma on long-term outcomes after the curative resection: A single center study on 800 cases
  • 1689: Subjective Global Assessment is not a Suitable Screening Tool for Detecting Sarcopenia and Mortality Risk of Malnutrition in Cirrhosis
  • 1690: European and American Temporal Trends and Outcomes in Liver Transplant (LT) Patients with Human Immunodeficiency Virus (HIV)
  • 1691: The impact of diet-induced hepatic steatosis in a murine model of hepatic ischemia-reperfusion injury.
  • 1692: Presence of donor-specific HLA alloantibodies (DSAs) after liver transplantation is a frequent fact. Prospective study in a pilot cohort
  • 1693: Low serum levels of ceramides and dihydroceramides reflect liver graft dysfunctions in a prospective real-world cohort of patients post liver transplantation
  • 1694: Immunosuppression Strategies Influence Neurotoxicity Events after Liver Transplantation.
  • 1695: Hypoalbuminemia is Associated with Significantly Higher Liver Transplant Waitlist Mortality and Lower Probability of Receiving Liver Transplant in the U.S.
  • 1696: Non-alcoholic steatohepatitis is an important growing indication for liver transplantation in Australia and New Zealand.
  • 1697: Severe Hepatic Encephalopathy is an Independent Predictor of Waitlist Mortality in Patients with High MELD
  • 1698: Bile Acid Metabolites in Urine: A Promising Novel Biomarker Predicting Renal Recovery After Liver Transplantation
  • 1699: Endoscopic Intragastric Balloon Placement for Weight Loss in Liver Transplant Candidates
  • 1700: Perioperative Glucose Management and Outcomes in Liver Transplant Recipients: A Qualitative Systematic Review
  • 1701: Donor CD163 and Nestin Positive Cells Predict Graft Functions in Living Donor Liver Transplant
  • 1702: Effect of non-alcoholic fatty liver disease and metabolic risk factors on waitlist outcome in patients with hepatocellular carcinoma
  • 1703: Sustained virologic response is associated with a decreased risk of post-transplant diabetes mellitus in patients with hepatitis C
  • 1704: Predicting cardiovascular risk in liver transplant recipients
  • 1705: BNP to Predict Post-Liver Transplant Mortality: Systematic Review and Meta-Analysis
  • 1706: Deficiencies in Reproductive Health Counseling in Liver Transplant Recipients
  • 1707: Effect of eGFR at time of liver transplantation on post-transplant renal and patient outcomes
  • 1708: Diagnostic Accuracy of Non-invasive Test of Hepatic Fibrosis in Liver Transplant Recipients
  • 1709: Proximity to transplant centre does not affect outcome among UK liver transplant patients
  • 1710: Prevalence of graft steatosis after liver transplantation using controlled attenuation parameter measurements: a large cohort study
  • 1711: The impact of new-onset diabetes mellitus after transplantation (NODAT) on post-liver transplant outcomes – the largest non-registry study
  • 1712: Metabolic syndrome and the risk of cardiovascular disease after pediatric liver transplantation in long-term recipients.
  • 1713: Post-Transplant Complications in Obese Liver Transplant Recipients: A Systematic Review and Meta-Analysis
  • 1714: Impact of Nutritional Status and Vitamin Deficiencies on Pre- and Post-Liver Transplant Rates of Hospitalization or Death
  • 1715: Efficacy and Safety of Covered Self-Expandable Metal Stents versus Multiple Plastic Stents for the Treatment of Anastomotic Biliary Strictures in Liver Transplant Patients: A Meta-Analysis
  • 1716: Strain Analysis in Preoperative Echocardiograms Does Not Predict Acute Heart Failure after Liver Transplantation
  • 1717: Is More Transplant Center Care Better? Geographic Proximity Is Associated With More Post Liver Transplant Visits But No Effect on Outcomes
  • 1718: Incidence and treatment of biopsy proven rejection in patients converted to Everolimus (EVL) after liver transplantation (LT): longterm histological data from the Everoliver multicenter observational French registry.
  • 1719: Is Obesity associated with Increased Risk of Mortality and Re-transplantation in Liver Transplant Recipients? A Systematic Review and Meta-Analysis
  • 1720: Characteristics and Outcomes of Liver Transplantation for Primary Biliary Cholangitis in Young patients: Analysis of the Untied Network for Organ Sharing Database
  • 1721: Outcomes After Liver Transplantation in the Severely Obese
  • 1722: Retransplantation in NASH is associated with lower graft survival: A study based on national UNOS data
  • 1723: Clinical Predictors of Biliary Obstruction at ERCP After Orthotopic Liver Transplantation (OLT)
  • 1724: Development of Heparin-Induced Thrombocytopenia in patients transplanted for Budd-Chiari Syndrome is associated with early and late post-transplant outcomes
  • 1725: Early atherosclerotic and cardiac damage in patients undergoing liver transplantation
  • 1726: Severe renal dysfunction at liver transplant in patients with NASH: Is the current approach for selection for kidney transplant optimal?
  • 1727: Outcomes of Liver transplantation using organ donation after brain death (DBD) versus organ donation after cardiac death (DCD): A single center experience
  • 1728: Everolimus Post Liver Transplantation: A Systematic Review
  • 1729: Predictors of Hospital Readmission Within 90 Days Following Liver Transplantation: A Single Centre Experience
  • 1730: Pregnancy Outcomes and Reproductive Health After Liver Transplantation

Pediatric Liver Transplantation

  • 1731: Pediatric Acute Liver Failure and Acute Hepatitis of Indeterminate Cause Treated with Steroids
  • 1732: Late occult biliary strictures identified in “clinically ideal” pediatric liver transplant (LT) recipients during immunosuppression (IS) withdrawal (iWITH trial)
  • 1733: Predictors of long-term normal histology on protocol allograft biopsies
  • 1734: Outcomes Analyses of Pediatric Acute Liver Failure (PALF) Subjects Listed for Liver Transplantation using Scientific Registry of Transplant Recipients (SRTR) Database
  • 1735: Listing Hyponatremia Associated with Increased Mortality Risk in Pediatric Liver Transplant Candidates: A UNOS database analysis from 2005-2015
  • 1736: Acceptance Benefit for Organ Offers in Pediatric Liver Transplantation
  • 1737: Indicators of biliary strictures in pediatric liver transplant
  • 1738: Liver biopsy can be safely performed in pediatric acute liver failure to aid in diagnosis and management.
  • 1740: Retrospective study of renal replacement therapy after pediatric liver transplantation

Poster Session IV: Monday, October 23, 8 am-5:30 pm

Presentation time 12:30 pm – 2:00 pm

Cholangiocyte Biology and Experimental Cholestasis

  • 1741: The secretin (SCT)/secretin receptor (SR) axis alters microRNA levels carried in extracellular vesicles that are responsible for cell-cell communication between cholangiocytes
  • 1742: Role of endothelial dysfunction in microRNA-34a knockout mice with cholestatic liver injury
  • 1743: YAP/β-catenin cross-talk promotes a pro-inflammatory phenotype in Fibrocystin-defective cholangiocytes
  • 1744: An essential role of macrophages in cholangiocyte regeneration in a model of specific cholangiocyte injury
  • 1745: Heritable variation of redox homeostasis is a potential risk factor for biliary disease
  • 1746: Hedgehog signaling regulates cell differentiation and proliferation in the biliary progenitor cell niche of the extrahepatic bile ducts in vivo, and in the biliary progenitor cell-derived organoids ex vivo
  • 1747: Targeting YAP in Cholangiocarcinoma (CCA) induces cell senescence while blocking cell proliferation
  • 1748: Cholangiocytes from Patients with Primary Biliary Cholangitis Display The Warburg Effect with Increased Mitochondria, Oxygen Consumption and Glycolytic Activity
  • 1749: Inhibition of HDAC6 and autophagy reverts ciliary loss and decreases proliferation rates in cholangiocarcinoma cells
  • 1750: Changing Expression Profiles of lncRNAs, mRNAs, circRNAs and miRNAs in Biliary Epithelial Cells after Bile Acid (TDCA) Stimulation
  • 1751: Knockdown of vimentin reduces mesenchymal phenotype of cholangiocytes in the Mdr2-/- mouse model of primary sclerosing cholangitis (PSC).
  • 1752: Bile acids induce release of pro-inflammatory extracellular vesicles from mouse hepatocytes
  • 1753: The microRNA-200c Is a Critical Novel Regulator of Cholestatic Liver Fibrosis
  • 1754: Pharmacological inhibition of ASBT-mediated intestinal reuptake of bile acids promotes hepatic expansion of regulatory T cells in murine sclerosing cholangitis
  • 1755: CCL4-induced cirrhosis and aging differentially modulate spingosine-1 phosphate receptors and sphingosine kinases in the brain
  • 1756: The Apelin/Apelin receptor axis promotes biliary proliferation and liver fibrosis during biliary cholestasis
  • 1757: NTCP inhibition has hepatoprotective effects in cholestasis by lowering bile salt load on hepatocytes and increasing the biliary phospholipid vs bile salt ratio
  • 1758: Cenicriviroc, a cytokine receptor antagonist, potentiated the effects of all-trans retinoic acid by reducing neutrophils and T cells in the liver of rodent cholestatic models
  • 1759: The thyromimetic GC-1 improves biliary injury but exacerbates hepatocyte injury in a mouse model of cholestasis
  • 1760: Macrophage involvement in the development of a fibrous cholangiopathy in a mouse model of primary sclerosing cholangitis (PSC).
  • 1761: Coffee mediated effects on transcriptional regulation of human UDP-glucuronosyltransferases (UGTs) during obstructive cholestasis (BDL) in a humanized transgenic UGT1A mouse model
  • 1762: Treatment of cholestatic bile duct ligated (BDL) mice with a menin-MLL inhibitor reduces biliary damage and liver fibrosis
  • 1763: Obesity exacerbates the neurological impairments associated to hepatic encephalopathy in chronic liver disease
  • 1764: Protective effect of phosphatidylcholine against lysophosphatidylcholine-induced cytotoxicity in cholangiocytes: a potential therapeutic target in cholangiocarcinoma
  • 1765: Exposure to gulf war illness-related chemicals increases susceptibility to cholestatic liver injury by enhancing CD11b+ macrophage/monocyte infiltration into the liver
  • 1766: Cholecystectomy increases secondary bile acids in the liver and results in liver injury in male but not female mice

Complications of Cirrhosis II

  • 1767: NK cells in the ascites of patients with advanced liver cirrhosis are phenotypically distinct from blood and liver NK cells and may be involved in antibacterial defense
  • 1769: Rising Trend and Poor Waitlist Outcomes in Young Adult Liver Transplant Registrants with Alcoholic Liver Disease
  • 1770: Performance of the calprotectin assay in ascitic fluid using the Quantum Blue® Reader for the diagnosis of spontaneous bacterial peritonitis in cirrhotic patients (The CADRISLA Study)
  • 1771: A novel TIPS-controlled expansion stent for the treatment of severe portal hypertension. A single center experience.
  • 1772: Frailty index is a strong predictor of both in-hospital outcomes and after-discharge mortality in cirrhotic patients.
  • 1773: Fractional Excretion Of Urea Is A Simple Tool To Aid The Differential Diagnosis of Acute Kidney Injury in Advanced Liver Disease
  • 1774: Terlipressin Use, Transplant Rate, and Post-Transplant Outcomes in Patients With Type 1 Hepatorenal Syndrome (HRS)
  • 1775: Dose Dependent Impact of Proton Pump Inhibitors on the Clinical Course of Spontaneous Bacterial Peritonitis
  • 1776: Trajectory of Serum Creatinine in Liver Transplant Candidates Identifies Patients at High Risk of Mortality
  • 1777: Albumin treatment is Associated with Hyponatremia Correction in Large Multi-center Cirrhotic Inpatient Cohort
  • 1778: Chronic kidney disease in cirrhosis: Patient characteristics and its effects on patient outcomes
  • 1779: The Impact of Medical Complications in the Treatment of Decompensated Cirrhosis and Ascites Requiring Large Volume Paracentesis
  • 1780: Acute kidney injury on the transplant waiting list: Effect on post-liver transplantation renal and patient outcomes
  • 1781: Clinical significance of urinary neutrophil gelatinase-associated lipocalin measurement in differentiating various etiologies of acute kidney injury in cirrhotic patients
  • 1782: Baseline Serum Creatinine and Delta Creatinine Predict Persistent Acute Kidney Injury in Outpatient Cirrhotics
  • 1783: Acute kidney injury, but not sepsis, is associated with higher procedure-related bleeding in hospitalized patients with decompensated cirrhosis
  • 1784: Transjugular Intrahepatic Portosystemic Shunting as a therapeutic option in Hepatorenal Syndrome – promising results from a nationwide cohort.
  • 1785: Outcomes of TIPS for Ascites as a Function of Baseline Renal Function
  • 1786: Comparison of MELD-Na and MELD scores in predicting survival following transjugular intrahepatic portosystemic shunt in patients with cirrhosis
  • 1787: Rapid Decrease of Intracellular Water Predicts Short-term Efficacy of Vasopressin Type 2 Receptor Antagonism in Decompensated Cirrhosis for Refractory Ascites
  • 1788: Cost-effectiveness of Transjugular Intrahepatic Portosystemic Shunt (TIPS) insertion compared to serial large volume paracentesis (LVP) in recurrent ascites
  • 1789: A Randomized Controlled Study to Compare Efficacy of Terlipressin 6 mg/day and Terlipressin 4 mg/day in Patients with Hepatorenal Syndrome
  • 1790: Improvement in QoL and Reduction in LVP Requirement from the MOSAIC Study: A Multicenter, Open-Label, Prospective 3-Month Study of the Alfapump System in Refractory Ascites
  • 1791: Hepato-cardiac Axis: Is It a Fact or a Myth?
  • 1792: The Clinical and Economic Toll Associated with Hepatorenal Syndrome from a Hospital Perspective in the United States: 2009-2015
  • 1793: Early Paracentesis Decreases All-Cause Mortality, But Not Mortality from Spontaneous Bacterial Peritonitis Between 2006-2014
  • 1794: New approaches to hepatic edema by tolvaptan in the elderly population of liver cirrhosis
  • 1795: Non-selective beta-blockers and acute kidney injury related in decompensated cirrhosis.
  • 1796: Hospital-Acquired Acute Kidney Injury in Patients with Cirrhosis: Predictors and Outcomes
  • 1797: Treatment of type-1 hepatorenal syndrome with pentoxifylline: a randomized placebo controlled, blinded pilot clinical trial
  • 1798: Utilization of palliative care in patients with cirrhosis
  • 1799: Transjugular Intrahepatic Portosystemic Shunt Prior to Abdominal Surgery: Outcomes in Cirrhotics
  • 1800: Efficacy and safety of tolvaptan in the treatment of patients with decompensated liver cirrhosis and severe chronic kidney disease
  • 1801: Transjugular intrahepatic portosystemic shunt (TIPS): a safe and efficacious treatment strategy for cirrhotic patient with splanchnic vein thrombosis
  • 1802: Sequential CLIF-SOFA (C-S) scores decrease with terlipressin therapy and correlate more strongly with survival than baseline scores, in subjects with acute-on-chronic-liver failure (ACLF) and hepatorenal syndrome Type 1 (HRS-1)
  • 1803: Alcoholic liver disease is associated with improved outcomes after TIPS performed for refractory ascites and hepatic hydrothorax
  • 1804: Early paracentesis is associated with lower mortality and shorter length of stay in hospitalized cirrhotics with and without spontaneous bacterial peritonitis in a multi-year national inpatient sample.
  • 1805: Benefit of Supplemental Nutrition Education for Severely Malnourished Cirrhotic Patients

HCC Experimental

  • 1806: Whole-genome pooled CRISPR/Cas library screens to identify new hepatocellular carcinoma drivers and drug targets in conjunction with sorafenib
  • 1807: MicroRNA-195 regulates chemoresistance via inhibition of epithelial–mesenchymal transition in human cholangiocarcinoma
  • 1808: Effect of CCL1 depletion on the antitumor defense in chimeras created with monocytes derived from patients with several stages of HCC
  • 1809: Promoted liver fibrosis and malignant phenotype in HCV/PDGF-C transgenic mice are accompanied by abnormal expression of the glycolysis-related gene pyruvate kinase M
  • 1810: Targeting aspartate β-hydroxylase suppresses cholangiocarcinoma metastasis
  • 1811: NLRC4 inflammasome contributes to the growth of liver metastasis in non-alcoholic fatty liver disease through modulating M1-M2 phenotype
  • 1812: Dysbiosis of gut microbiota promote inflammation and carcinogenesis in the liver
  • 1813: Promoting effect of connective tissue growth factor (CTGF) in hepatocellular carcinoma via the interaction with hepatic stellate cells and potential of anti-CTGF neutralizing antibody therapy.
  • 1814: MYC is the master switch between tumor dormancy and relapse in Hepatocellular carcinoma (HCC)
  • 1815: Development of Hepatocellular Carcinoma (HCC) in Fibroblast Growth Factor 21 (FGF21) Deficient Mice With Chronic Consumption of Obesogenic Diet
  • 1816: PLOD2 induced under hypoxia is involved in resistance to gemcitabine and poor prognosis in biliary tract cancer
  • 1817: Targeting CD44v9-xCT system by sulfasalazine to overcome cisplatin resistance in human liver cancer cells
  • 1818: Src Family Kinases regulates YAP nuclear localization and activity via tyrosine phosphorylation in cholangiocarcinoma.
  • 1819: Stromal Sulfatase-2 – a critical regulator of hepatocellular carcinoma growth and migration.
  • 1821: Differential Notch Signaling Modulates Experimental Hepatic Carcinogenesis in Mice
  • 1822: NPR-C Accelerates Obesity Induced NASH and Potentiates the Development of HCC
  • 1823: Chemoprevention of Hepatocellular Carcinoma with Pioglitazone in a Rat Model of Cirrhosis.
  • 1824: MSI2 promotes liver fibrosis and hepatocarcinogenesis via activation of hepatic stellate cells
  • 1825: Polyploidy and somatic copy number alterations in hepatocellular carcinoma
  • 1826: MYL6B, a myosin light chain, promote p53 degradation and drive HCC development by interacting with MDM2 and p53
  • 1827: The Wnt Target Gene CLAUDIN-2 Regulates Tumorigenesis of Combined Hepatocellular-Cholangiocarcinoma Cells
  • 1828: The significance of Sox2 expression in hepatocellular carcinoma occurring on liver cirrhosis
  • 1829: A Novel Vaccine Targeting Glypican-3 as a Treatment for Hepatocellular Carcinoma
  • 1830: PD-1H is a Novel Negative Checkpoint Regulator for Hepatocellular Carcinoma Immunotherapy
  • 1831: MAGE-1-targeting Aptamer Inhibits Hepatocellular Carcinoma Cell Growth via Suppression of PFKFB4 Expression
  • 1832: Lipid metabolism regulates oncogenic FoxM1 transcription factor in human hepatocellular carcinoma via the mevalonate-Rho pathway
  • 1833: Specific ZnPP inhibition and degradation of telomerase in human hepatoma cells
  • 1834: TAP-1 Mediates Drug Resistance in Hepatoma Cells through Activation of Hedgehog Signaling
  • 1835: The protein kinase CK2 contributes to the protumorigenic properties of cholangiocarcinoma cells
  • 1836: Establishment of Hepatocellular Carcinoma derived from a cancer stem cell line is characterized by significant metabolic reprogramming
  • 1837: DPP4 Inhibitor Suppressed Progression of NASH-related Hepatocellular Carcinoma with Inhibition of Metabolic Reprograming in p62-Keap1-Nrf2-Pentose Phosphate Pathway in a Mouse Model: A Metabolomic Analysis
  • 1838: Dipeptidyl peptidase 4 inhibitors reduce hepatocellular carcinoma by activating natural killer cell chemotaxis in mice
  • 1839: Pharmacological activator of NRF2, sulforaphane, inhibits hepatic cancer cell growth with attenuating angiogenesis
  • 1840: miRNA-216 cluster in non-B and non-C hepatocellular carcinoma is related with disease-free survival
  • 1841: Immunomodulation of aggressive liver cancer by EpCAM+ cancer stem cells through the activation of CCL20-CCR6 axis.
  • 1842: Continuous hepatocyte apoptosis accelerates diethylnitrosamine-induced liver tumor development
  • 1843: Strategies to inhibit MICA shedding in HCC cells for immunosurveillance
  • 1844: Role of the protease-inhibitor SerpinB3 in the cholangiocarcinoma stem-like compartment
  • 1845: Using CRISPR and Sleeping Beauty Transposons in Forward and Reverse Genetic Screens Aimed at Developing a Non-Human Primate Model of Hepatocellular Carcinoma
  • 1846: Bilateral function of Mdm2 in the carcinogenesis and progression of hepatocellular carcinoma.
  • 1847: The novel tumor suppressor Trefoil Factor Family 1 (TFF1) inhibits the development of hepatocellular carcinoma in mice
  • 1848: Growth Differentiation Factor 11 restricts HCC clonal expansion by disrupting glycolysis and decreasing lipid accumulation
  • 1849: Synergistic effect of cytokine-induced killer cell with valproate inhibits growth of hepatocellular carcinoma cell in a mouse model
  • 1850: Inhibition of systemic hyaluronan synthesis exacerbates murine hepatic carcinogenesis
  • 1851: Genome-wide methylation analysis identified a new intrahepatic angiogenesis marker associated with induction of tumorigenesis after successful eradication of HCV
  • 1852: Identification of long non-coding RNAs that serve as therapeutic targets for Hepatocellular Carcinoma
  • 1853: Hepatitis C virus (HCV) mimics effects of Glypican-3 (GPC3) on CD81 and promotes development of hepatocellular carcinomas via activation of Hippo pathway in normal hepatocytes.
  • 1854: Mechanisms of Selective Deletion of MYCN+CD133+ Liver Cancer Stem Cells by Acyclic Retinoid via Induction of Nuclear Transglutaminase 2
  • 1855: miR-19a−3p regulates the expression of the PTEN via PI3K/Akt pathway in hepatocellular carcinoma
  • 1856: HMGB1 inhibits hypoxia-induced ferroptosis in hepatocellular carcinoma cells
  • 1857: Impact of ARMC/ARMCX family genes in HCC development
  • 1859: Lipogranulomas, neutrophils and the progression of NAFLD to NASH and HCC
  • 1860: Cancer metabolic reprogramming allows hepatocarcinoma cells to efficiently adapt to their microenvironment.
  • 1861: Targeting the Warburg effect prevents cancer metabolic reprogramming in hepatocellular carcinoma cells and promotes cell death.
  • 1862: Extracellular signal-regulated kinase 5 (ERK5) regulates growth, migration and invasion of cholangiocarcinoma (CCA) cells.

Hepatitis B: Epidemiology and Natural History

  • 1863: Low incidence of HBV reactivation and consequent hepatitis in patients with chronic hepatitis C receiving direct-acting antiviral therapy
  • 1864: A multicenter study revealing chronic hepatitis B comorbidity trends over the last 15 years in the United States
  • 1865: Antibody and Cell-mediated Immunity against PreS1, PreS2 and S Antigens after Immunization with a Third Generation Hepatitis B Vaccine
  • 1866: Hepatitis B core-related antigen (HBcrAg) is useful marker in HBV/HDV co-infection and can help to predict response to pegylated interferon therapy
  • 1867: A Pilot Program Integrating Hepatitis B Virus (HBV) Screening Into An Outpatient Endoscopy Unit Improves HBV Screening from 24.5% to 75.6% Among An Ethnically Diverse Safety-Net Public Hospital
  • 1868: Prevalence of Hepatitis B Serological Markers and Receipt of Hepatitis B Vaccine among a Cohort of Hepatitis C Infected Patients in a Large, Urban Health System, 2004--2016
  • 1869: Clinical application of the electronic medical record-based "alert ordering system", designed to prevent hepatitis B virus reactivation in patients receiving systematic chemotherapy or immunosuppressive therapy.
  • 1870: Minimal increases of alpha-fetoprotein strongly predict HCC development in caucasian compensated HBV cirrhotics treated by entecavir or tenofovir: a 8-year longitudinal cohort study in 262 patients – final results
  • 1871: HBsAg and HBcrAg concentrations differ between genotype A1 and A2 HBeAg negative patients with chronic hepatitis B: complexity within sub-genotypes has implications for newer therapy paradigms
  • 1872: Age and gender-specific disease progression rates to cirrhosis and hepatocellular carcinoma (HCC) in treated and untreated patients with chronic hepatitis B
  • 1873: Validation of the PAGE-B Model in Asian Chronic Hepatitis B Patients Receiving Entecavir or Tenofovir
  • 1874: Cost-effectiveness of Screening for Hepatitis B Infection Prior to Solid Tumor Chemotherapy
  • 1875: Variability in Hepatitis B surface Antigen (HBsAg) Levels during Nucleos(t)ide (NUC) Therapy in Subgroups of Immune Active CHB Patients
  • 1876: A Retrospective Nationwide Study on Hepatitis B Epidemiology and Genotypes. The Canadian HBV Network
  • 1877: Serum HBsAg levels predict the severity of liver fibrosis among HBeAg-positive patients across all major HBV genotypes and among patients with low ALT levels: results from the SONIC-B cohort
  • 1878: Using Surveillance Data to Monitor Hepatitis B Reactivation in Patients Receiving Direct Acting Antivirals for Hepatitis C, New York City
  • 1879: Liver stiffness measurement after complete viral response in predicting hepatoma development for patient with hepatitis B virus-related cirrhosis underwent anti-viral therapy
  • 1880: Changes of Serum Pregenomic RNA, Quantitative Anti-HBc and Intrahepatic Covalently Closed Circular DNA during Treatment of Chronic Hepatitis B
  • 1881: Durability of Spontaneous- And Treatment-Related HBsAg Loss
  • 1882: Antibody Levels and Protection after Hepatitis B Vaccine: Results of a 35 year Follow-up Study and Response to a Booster Dose
  • 1883: Genetic characteristics and evolution of pre-S/S genes in the occult hepatitis B virus infection.
  • 1884: Use of various complementary and alternative medicine practices in an ethnically diverse chronic hepatitis B population: role of ethnicity and acculturation
  • 1885: Effectiveness of a Statewide Hepatitis B Virus (HBV) Vaccination Program in Preventing Symptomatic HBV Infection Among Alaska Native (AN) Persons, Alaska 1987–2011
  • 1886: High Prevalence of Naturally Occurring HBV Variants Across HBV Phenotypes and Genotypes in Racially Diverse Patients with Chronic Hepatitis B in the United States and Canada
  • 1887: Critical role of B cell lineage in dictating response and non-response to hepatitis B vaccine; A retrospective and prospective study with healthy adults
  • 1889: Mortality among Adults with Chronic Hepatitis B Infection in the United States (US) from 1999 to 2010: Analysis of National Health and Nutrition Examination Surveys (NHANES) Data
  • 1890: Suboptimal rates, trends and predictors of hepatitis B vaccination in a population-based sample of children and adolescents in the United States (U.S.) between 1999 and 2014
  • 1891: HBV reactivation is rare in chronic hepatitis C patients with resolved HBV receiving direct acting antivirals: A systematic review and meta-analysis in cohort studies
  • 1892: Prevalence and predictors of hepatitis B immunization in adults without immunity for hepatitis B from 1999-2014: a population-based study of 27,713 adults in the U.S.
  • 1893: Severe Acute Hepatitis B: Predictive Clinical and Demographic Factors
  • 1894: Hepatitis B Virus Reactivation Rate is Considerably High during Sorafenib Therapy without Antiviral Treatment in Patients with Advanced Hepatocellular Carcinoma
  • 1895: Application of Different Hepatitis B Treatment Guidelines to a Cohort of Infected Adults
  • 1896: High Rates of Current & Past HBV Infection with Increasing Age and in Foreign-Born: Importance of Hepatitis Core Antibody Testing
  • 1897: A dynamic change in Albumin-Bilirubin grade can effectively stratify patient’s risk for developing hepatocellular carcinoma for patients treated with entecavir
  • 1898: Development and Validation of a Risk Score for Hepatocellular Carcinoma in Chronic Hepatitis B Patients under Antiviral Treatment
  • 1899: Do HBsAg concentrations > 4 log10IU/ml represent a risk for mother to child transmission of HBV infection in all chronic hepatitis B patients?
  • 1900: Web-based education program improves patient education and understanding of chronic Hepatitis B
  • 1901: Reactivation of Hepatitis B in Patients With Isolated Hepatitis B core Antibody Who Received Chemotherapy: Meta-analysis
  • 1902: Feasibility of strategic monitoring in patients with prior HBV exposure undergoing anti-CD20 monoclonal antibody therapy: a prospective observational study
  • 1903: Can Quantitative HBsAg Threshold Predict High Viral Load and Risk of Mother to Child Transmission? Like Life, You Get What You Pay For
  • 1904: ALT Flares are Associated with Increased Rates of HBeAg Seroconversion and HBV DNA Decline in Chronic Hepatitis B Infection: A Prospective Cohort Study from the Hepatitis B Research Network (HBRN).
  • 1905: Serum Alanine Aminotransferase Level and Liver-related Mortality in Patients with Chronic Hepatitis B
  • 1907: Rate and Predictors of Phase Transition Among North American Adults with HbeAg-Negative Chronic Hepatitis B and Low Level Viremia: a Hepatitis B Research Network (HBRN) Study
  • 1908: Prediction model of the progression of patients with acute deterioration of hepatitis B virus related chronic liver disease to acute-on-chronic liver failure
  • 1909: Distribution of hepatitis B virus genotypes in Spain during the period 1999-2016 (Preliminary data of GEHEP 010 Study)
  • 1910: Assessing trends in hepatitis B virus (HBV) infection and immunity at a community health center with universal screening practices
  • 1911: Statin Use is Independently Associated with Less Severe Liver Fibrosis in Patients with Chronic Hepatitis B
  • 1912: Performance of fibrosis biomarkers for stratifying hepatocellular carcinoma risk in patients under antiviral therapy for chronic hepatitis B
  • 1913: Electronic Alerts Increase Screening for Chronic Hepatitis B: A Randomized, Double-Blind, Controlled Trial
  • 1914: HBsAg and HBcrAg as predictors of seroconversion in a pan-genotypic population of hepatitis B e antigen positive patients treated with nucleos(t)ide analogues
  • 1915: Performance of an automated prototype assay for the detection and quantification of Hepatitis B pregenomic RNA in chronic HBV patients receiving nucleo(t)side analogue therapy
  • 1916: Evaluation of in vitro diagnostic kits for detection and quantification of HBV DNA and HBsAg using HBV reference panel
  • 1917: Hepatitis B virus replication enhances promoter activity of alpha-fetoprotein in human liver cell line
  • 1918: Hepatitis B virus (HBV) reactivation in patients treated with Ibrutinib for hematologic malignancies
  • 1919: Risk of hepatitis B virus (HBV) infection and re-activation after discontinuation of tenofovir and/or lamivudine as part of antiretroviral therapy in a high HBV endemicity setting
  • 1920: Linkage to Care for Alaska Native Persons with Chronic Hepatitis B Virus
  • 1921: Comparative effectiveness of prophylactic strategies for perinatal transmission of hepatitis B virus: a network meta-analysis of randomized controlled trials
  • 1922: Establishment and development of national demonstration areas to achieve control targets for hepatitis B in China
  • 1923: Validation of risk prediction models for the development of HBV-related HCC: a retrospective multi-center 10-year follow-up cohort study
  • 1924: The impact of treatment of chronic hepatitis B (CHB) on patient-reported outcomes (PROs)
  • 1925: Awareness, knowledge and treatment acceptance of hepatitis B infection in Southeast Asia: a cross-sectional study
  • 1926: Hospital Wide Electronic Medical Record (EMR) Aquisition of Country of Birth During Registration to Identify Patients At Risk for Hepatitis B and/or Hepatitis C Infection to Implement Automated Order Entry For Blood Testing and Provide Linkage to Care (LTC).
  • 1927: Clinical evaluation of a newly developed chemiluminescence enzyme immunoassay for hepatitis B core antibody.
  • 1928: Profile of serum alanine aminotransferase (ALT) levels in a cohort of inactive European hepatitis B (HBV) carriers: 4 years follow-up of a prospective longitudinal study (ALBATROS Study)
  • 1929: Development and External Validation of Prognostic Nomogram for Acute Decompensation of Chronic Hepatitis B Cirrhosis
  • 1930: Non-invasive diagnosis of significant fibrosis in antiviral-naive chronic HBV infection could be improved by using the novel GP73-LS algorithm
  • 1931: Passive Transfer of Hepatitis B Core Antibody after Intravenous Immunoglobulin Administration in Patients Receiving Anti-cancer Therapy
  • 1932: Prospective Assessment Of Frequency And Factors Associated With Bone Loss During Tenofovir Therapy In Patients With Chronic Hepatitis B
  • 1933: Natural course of chronic hepatitis B virus infection in children: A retrospective real-world data analysis
  • 1934: Clinical performance of a new automated assay for the detection of total antibodies against the Hepatitis Delta Virus
  • 1935: Combination of HBsAg composition and a common TLR3 polymorphism increases prediction of serologic response during treatment with nucleos(t)ide analogues
  • 1936: HBV Knowledge, Screening & Linkage to Care in a Diverse Suburban New Jersey Community: Novel Strategies in a Primary Care Setting
  • 1937: FIB-4, not APRI predicts the regression of fibrosis in chronic hepatitis B patients treated with nucleos(t)ide analogs.
  • 1938: Clinical significance of an ultra-high sensitive HBsAg assay to diagnosing HBV reactivation using stored samples of a prospective HBV DNA monitoring study in B-cell non-Hodgkin lymphoma patients
  • 1939: Renal tubular damage worsens over time in HBV monoinfected patients long-term treated with tenofovir: a prospective, single center, real-life study in 391 patients
  • 1940: High HBV Viral Load is associated with Mixed HBV Genotypes and Liver Stiffness in Co-infected HIV Mexican Patients
  • 1941: Screening For Hepatitis B Virus In Patients Receiving Immunosuppressive Therapy
  • 1942: Decrease of Platelet Count Predicts de novo Hepatocellular Carcinoma in Chronic Hepatitis B Patients Who Achieved Sustained Virological Effect Under Long-term Nucleos(t)ide Analogues
  • 1943: Hepatitis B virus infection after the implementation of the vaccine program in Israel

Portal Hypertension and Cirrhosis: Experimental

  • 1944: Characterization of circulating microparticles in cirrhotic patients and their evolution during a six-month follow-up period: a pilot study
  • 1945: Cathepsin L inhibitor improves liver regeneration impaired in fibrotic liver.
  • 1946: Ammonia withdrawal reverses impaired skeletal muscle mitochondrial function.
  • 1947: L-leucine supplementation reverses hyperammonemia induced skeletal muscle mitochondrial dysfunction
  • 1948: Cirrhosis resolution dose not resolve all derangements of portal hypertension
  • 1949: Left Atrial Dynamics assessed with Real Time 3-Dimensional Echocardiography in relation to Liver Function in Cirrhosis
  • 1950: Use of numerical modeling analysis to obtain free cortisol secretion and elimination in patients with cirrhosis: Relationship to liver disease variables
  • 1951: Human amniotic epithelial stem cells as a new therapeutic option for portal hypertension and cirrhosis.
  • 1952: 13C-Methacetin Breath Test detects early clinically significant improvement in liver function after achieving SVR in cirrhotic HCV patients when compared to HVPG and liver stiffness
  • 1953: Prognostic significance of vitamin D receptor (VDR) gene polymorphisms in liver cirrhosis
  • 1954: A new method for the direct quantification of lipopolysaccharide by High Performance Liquid Chromatography coupled with Mass Spectrometry in non-infected cirrhotic patients (The MICROCIR cohort).
  • 1955: Liver Functional Assessment by Dual Cholate Testing Is Strongly Correlated with Direct Portal Pressure and Ishak Fibrosis Stage
  • 1956: The Influence Of Transjugular Intrahepatic Portosystemic Shunt In The Need For Medical Care Of Cirrhotic Patients
  • 1957: Cirrhosis and Aging Concomitantly Affect Brain Inflammation and Neurotransmitter Expression: Implications for Hepatic Encephalopathy in Elderly Cirrhotics

Steatohepatitis: Experimental

  • 1958: Evaluation of the Thyroid Receptor Agonist VK2809 on Liver Disease in DIO-NASH Mice
  • 1959: Development and Characterization of High Fat Diet-induced Non-human Primate Models of Liver Diseases: Steatosis, NASH and Fibrosis
  • 1960: TRAIL Deletion Prevents Liver, but Not Adipose Tissue, Inflammation during Murine Diet-Induced Obesity
  • 1961: Chitinase 3-like 1 plays a key role in the progression of nonalcoholic steatohepatitis in mice.
  • 1962: Nox1 as a Novel Source of Hepatic Oxidant Stress during Obesity to Promote Lipotoxicity in Humans and Mice with Non-alcoholic Fatty Liver Disease
  • 1963: Modeling NAFLD Using 3D Bioprinted Human Liver Tissue
  • 1964: Adipose tissue derived stromal/stem cells retarded progression of hepatic fibrosis by suppressing IL17A related inflammation in early stage of NASH.
  • 1965: Role of Intestine-Specific Sirt1 in the Protective Action of Salvianolic Acid B against Ethanol-Induced Inflammation and Liver Injury in Mice
  • 1966: Suppression of DNase II activity in fatty livers contributes to induction of RIP1-dependent hepatocyte necrosis through TLR9-IFNβ pathway.
  • 1967: Differential Effects of Hepatic DGAT2 or DGAT1 Knockdown on Steatosis and the Metabolic Flux of Exogenously Administered D5-glycerol or 13C18 -oleic acid into VLDL-TG
  • 1968: β-Oxidation is Decreased in Non-Alcoholic Fatty Liver Disease: A Non-invasive Assessment Utilizing Palmitate and Acetate Breath Tests
  • 1969: MGL-3196, a β-Selective Thyroid Hormone Receptor (THR) Agonist, Demonstrates Metabolic, Anti-inflammatory and Anti-fibrotic Benefits in a Long-term High Fat Diet (HFD) Mouse NASH Model
  • 1970: Detailed Analyses of the Antifibrotic effects of INT-767, a dual FXR/TGR5 agonist, in an obese mouse model of diet-induced and biopsy-confirmed NASH
  • 1971: miR-122 Inhibition in a Human Liver Spheroid Model Leads to Liver Inflammation, Necrosis, Steatofibrosis and Dysregulated Insulin Signaling
  • 1972: Pharmacologic inhibition of FASN reverses diet-induced steatohepatitis in mice and inhibits lipogenesis in humans
  • 1973: Toll-like receptor 7-mediated Type I Interferon signaling promotes non-alcoholic steatohepatitis by inhibition of regulatory T cell
  • 1974: Sphingomyelin synthase 2 contributes to liver fibrosis progression through altered hepatic sphingosine 1-phospate metabolism in mice
  • 1975: Sphingosine 1-Phosphate (S1P) and its receptor S1PR2 regulate ductular reaction in a mouse model of nonalcoholic steatohepatitis
  • 1976: Hepatocyte Notch activation induces liver fibrosis in NASH
  • 1977: GPR125 as a Novel Hepatocyte Lipotoxicity Mediator in Preclinical Models of Nonalcoholic Fatty Liver Disease
  • 1978: Deficiency of cholesterol 7α hydroxylase (Cyp7a1) in bile acid synthesis exacerbates alcohol-induced liver injury in mice
  • 1979: Pharmacological inhibition of RGD-binding integrins reverses liver fibrosis in a diet-based mouse model of nonalcoholic steatohepatitis
  • 1980: Efficacy of MET409, a potent, novel non-bile acid FXR agonist, in rodents and cynomolgus monkeys
  • 1981: Early Anti-steatotic Actions of an Ileal Apical Sodium-dependent Bile Acid Transporter Inhibitor in High Fat Diet Fed Mice
  • 1982: Preclinical analysis of liver-targeted, mild mitochondrial protonophores for treatment of non-alcoholic fatty liver disease and steatohepatitis
  • 1983: B-hydroxybutyrate protects from alcoholic hepatitis via a Hcar2-cAMP dependent pathway
  • 1984: Disruption of hepatic IL-1 signaling improves insulin sensitivity and hepatic inflammation in a model of non-alcoholic fatty liver disease (NAFLD).
  • 1985: DEPTOR overexpression improves glucose tolerance and lipid metabolism in obese mice
  • 1986: Hepatocyte death-triggered CD11c-positive macrophage accumulation induces liver fibrosis in a murine model of non-alcoholic steatohepatitis
  • 1987: Loss of miRNA-141/200c Cluster Ameliorates Hepatic Steatosis and Inflammation in Non-alcoholic Steatohepatitis
  • 1988: EDP-305 favorably regulates lipoprotein mechanism in vitro
  • 1989: Modulation of Nonalcoholic Fatty Liver Disease and Steatohepatitis by Targeting the Retinoic Acid Receptors Alpha and Beta
  • 1990: YH25724, a novel long-acting GLP-1/FGF21 dual agonist, induces body weight loss and improves glucose and lipid metabolism in obese diabetic monkeys
  • 1991: Cross talk between Sirtuins and TGF-β signaling – new models for non alcoholic steatohepatitis and progression to HCC
  • 1992: Vitamin D significantly decrease lipid accumulation in Nonalcoholic Fatty Liver Disease (NAFLD) in Zebrafish model and affects genes associated with metabolic pathways
  • 1993: Polymorphisms in TFAM (rs1937) and NOS2 (rs2297518) Which Are Markers of Mitochondrial Dysfunction Are Associated with Significant Hepatic Fibrosis in Non-alcoholic Fatty Liver Disease (NAFLD)
  • 1994: Fatty acid synthase inhibitor TVB-3664 reduces collagen accumulation in bleomycin-induced murine skin fibrosis and reverses multiple components of diet-induced and biopsy-confirmed nonalcoholic steatohepatitis in mice treated with or without co-administered pirfenidone
  • 1995: A Novel Retinol Dehydrogenase, HSD17B13 Contributes to the Pathogenesis of Non-Alcoholic Fatty Liver Disease
  • 1996: Somatotropic Axis Dysfunction In Non-Alcoholic Fatty Liver Disease: Beneficial Hepatic And Systemic Effects Of Hormone Supplementation
  • 1997: Loss of iron upregulates mitochondria ferritin and triggers mitophagy
  • 1998: Neutrophil Extracellular Traps (NETs) regulate monocyte infiltration and development of HCC in murine NASH
  • 1999: High fat diet-induced hepatic transcription and enhancer activity changes are reversed by weight loss in mice
  • 2000: Beneficial effects of combined farnesoid X receptor agonist (INT747) and dipeptidyl peptidase-4 inhibitor (sitagliptin) on hepatic fibrogenesis in a rat model of nonalcoholic steatohepatitis
  • 2001: Hepatocyte high-mobility group box 1 (HMGB1) protects against hepatic steatosis
  • 2002: Comparative efficacy of obeticholic acid and INT-767 in the Gubra mouse NASH model of diet induced and biopsy-confirmed nonalcoholic steatohepatitis (NASH)
  • 2003: Impact of PCSK7 genetic variation in patients with Non-Alcoholic Fatty Liver Disease
  • 2004: A novel long-acting FGF21 analogue significantly improves liver steatosis and halters progression of fibrosis in pre-clinical models of NASH
  • 2005: Hepatic Signature Expression of miR-199a-5p, miR-21-3p, miR-224-5p, and miR-150-5p Detected by NextSeq Technology are Independently Associated with Fibrosis in Non-alcoholic Steatohepatitis (NASH) and Non-alcoholic Fatty Liver Disease (NAFLD)
  • 2006: Identification of Novel Targets For Nonalcoholic Steatohepatitis Using A Human Surrogate System
  • 2007: Decreased Phosphatidylcholine (PC) in Non-alcoholic Steatohepatitis (NASH) livers is attributed to the reduction of long chain PC fraction and is Associated with ELOVL6 Genetic Variants
  • 2008: NGM282 Ameliorates Hepatic Lipotoxicity as Measured by Lipidomics and Gene Expression in a Diet-Induced Mouse Model of Nonalcoholic Steatohepatitis (NASH)
  • 2009: The effect of saroglitazar treatment on NAFLD Activity Score and Fibrosis Stage in a diet-induced obese mouse model of biopsy-confirmed non-alcoholic steatohepatitis
  • 2010: CB4209 and CB4211 Reduce the NAFLD Activity Score in the STAM Model of NASH, Reduce Triglyceride Levels, and Induce Selective Fat Mass Loss in DIO Mice
  • 2011: Metabolic and hepatic effects of clinical candidates liraglutide, elafibranor and obeticholic acid in obese mouse models with diet-induced and biopsy-confirmed NASH
  • 2012: Fully human in vitro gut-liver model of non-alcoholic steatohepatitis
  • 2014: Apical Sodium-Dependent Bile Acid Transporter Inhibition with Volixibat Impacts Metabolic and Physiologic Parameters Associated with the Development of Nonalcoholic Steatohepatitis (NASH) in a High-Fat Diet-Fed Mouse Model
  • 2015: A novel ASBT inhibitor, Benzamide Derivative IMB17-15 repressed NAFLD development in high fat diet-fed Syrian golden hamster
  • 2016: PBI-4050 Reduces Liver Damage in a High-Fat Diet Mouse Model of Obesity and Metabolic Syndrome
  • 2017: PBI-4547 Reverses Liver Steatosis and Fibrosis, and Improves Metabolic Syndrome in ob/ob Mice
  • 2018: PPARα interplays with CYP2A5 to protect against fatty liver disease
  • 2019: The Dual Amylin and Calcitonin Receptor Agonist, KBP-089, Reduces Liver Steatosis, Inflammation and Fibrosis Stage in High Fat, High Cholesterol Fed Rats
  • 2020: Liver Rhythms and Bile Acid Metabolism in Mice Fed Chronic Alcohol + Binge
  • 2021: The CD25 expression on CD4+ FoxP3- T cells in non-alcoholic fatty liver disease
  • 2022: Role of CREB regulated transcription co-activator 3 (Crtc3) in fasting and diet-induced fatty liver
  • 2023: Inhibition of microRNA-200b/c improved liver inflammation and liver fibrosis in NASH model mice
  • 2024: Acute mitochondrial pyruvate carrier-dependent and -independent effects of MSDC-0602 in hepatocytes on insulin sensitivity and NASH endpoints in mice.
  • 2025: Nanostring nCounter® transcriptome analysis identifies immunologic mediators of disease progression from non-alcoholic fatty liver (NAFL) to non-alcoholic steatohepatitis (NASH) in paraffin-embedded liver tissue
  • 2026: Efficacy of the FXR agonist, MET409, in male and female mouse models of NASH and fibrosis
  • 2028: Altered liver methylome and transcriptome provide evidence for epigenetic contribution to NAFLD pathogenesis
  • 2029: Activation and Increased IFNγ Secretion of Invariant Natural Killer T Cells in a Human in-vitro Model of Nonalcoholic Steatohepatitis
  • 2030: The role of nitric oxide-mediated mechanisms in the increased intrahepatic vascular resistance in a rat model of non-alcoholic fatty liver disease
  • 2031: Chemokine receptor 9 plays a crucial role in obesity-induced liver injury and glucose tolerance by modulating ectopic fat distribution with macrophage recruitment
  • 2032: Inhibition of fibrosis and inflammation by a soluble guanylate cyclase stimulator in models of liver disease
  • 2033: Different Fecal and Blood Microbiota Profiles in Obese Versus Lean Nonalcoholic Fatty Liver Disease
  • 2034: Lipopolysaccharide increases the release of CXCL5 in an ex-vivo model for human non-alcoholic fatty liver disease
  • 2035: MALDI Imaging and High Resolution Mass Spectrometry as a Lipidomic Approach to Assess Nonalcoholic Fatty Liver Disease Pathophysiology and Biomarkers
  • 2036: Assessment of intestinal barrier function in mice with non-alcoholic fatty liver disease subjected to intermittent hypoxia
  • 2037: Synthesis, Biological and Structure-Activity Relationship Evaluation of Bile Acid Derivatives as FXR Agonists for treatment of NASH and PBC
  • 2038: Obesity-Inducing Diet during Conception and Lactation Enhances the Progression of Murine Nonalcoholic Steatohepatitis in Offspring
  • 2039: Long-term follow-up of diet-induced murine NASH models with hyperinsulinemia, steatohepatitis, and fibrosis
  • 2040: Reintroduction of mast cells induces biliary damage/senescence, steatosis, inflammation and hepatic fibrosis in mast cell deficient mice fed high fat diet
  • 2041: Portal fibrosis predominantly in MCD-induce juvenile Nonalcoholic Steatohepatitis mouse models
  • 2042: Novel Mouse Model of Nonalcoholic Steatohepatitis
  • 2043: Oxidized linoleic acid metabolites (OXLAMs) lead to oxidative stress-induced mitochondrial dysfunction, apoptosis and Nlrp3 inflammasome activation in the liver
  • 2044: Chronic Polychlorinated Biphenyl (PCB) Exposure Disrupts Hepatic Xenobiotic and Intermediary Metabolism and Increases Hepatic Inflammation/Injury
  • 2045: Oleate- but not palmitate-enriched diets induce iNKT cell activation in adipose tissue, resulting in hepatic steatosis
  • 2046: Hepalatide Ameliorated Progression of Mouse Nonalcoholic Steatohepatitis Caused by Feeding High Fat/Calorie Diet plus High Fructose and Glucose in Drinking Water
  • 2047: Dicosylhexaenoic Acid Reversed Progression of NASH to Hepatic Fibrosis in Mice by Increasing Ratio of ω-3 over ω-6 Fatty Acids
  • 2048: CCL25 promotes progression of nonalchoholic fatty liver disease via macrophages activation
  • 2049: Hepatic CD36 expression and traslocation to the plasma membrane are increased under hypoxic conditions
  • 2050: Transferrin and ceruloplasmin kinetics discriminate simple steatosis from nonalcoholic steatohepatitis.
  • 2051: VEGFR3 dependent lymphangiogenesis regulates the progression of liver fibrosis in a mouse model of NASH.
  • 2052: Combination treatment of LJN452 and Cenicriviroc Shows Additive Effects in a Diet-Induced NASH Model
  • 2053: A Liver-Targeted Acetyl-CoA Carboxylase Inhibitor Increases Fatty Acid Oxidation, Improves Mitochondrial Function and Reduces Bile Acids and Oxidative Stress in a Murine Model of NASH
  • 2054: Methionine Aminopeptidase 2 Inhibition Attenuates Liver Pathology in Mouse Model of NASH
  • 2055: Cross-talk between the IDO-kynurenine and NRLP3 inflammasome pathways in experimental NASH
  • 2056: Oral administration of CardioAid and LunaRichX plant sterols alleviates liver damage in a high-fat diet NASH model
  • 2057: The Physiological, Pathological and Molecular Basis of Nonalcoholic Steatohepatitis Associated Cardiomyopathy
  • 2058: Sitagliptin can prevent the development of NAFLD in obese diabetic mice under lipopolysaccharides existence.
  • 2059: Nuclear expression of p53-binding protein 1, a DNA damage response molecule, is increased in NAFLD liver
  • 2060: The effect of Aramchol on fibrosis is mediated by elevation of glutathione, improvement of fatty acid oxidation and maintenance of redox homeostasis
  • 2061: Periodontal pathogenic bacteria, Aggregatibacter actinomycetemcomitans affect non-alcoholic fatty liver disease by altering gut microbiota and glucose metabolism
  • 2062: Insulin signaling as a potential NK cell checkpoint in Fatty Liver Disease
  • 2063: Bile Acid and Steroid Transporter OSTα/β is Over-Expressed in Liver from Patients With Non-alcoholic Steatohepatitis (NASH) and Primary Biliary Cirrhosis (PBC), and Modulated by Drugs Using a Novel In Vitro Cell System
  • 2064: Inhibition of NADPH Oxidase in Phagocytes Improves Hepatic Steatosis, Inflammation and Fibrosis in a Mouse Model of Severe Nonalcoholic Steatohepatitis (NASH)
  • 2065: Identification of circulating microRNAs altered by an Apoptosis Signal-Regulating Kinase 1 (ASK1) inhibitor in a Fast Food Diet NAFLD mouse model
  • 2066: Dietary cholesterol triggers liver fibrosis and a tissue-remodeling and lipid-metabolizing phenotype in Kupffer Cells in a murine model of NAFLD
  • 2067: The utility of the serum C16:1n7/C16:0 ratio as a diagnostic marker of non-alcoholic steatohepatitis
  • 2068: Single cell characterization of patatin-like phospholipase domain-containing protein 3 (PNPLA3) transcription pattern in human liver biopsies of nonalcoholic fatty liver disease
  • 2069: Development of A Novel Potent and Highly Selective PPAR a/d Dual Agonist (WXFL078) For the Treatment of NASH
  • 2070: Relaxin-2 Attenuates Hepatic Steatosis in Mice Fed a High-Fat or Methionine–Choline-Deficient Diet
  • 2071: Reverse translation of clinical biomarkers into experimental models of NASH
  • 2072: Establishment of mouse Mac-2 binding protein ELISA and its application for mouse chronic liver disease models
  • 2073: Introducing a new pre-clinical rat model of advanced steatohepatitis that mimics the main characteristics of the human disease.
  • 2074: Global Deletion of COX-2 Attenuates Obesity-linked Inflammation but Impairs Hepatic Cholesterol Metabolism in Diet-induced Obesity
  • 2075: Global characterization of gene expression regulation by clinical candidates liraglutide, elafibranor and obeticholic acid in a diet-induced obese mouse model with biopsy-confirmed NASH
  • 2076: GPBAR1 (TGR5) is a positive regulator of autophagy in response to fast-to-fed transition and its activation improves lipid metabolism in mice feed a high fat diet
  • 2077: Aging exacerbates high-fat diet-induced steatohepatitis through blunting of lipid metabolic response in mice
  • 2078: Semaglutide, a novel long acting GLP-1 receptor agonist, reduced features of NASH in two different diet-induced mouse models
  • 2079: IL-33/Cyclin D1 Imbalance in Severe Liver Steatosis Predicts Susceptibility to Ischemia Reperfusion Injury in Rats.
  • 2080: Collagen turnover biomarkers distinguish healthy from NAFLD patients and aid identification of patients with evidence of histologically active NASH
  • 2081: Oxidized mtDNA induced steatohepatitis through cGAS signaling pathway
  • 2082: Non-alcoholic fatty liver disease impairs expression of the type II inositol 1,4,5-trisphosphate receptor
  • 2083: Phosphoproteomics analysis of animal models of nonalcoholic fatty liver disease reveals that interactions between diet and environmental chemicals regulate hepatic nuclear receptor protein levels and phosphorylation status
  • 2084: ITIH4 as a Novel Biomarker of Hepatocellular Carcinoma Associated with Nonalcoholic Fatty Liver Diseases in a Newly Established Pig Model
  • 2085: Analysis of fibrogenic roles of liver infiltrating macrophages in a novel Non-alcoholic steatohepatitis (NASH) rat model with liver cirrhosis
  • 2086: Functional roles of AGE-RAGE system for the development of hepatic fibrosis of NASH
  • 2087: Gemcabene Attenuates the NAFLD Activity and Fibrosis Scores, and Downregulates Hepatic Inflammatory Genes in the STAMTM Murine Model of NASH-HCC
  • 2088: Effects of beta-carotene on diet induced non-alcoholic steatohepatitis in mice
  • 2089: Novel Nonalcoholic Fatty Liver disease zebrafish model induced by Western Style Diet and aging.
  • 2090: disruption of the homeostasis in lipid metabolism by knock-down of bile salt export pump may be involved in NASH pathogenesis in mouse model
  • 2091: Patients with Non-alcoholic Fatty Liver Disease (NAFLD) and Depression Have Altered TGF-b Signaling in their Visceral Adipose Tissue (VAT)
  • 2092: Low Level Palmitate Acid Mediates an Adaptive Mitochondrial Homeostasis Against the Hepatotoxicity Induced by High Level Palmitate Acid or CCL4---A Little Bad Fat Is Good
  • 2093: Consumption of decaffeinated coffee protects mice from the development of early non-alcoholic steatohepatitis: Role of intestinal barrier function
  • 2094: Oral digoxin inhibits liver injury to a comparable degree to obeticholic acid in a high fat model of NASH
  • 2095: Fructose-Related Hepatic ATP Depletion Induces Hyperuricemia in Healthy Volunteers and Patients with Biopsy-Proven Nonalcoholic Fatty Liver Disease.

Steatosis and Steatohepatitis

  • 2096: Lipoprotein sub-fractions show increased cardiovascular disease risk in pediatric non-alcoholic steatohepatitis compared to non-alcoholic fatty liver
  • 2097: Controlled Attenuation Parameter (CAP) diagnostic performance in Vibration Controlled Transient Elastography (Fibroscan®) for steatosis staging in comparison to direct quantification through digital morphometric analysis of liver biopsy
  • 2098: Elastogram quality in Vibration Controlled Transient Elastography: implications for Controlled Attenuation Parameter steatosis grading compared to digital morphometric analysis of liver biopsy.
  • 2099: Dietary counselling focusing only on fructose consumption improves hepatic inflammation in patients with NAFLD - a prospective, controlled, randomized open-label study (NUCES NASH)
  • 2100: Cytotoxic CD8 T cells associated with ballooning and liver inflammation link Non-alcoholic Steatohepatitis with Type 2 diabetes mellitus.
  • 2101: Pro-C3 in combination with clinical parameters is associated with severity of histological features of non-alcoholic steatohepatitis and fibrosis
  • 2102: Increase in Hepatocellular carcinoma (HCC) in patients with underlying Non-alcoholic fatty liver disease (NAFLD)
  • 2103: Accuracy and Repeatability of Magnetic Resonance Imaging Based Volumetric Liver Fat Fraction Compared to Liver Histology and Magnetic Resonance Spectroscopy as Reference Standards
  • 2104: Reductions in liver stiffness by magnetic resonance elastography (MRE) predict fibrosis improvement in a multi-center clinical trial of subjects with nonalcoholic steatohepatitis (NASH)
  • 2105: Associations of the Grade and Relative Dominance of Perisinusoidal versus Portal Fibrosis In Nonalcoholic Fatty Liver Disease (NAFLD)
  • 2106: Prevalence and Factors Associated with Cardiovascular Events and Mortality among 21,984 Veterans with Cirrhosis
  • 2107: Prospective validation of hepatic collagen content for the prediction of clinical disease progression in patients with advanced fibrosis due to NASH
  • 2108: Non-invasive stratification of fatty liver disease with high-throughput multiparametric MRI
  • 2109: The prevalence of liver stiffness and hepatic steatosis as measured by vibration-controlled transient elastography in a community-based cohort: The Framingham Heart Study.
  • 2110: A Quantitative Imaging Biomarker Assessment Metric for MRI-estimated Proton Density Fat Fraction
  • 2111: Assessing the severity of liver fibrosis and steatosis in biopsy-proven NAFLD patients using MR imaging, transient elastography and serum biomarker
  • 2112: Baseline Serum Pro-C3 Predicts Response to BMS-986036 (peg-FGF21): A Secondary Analysis of a Multi-Center Clinical Trial in Non-Alcoholic Steatohepatitis (NASH)
  • 2113: Effective Biomarkers for advance fibrosis NASH and reflect biomarkers as changes of liver fibrosis with NASH
  • 2114: Burden of Illness Economic Model for Patients with Non-alcoholic Steatohepatitis (NASH) in the United States
  • 2115: Dysregulated Expression of the Long non-coding RNA (lncRNA) MALAT1 in the Liver of Patients with Nonalcoholic fatty liver Disease (NAFLD) Stratifies Patients into the Histological Phenotypes Associated with the Disease Severity
  • 2116: Trend in Prevalence and Incidence of Diagnosed Hepatocellular Carcinoma (HCC) and Hepatocellular Carcinoma in Non Alcoholic Fatty Liver Disease (HCC-NAFLD) Patients in the Us, 2009 - 2014
  • 2117: Low Testosterone in Young Men Is Associated With Non-Alcoholic Fatty Liver Disease (NAFLD) in Midlife: Results from the Coronary Artery Risk Development in Young Adults (CARDIA) Study
  • 2118: Improvements in serum aminotransferase levels are associated with improvements in liver histology in children with nonalcoholic fatty liver disease (NAFLD)
  • 2119: Hepatocellular Carcinoma (HCC) in Patients with Non-Cirrhotic and Cirrhotic Nonalcoholic Fatty Liver Disease.
  • 2120: Type 2 diabetes and anti-diabetic medications modify the risk of liver-related outcomes in subjects with non-alcoholic fatty liver disease and advanced fibrosis. Results of a multicenter international cohort study.
  • 2121: Latent Class Analysis Reveals Distinct Classes of Nonalcoholic Fatty Liver Disease
  • 2122: Prospective validation of the Enhanced Liver Fibrosis (ELF) test for the prediction of disease progression in patients with nonalcoholic steatohepatitis (NASH) and advanced fibrosis
  • 2123: Novel multicenter validation of association between decline in MRI-PDFF and histologic response: A secondary analysis of FLINT Trial
  • 2124: Prevalence of liver fibrosis as defined by non-invasive markers in non-HBV Chinese general population with Normal ALT: a large population study
  • 2125: Role of common prosteatotic gene variants in primary sclerosing cholangitis
  • 2126: High-throughput RNA sequencing on liver biopsy material stratifies patients with non-alcoholic fatty liver disease
  • 2127: Prediction of advanced fibrosis in morbidly obese patients with nonalcoholic fatty liver disease
  • 2128: Liver function tests do not predict liver damage in diabetes. Analysis of liver steatosis and fibrosis by transient elastography in routine diabetes care
  • 2129: A simple clinical model predicts incident hepatic steatosis in a community-based cohort: The Framingham Heart Study
  • 2130: One Carbon Cycle Disturbances in Kwashiorkor; a Childhood Syndrome of Malnutrition and Hepatic Steatosis
  • 2131: Liver fibrosis as assessed by the FIB-4 index and metabolic markers in subjects with type 2 Diabetes
  • 2132: Evaluation of Cytochrome P450- and Transporter-Mediated Drug-Drug Interactions between the Apoptosis Signal-Regulating Kinase 1 (ASK1) Inhibitor Selonsertib and Phenotypic Probe Substrates or Prototypic Inhibitors/Inducers
  • 2133: Specific activation of apoptosis inhibitor of macrophage (AIM) in patients with NASH–associated hepatocellular carcinoma
  • 2134: Cryptogenic Cirrhosis is not NASH Cirrhosis
  • 2135: Hepatocellular carcinoma in non-alchoolic steatohepatitis (NASH): Clinical, histopathological aspects and immunohistochemical of metabolic and proliferative related-markers.
  • 2136: Short and long-term survival of patients suffering from non-severe alcoholic hepatitis
  • 2137: Evaluating the Response to Placebo in Randomized Controlled Trials of Nonalcoholic Steatohepatitis: A systematic review and meta-analysis
  • 2138: Improvement in Hepatic Transaminases Over 12 Months After Single Procedure Duodenal Mucosal Resurfacing in Type 2 Diabetes Patients
  • 2139: Nonalcoholic steatohepatitis: modulation of histological phenotype by the missense Thr174Met (rs4762) polymorphism of the angiotensinogen (AGT) gene
  • 2140: Screening for therapeutic trials, treatment indication in clinical practice: a new blood test to diagnose fibrotic NASH
  • 2141: Nonalcoholic fatty liver disease is associated with impaired bone strength in men with abdominal obesity
  • 2142: Rising Healthcare Costs and Comorbidities Among Nonalcoholic Steatohepatitis (NASH) Patients with Advanced Fibrosis and Cirrhosis: A Longitudinal Real-World Analysis of US Patients
  • 2143: NGM282 Induces Low Density Lipoprotein Cholesterol (LDLc) Changes, Consistent with Potent FGFR4 Signaling, which are Rapidly Mitigated with Statin Therapy in Patients with Biopsy-Confirmed Nonalcoholic Steatohepatitis (NASH)
  • 2144: High dietary acid load is associated with non–alcoholic fatty liver disease (NAFLD) in a large population–based study: The Rotterdam Study
  • 2145: Severity of Nonalcoholic Fatty Liver Disease and Risk of Cardiovascular Morbidity and All-Cause Mortality Among Patients Undergoing Weight Loss Surgery
  • 2146: Serum Wisteria floribunda agglutinin-positive Mac-2-binding Protein Levels Predict the Presence of Fibrotic Nonalcoholic Steatohepatitis (NASH) and NASH Cirrhosis
  • 2147: Comparison of published noninvasive biomarkers to reliably exclude severe fibrosis in NAFLD patients.
  • 2148: Insulin secretion and decreased glucose clearance are associated with enhanced fibrogenesis and a high risk of disease progression in non-diabetic patients with Non Alcoholic Fatty Liver Disease
  • 2149: Racial Disparities in the Relationship between Metabolic Syndrome Severity and the Risk of Mortality in Adults with Non-alcoholic Fatty Liver Disease
  • 2150: The Impact Of Obeticholic Acid (OCA) On Atherogenic Lipoproteins In Nonalcoholic Steatohepatitis
  • 2151: Nonalcoholic Steatohepatitis (NASH) Impairs Ventricular Diastolic Distensibility And Function Independent Of Underlying Type 2 Diabetes Or Hypertension
  • 2152: Long-term Clinical Outcomes and Mortality Related to Nonalcoholic Steatohepatitis: Predictions of a Mathematical Model
  • 2153: Birth Cohort Effects on Cirrhosis Incidence from 1997-2015: A Population-based Study
  • 2154: Clinical features and risk factors associated with NAFLD in non-obese type 2 diabetes patients
  • 2155: Fatty Liver Prevalence in Hepatitis C patients after Sustained Virological Response with Direct-Acting Antivirals
  • 2156: Early body weight reduction after the administration of SGLT-2 inhibitor is an independent factor contributed to rapid improvement of NAFLD
  • 2157: Increased risk of venous thromboembolism in patients with cirrhosis due to non-alcoholic steatohepatitis
  • 2158: Validity of Noninvasive Scores to Detect Nonalcoholic Fatty Liver Disease and its Advanced Form in Patients with Type 2 Diabetes.
  • 2159: Search for Rare Mutations in Metabolic Pathways Associated with Nonalcoholic Fatty Liver Disease: The role of Glucokinase regulator (GCKR) Sequence Variation
  • 2160: Clinical and histological characteristics of nonalcoholic fatty liver disease in Japanese non-obese patients
  • 2161: Growth differentiation factor 15 predicts advanced fibrosis in biopsy-proven nonalcoholic fatty liver disease
  • 2162: Long-Term Outcomes of Diabetic Patients with Non-alcoholic Fatty Liver Disease (NAFLD)
  • 2163: Presumed Non-alcoholic Steatofibrosis Can Independently Predict Mortality in Patients with Non-Alcoholic Fatty Liver Disease (NAFLD)
  • 2164: Light-to-Moderate Alcohol Consumption Protects Against Fatty Liver and Improves Insulin Resistance
  • 2165: The Impact of Inadequate HCC Screening in patients with NASH Cirrhosis on Tumor Size
  • 2166: Trend In Prevalence and Incidence of Diagnosed Non Alcoholic Fatty Liver Disease (NAFLD)/Non Alcoholic Steatohepatitis (NASH) in the US, 2009 - 2014.
  • 2167: Combining genetics and IR-DRF, a novel measurement of insulin resistance, in predicting histological features of nonalcoholic steatohepatitis
  • 2168: Evaluation with transient elastography and controlled attenuation parameter of a cohort of patients with chronic liver diseases admitted in a hepatology tertiary center
  • 2169: Reductions in hepatic proton density fat fraction (PDFF) predict histologic improvement in a multi-center clinical trial of subjects with nonalcoholic steatohepatitis (NASH)
  • 2170: Macrophage specific delivery of TNF-α siRNA complexed with schizophyllan inhibits inflammation and fibrosis in a murine NASH model
  • 2171: Metagenomic analysis shows a shift in taxonomic and functional composition of the gut microbiota in NASH patients
  • 2172: Evaluation of the safety, pharmacokinetics, and pharmacodynamic effects on de novo lipogenesis of the acetyl-CoA carboxylase inhibitor GS-0976 in healthy volunteers
  • 2173: Nonalcoholic Fatty Liver Disease in the U.S.: Clinical Characteristics of Patients Enrolled in TARGET-NASH
  • 2174: Preliminary evidence of an association between mtDNA D-loop polymorphisms and the clinicopathological features of nonalcoholic steatohepatitis
  • 2175: Impact of a Structured Exercise, Nutrition and Patient Education Program on Short Term Outcomes in Patients with Non-Alcoholic Fatty Liver Disease
  • 2176: Low serum concentration of carotenoids is associated with non-alcoholic fatty liver disease (NAFLD)
  • 2177: Parent Metabolic Risk Factors Are Associated With Concurrent Nonalcoholic Fatty Liver Disease In Adolescent Offspring
  • 2178: NGM282 Significantly Reduces Hepatic Steatosis Independent of Baseline Patient Characteristics and Highly Correlates with Markers of FGFR4 Target Engagement: Results from a Phase 2 Trial in Biopsy-Confirmed NASH Patients
  • 2179: Could inherited predisposition drive fatty liver disease in non-obese Caucasians? Results from eight German tertiary referral centers
  • 2180: ZJU index independently predict the development of non-alcoholic fatty liver disease: a 7-year prospective study
  • 2181: Hepatocellular injury and senescence in NASH are linked to Hedgehog and Hippo pathway activity and accumulation of hepatic progenitor cells
  • 2182: Subjects with Non-alcoholic Fatty Liver Disease and Severe Fibrosis Face a Significant Number of Adverse Events: Cryptogenic Cirrhosis and Severe Steatofibrosis
  • 2183: Plasma Selenoprotein P levels are related to adipose tissue insulin resistance, composition of free fatty acids and liver fibrosis in non-diabetic patients with Non Alcoholic Fatty Liver Disease
  • 2184: Association of sarcopenia with non-alcoholic fatty liver disease (NAFLD) and fibrosis models in US adults
  • 2185: Increased urinary arsenic is associated with elevated ALT in U.S. adolescents and adults
  • 2186: Quantification of hepatic steatosis in patients undergoing liver resection: A comparative study of preoperative controlled attenuation parameter (CAP) versus Fourier transform-infrared spectroscopy (FTIR) and histopathological estimation (HPE) on surgical specimens
  • 2187: Plasma metabolites for de novo lipogenesis and pharmacodynamic activity of acetyl-CoA carboxylase inhibitor GS-0976
  • 2188: Body composition and muscle fitness associate with nonalcoholic fatty liver disease (NAFLD)
  • 2189: A prospective evaluation of noninvasive modalities of liver fibrosis assessment in biopsy-proven nonalcoholic fatty liver disease
  • 2190: PNPLA3 but not TM6SF2 polymorphisms were associated with higher degrees of steatosis and liver fibrosis among Brazilian NAFLD patients
  • 2191: High Prevalence of Probable NAFLD and Advanced Fibrosis in a Population of Type II Diabetes Patients Followed by Endocrinology and Primary Care
  • 2192: The Relationship Between NAFLD and the Risk of Obstructive Sleep Apnea
  • 2193: Noninvasive methods predict long term overall survival and specific complications in non-alcoholic fatty liver disease
  • 2194: Increase of serum chylomicron triglyceride concentration associated with intestinal overproduction of chylomicron triglyceride in nonobese, nondiabetic and normolipidemic NASH patients
  • 2195: Hyperuricemia is independently associated with nonalcoholic fatty liver disease in the United States
  • 2196: Looking to the Pancreas: Nonalcoholic Fatty Pancreas Disease is a Predictor of Nonalcoholic Steatohepatitis
  • 2197: Under Utilization of Liver Ultrasound and Biopsy to Diagnose Nonalcoholic Fatty Liver Disease in Patients with Type-2 Diabetes.
  • 2198: NAFLD Patients with Metabolic Syndrome Have Significantly More Fat Deposition and Myosteatosis
  • 2199: Non-obese fatty liver disease is independently associated with lacunar infarct
  • 2200: Diet/exercise programs are used by only one in five severely obese patients with biopsy-defined Nonalcoholic Fatty Liver Disease (NAFLD) advanced fibrosis in the Veterans Health Administration (VHA)
  • 2201: Genetic variants predict the histological severity of nonalcoholic fatty liver disease independent of insulin resistance
  • 2202: The relationship between the plasma free amino acids and the pathological features in nonalcoholic fatty liver disease (NAFLD)
  • 2203: Onset of, but not Capacity beyond, Anaerobic Threshold (AT) during Graded Treadmill Testing is Reduced in Patients with Non-alcoholic Fatty Liver Disease (NAFLD)
  • 2204: Noninvasive Indices for the Prediction of Presence and Severity of Nonalcoholic Fatty Liver Disease in Patients with Chronic Kidney Disease
  • 2205: The Association of Male Sex Hormone with Severity of Non-alcoholic Fatty Liver Disease: Results from National Health and Nutrition Examination Survey
  • 2206: Correlation between of Non Alcoholic Fatty Liver Disease (NAFLD) Fibrosis Score (NFS) and Left Ventricular Mass Index (LVMI) in NAFLD
  • 2207: Correlation of mammographic fat infiltrated axillary lymph nodes with non-alcoholic fatty liver disease
  • 2208: The Association of Nonalcoholic Steatohepatitis and Obstructive Sleep Apnea
  • 2209: IRGM gene variants modify the relationship between visceral adipose tissue and NAFLD in patients with Crohn’s Disease
  • 2210: Characteristics and Costs of NASH Advanced Fibrosis and Cirrhosis in Patients with and without Diabetes Mellitus (DM): Results of a US Real-World Cohort Study
  • 2211: Steatohepatitis and Advanced Fibrosis in NAFLD Patients with Normal Aminotransferases Levels: Prevalence and Clinical features
  • 2212: Fibrotic burden in non-alcoholic fatty liver disease independently predicts the chronic kidney disease incidence: A large prospective cohort study
  • 2213: Improvements of Hepatic Fibrosis and Hepatic Collagen Deposition in Non-Alcoholic Steatohepatitis (NASH) Treated with Selonsertib are Associated with Improvement of Patient-Reported Outcomes (PROs)
  • 2214: Predictors of Fibrosis Progression and Regression by Histology and Morphometrically Quantified Collagen in Patients with Nonalcoholic Steatohepatitis (NASH) and Advanced Fibrosis
  • 2215: Clinical Characteristics and Epidemiology of Patients with Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH) in a Large Community-based Healthcare Delivery System in the U.S.
  • 2216: Progression to advanced liver disease in nonalcoholic fatty liver disease (NAFLD) differs among Asians compared to Caucasians and Hispanics
  • 2217: Hepatic de novo lipogenesis is elevated in patients with NASH independent of disease severity
  • 2218: A study of the genetic variants associated with non-alcoholic fatty liver disease in ethnic-Chinese population in Singapore
  • 2219: Hispanic Ethnicity Is Associated with Biomarkers of Nonalcoholic Steatohepatitis (NASH) in Women With Polycystic Ovary Syndrome (PCOS)
  • 2220: Effect of semaglutide on alanine aminotransferase in subjects with type 2 diabetes and high cardiovascular risk
  • 2221: Development of an algorithm for the prediction of cardiovascular events in patients with NAFLD: the role of mean platelet volume
  • 2222: Pilot report of the Steatohepatitis Obesity Longitudinal Active Registry and Data Repository (SOLAR-DR), an Innovative Public Healthcare Approach for Patients at Risk for NAFLD and NASH.
  • 2223: Involvement of 1-deoxy-sphinglolipids in steatogenesis in Non Alcoholic Fatty Liver Disease
  • 2224: Favorable safety and tolerability of the dual CCR2/5 antagonist cenicriviroc in over 1000 subjects treated to date
  • 2225: The Global Epidemiology of Non-alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Mellitus: A Systematic Review and Meta-analysis
  • 2226: Evaluation of kidney function in patients with Non-Alcoholic Fatty Liver Disease: The role of galectin-3
  • 2227: Metabolomics approach addresses the heterogeneity of NAFLD and determines subtypes associated with different metabolic alterations
  • 2228: Comparison of Sonic Hedgehog and keratin 8/18 immunostains as markers of ballooned hepatocytes in non-alcoholic fatty liver disease (NAFLD)
  • 2229: Serum Pro-C3 (N-terminal propeptide of type III procollagen) is associated with hepatic steatosis and fibrosis and responsive to changes in steatosis in patients with NASH
  • 2230: Gut-dysbiosis due to reduced Clostridium subcluster XIVa is associated with the progression of nonalcoholic fatty liver disease: analysis based on the serum bile acid profile
  • 2231: Differences in Clinical Characteristics between Eastern and Western Non-alcoholic Fatty Liver disease cohorts: A comparative study of 758 cases.
  • 2232: Understanding the Patient-Perceived Impact of Nonalcoholic Steatohepatitis: Raising the Volume on a Silent Disease
  • 2233: Evaluation of the presence of steatosis and fibrosis in lipodystrophic with diabetes type 2 patients using transient elastography and comparison with antropometric and densitometric parameters
  • 2234: Examining Changes in Liver Enzymes in Patients with Obesity Treated with Lorcaserin: A Post-hoc Analysis of the Pivotal Studies
  • 2235: PNPLA-3 gene polymorphism in diabetic patients – a prognostic marker of both liver disease and diabetes complications
  • 2236: Fatigue and Activity Level Self-Reports Do Not Predict Exercise Tolerance in Subjects with Non-alcoholic Fatty Liver Disease (NAFLD) Patients
  • 2237: A National Survey of Physicians Regarding Non-alcoholic Fatty Liver Disease (NAFLD), Non-alcoholic Steatohepatitis (NASH): The Disease and Clinical Trial Awareness Program for NASH
  • 2238: Exercise Tolerance is Frequently Preserved in Presence of Exercise Performance Deficits in Non-Alcoholic Fatty Liver Disease (NAFLD): Implications for Exercise Intervention
  • 2239: No differences in Physiological Response during Cardiopulmonary Exercise Testing in Patients with and without Non-alcoholic Fatty Liver Disease